Annual Review　神経　2019

出版社： 中外医学社
著者：
発行日： 2019-03-10
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784498328303
電子書籍版： 2019-03-10 （初版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

9,680 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

9,680 円(税込)

購入する
特記事項：

商品紹介

毎年の最注目トピックを厳選し，第一人者が内外の文献を踏まえて最新の知見を解説している，伝統と好評の年度版．2019年版では「glymphatic system」「神経難病への核酸医療、など」に関するトピックや，臨床の現場で近年直面する問題としての「抗血栓療法中の頭部外傷」「高齢発症てんかん」など，神経学分野各領域の進歩や最新の話題をいち早く伝える内容である．

目次

  • I. Basic Neuroscience
    　1．神経生理
    　2．神経病理
    　3．生化学（分子生物学）
    　4．画　像

    II. 本年の動向
    　1　筋萎縮性側索硬化症（ALS）の病態解析と新規の治療法の開発
    　2　自己免疫性脳炎研究の進歩
    　3　成人発症遺伝性白質脳症の医療基盤
    　4　エンテロウイルス等感染症を含む急性弛緩性麻痺
    　5　プリオン病update
    　6　脊髄性筋萎縮症に対する核酸医薬品治療と今後の展望
    　7　補体を標的とした神経免疫疾患の新規治療
    　8　脳表ヘモジデリン沈着症
    　9　虚血コアのMR imaging
    　10　脳神経外科領域における先進医療機器開発の現状

    III. 各種疾患
    　1．感染症・炎症疾患
    　2．脳血管障害
    　3．脳腫瘍
    　4．外　傷
    　5．変性疾患
    　6．中毒・代謝疾患
    　7．脱髄・免疫性疾患
    　8．末梢神経障害
    　9．神経筋疾患
    　10．自律神経疾患
    　11．機能性疾患

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. Basic Neuroscience

P.7 掲載の参考文献
1) Fuxe K, Dahlstrom AB, Jonsson G, et al. The discovery of central monoamine neurons gave volume transmission to the wired brain. Prog Neurobiol. 2010 ; 90 : 82-100.
 
2) Hnasko TS, Edwards RH. Neurotransmitter corelease : mechanism and physiological role. Annu Rev Physiol. 2012 ; 74 : 225-43.
PubMed
3) Boulland JL, Jenstad M, Boekel AJ, et al. Vesicular glutamate and GABA transporters sort to distinct sets of vesicles in a population of presynaptic terminals. Cereb Cortex. 2009 ; 19 : 241-8.
 
4) Yamasaki M, Matsui M, Watanabe M. Preferential localization of muscarinic M1 receptor on dendritic shaft and spine of cortical pyramidal cells and its anatomical evidence for volume transmission. J Neurosci. 2010 ; 30 : 4408-18.
PubMed
5) Yoshida T, Fukaya M, Uchigashima M, et al. Localization of diacylglycerol lipase-α around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci. 2006 ; 26 : 4740-51.
 
6) Uchigashima M, Yamazaki M, Yamasaki M, et al. Molecular and morphological configuration for 2-arachidonoylglycerol-mediated retrograde signaling at mossy cell-granule cell synapses in the dentate gyrus. J Neurosci. 2011 ; 31 : 7700-14.
PubMed
7) Yoshida T, Uchigashima M, Yamasaki M, et al. Unique inhibitory synapse with particularly rich endocannabinoid signaling machinery on pyramidal neurons in basal amygdaloid nucleus. Proc Natl Acad Sci USA. 2011 ; 108 : 3059-64.
PubMed
8) Omiya Y, Uchigashima M, Konno K, et al. VGluT3-expressing CCK-positive basket cells construct invaginating synapses enriched with endocannabinoid signaling proteins in particular cortical and cortex-like amygdaloid regions of mouse brains. J Neurosci. 2015 ; 35 : 4215-25.
PubMed
9) Freund TF, Powell JF, Smith AD. Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience. 1984 ; 13 : 1189-215.
PubMed
10) Uchigashima M, Ohtsuka T, Kobayashi K, et al. Dopamine synapse is a neuroligin-2-mediated contact between dopaminergic presynaptic and GABAergic postsynaptic structures. Proc Natl Acad Sci USA. 2016 ; 113 : 4206-11.
PubMed
11) Sarter M, Parikh V, Howe WM. Phasic acetylcholine release and the volume transmission hypothesis : time to move on. Nat Rev Neurosci. 2009 ; 10 : 383-90.
PubMed
12) Marcott PF, Mamaligas AA, Ford CP. Phasic dopamine release drives rapid activation of striatal D2-receptors. Neuron. 2014 ; 84 : 164-76.
PubMed
13) Ren J, Qin C, Hu F, et al. Habenula "cholinergic" neurons co-release glutamate and acetylcholine and activate postsynaptic neurons via distinct transmission modes. Neuron. 2011 ; 69 : 445-52.
PubMed
P.12 掲載の参考文献
1) Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 1995 ; 12 : 1-21.
PubMed
2) Basso DM, Beattie MS, Bresnahan JC. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp Neurol. 1996 ; 139 : 244-56.
PubMed
3) Basso DM, Fisher LS, Anderson AJ, et al. Basso mouse scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma. 2006 ; 23 : 635-59.
 
4) Hamers FP, Koopmans GC, Joosten EA. CatWalk-assisted gait analysis in the assessment of spinal cord injury. J Neurotrauma. 2006 ; 23 : 537-48.
PubMed
5) Vrinten DH, Hamers FF. 'CatWalk' automated quantitative gait analysis as a novel method to assess mechanical allodynia in the rat ; a comparison with von Frey testing. Pain. 2003 ; 102 : 203-9.
 
6) Krizsan-Agbas D, Winter MK, Eggimann LS, et al. Gait analysis at multiple speeds reveals differential functional and structural outcomes in response to graded spinal cord injury. J Neurotrauma. 2014 ; 31 : 846-56.
PubMed
7) Sparling JS, et al. Schwann cells generated from neonatal skin-derived precursors or neonatal peripheral nerve improve functional recovery after acute transplantation into the partially injured cervical spinal cord of the rat. J Neurosci. 2015 ; 35 : 6714-30.
PubMed
8) Kawabata S, Takano M, Numasawa-Kuroiwa Y, et al. Grafted human iPS cell-derived oligodendrocyte precursor cells contribute to robust remyelination of demyelinated axons after spinal cord injury. Stem Cell Reports. 2016 ; 6 : 1-8.
PubMed
9) Lindsay SL, Toft A, Griffin J, et al. Human olfactory mesenchymal stromal cell transplants promote remyelination and earlier improvement in gait co-ordination after spinal cord injury. Glia. 2017 ; 65 : 639-56.
PubMed
10) Francos-Quijorna I, Santos-Nogueira E, Gronert K, et al. Maresin 1 promotes inflammatory resolution, neuroprotection, and functional neurological recovery after spinal cord injury. J Neurosci. 2017 ; 37 : 11731-43.
PubMed
11) Jacobs BY, Lakes EH, Reiter A, et al. The open source GAITOR suite for rodent gait analysis. Sci Rep. 2018 ; 8 : 9797.
PubMed
12) Bhimani AD, Kheirkhah P, Amone GD, et al. Functional gait analysis in a spinal contusion rat model. Neurosci Biobehav Rev. 2017 ; 83 : 540-6.
 
13) Moraud EM, Capogrosso M, Formento E, et al. Mechanisms underlying the neuromodulation of spinal circuits for correcting gait and balance deficits after spinal cord injury. Neuron. 2016 ; 89 : 814-28.
PubMed
14) Chen K, Marsh BC, Cowan M, et al. Sequential therapy of anti-Nogo-A antibody treatment and treadmill training leads to cumulative improvements after spinal cord injury in rats. Exp Neurol. 2017 ; 292 : 135-44.
PubMed
15) Timoszyk WK, Nessler JA, Acosta C, et al. Hindlimb loading determines stepping quantity and quality following spinal cord transection. Brain Res. 2005 ; 1050 : 180-9.
PubMed
16) Nessler JA, De Leon RD, Sharp K, et al. Robotic gait analysis of bipedal treadmill stepping by spinal contused rats : characterization of intrinsic recovery and comparison with BBB. J Neurotrauma. 2006 ; 23 : 882-96.
PubMed
17) Neckel ND. Novel spatiotemporal analysis of gait changes in body weight supported treadmill trained rats following cervical spinal cord injury. J Neuroeng Rehabi. 2017 ; 14 : 96.
 
18) Li X, Wu Q, Xie C, et al. Blocking of BDNF-TrkB signaling inhibits the promotion effect of neurological function recovery after treadmill training in rats with Spinal Cord injury. Spinal Cord. 2018 ;
 
19) Mantilla CB, Gransee HM, Zhan WZ, et al. Motoneuron BDNF/TrkB signaling enhances functional recovery after cervical spinal cord injury. Exp Neurol. 2013 ; 247 : 101-9.
PubMed
20) Tashiro S, Shinozaki M, Mukaino M, et al. BDNF Induced by Treadmill Training Contributes to the Suppression of Spasticity and Allodynia After Spinal Cord Injury via Upregulation of KCC2. Neurorehabil Neural Repair. 2015 ; 29 : 677-89.
 
21) Hutchinson KJ, Gomez-Pinilla F, Crowe MJ, et al. Three exercise paradigms differentially improve sensory recovery after spinal cord contusion in rats. Brain. 2004 ; 127 : 1403-14.
PubMed
22) Giehl KM, Tetzlaff W. BDNF and NT-3, but not NGF, prevent axotomy-induced death of rat corticospinal neurons in vivo. Eur J Neurosci. 1996 ; 8 : 1167-75.
 
23) Khalki L, Sadlaoud K, Lerond J, et al. Changes in innervation of lumbar motoneurons and organization of premotor network following training of transected adult rats. Exp Neurol. 2018 ; 299 : 1-14.
PubMed
24) Udoekwere UI, Oza CS, Giszter SF. Teaching adult rats spinalized as neonates to walk using trunk robotic rehabilitation : Elements of success, failure, and dependence. The Journal of neuroscience. the official. J Soc Neurosci. 2016 ; 36 : 8341-55.
 
25) Shah PK, Garcia-Alias G, Choe J, et al. Use of quadrupedal step training to re-engage spinal interneuronal networks and improve locomotor function after spinal cord injury. Brain. 2013 ; 136 : 3362-77.
PubMed
26) Hamlin M, Traughber T Jr, Reinkensmeyer DJ, et al. A novel device for studying weight supported, quadrupedal overground locomotion in spinal cord injured rats. J Neurosci Methods. 2015 ; 246 : 134-41.
PubMed
27) de Leon RD, Dy CJ. What did we learn from the animal studies of body weight-supported treadmill training and where do we go from here. J Neurotrauma. 2017 ; 34 : 1744-50.
PubMed
28) Garcia-Alias G, et al. Chondroitinase ABC combined with neurotrophin NT-3 secretion and NR2D expression promotes axonal plasticity and functional recovery in rats with lateral hemisection of the spinal cord. J Neurosci. 2011 ; 31 : 17788-99.
PubMed
29) Maier IC, Ichiyama RM, Courtine G, et al. Differential effects of anti-Nogo-A antibody treatment and treadmill training in rats with incomplete spinal cord injury. Brain. 2009 ; 132 : 1426-40.
PubMed
30) Zhang L, Kaneko S, Sano A, et al. Rewiring of regenerated axons by combining treadmill training with semaphorin3A inhibition. Mol Brain. 2014 ; 7 : 14.
PubMed
31) Osuna-Carrasco LP, Lepez-Ruiz JR, Mondizabal-Ruiz EG, et al. Quantitative analysis of hindlimbs locomotion kinematics in spinalized rats treated with Tamoxifen plus treadmill exercise. Neuroscience. 2016 ; 333 : 151-61.
 
32) Shinozaki M, Iwanami A, Fujiyoshi K, et al. Combined treatment with chondroitinase ABC and treadmill rehabilitation for chronic severe spinal cord injury in adult rats. Neurosci Res. 2016 ; 113 : 37-47.
PubMed
33) Tashiro S, Nishimura S, Iwai H, et al. Functional Recovery from Neural Stem/Progenitor Cell Transplantation Combined with Treadmill Training in Mice with Chronic Spinal Cord Injury. Sci Rep. 2016 ; 6 : 30898.
PubMed
34) Tashiro S, et al. The Amelioration of Pain-Related Behavior in Mice with Chronic Spinal Cord Injury Treated with Neural Stem/Progenitor Cell Transplantation Combined with Treadmill Training. J Neurotrauma. 2018.
PubMed
35) Karimi-Abdolrezaee S, Eftekharpour E, Wang J, et al. Synergistic effects of transplanted adult neural stem/progenitor cells, chondroitinase, and growth factors promote functional repair and plasticity of the chronically injured spinal cord. J Neurosci. 2010 ; 30 : 1657-76.
PubMed
36) Nishimura S, Yasuda A, Iwai H, et al. Time-dependent changes in the microenvironment of injured spinal cord affects the therapeutic potential of neural stem cell transplantation for spinal cord injury. Mol Brain. 2013 ; 6 : 3.
PubMed
37) Kumamaru H, Saiwai H, Kubota K, et al. Therapeutic activities of engrafted neural stem/precursor cells are not dormant in the chronically injured spinal cord. Stem Cells. 2013 ; 31 : 1535-47.
 
P.20 掲載の参考文献
1) Iliff JJ, Goldman SA, Nedergaard M. Implications of the discovery of brain lymphatic pathways. Lancet Neurol. 2015 ; 14 : 977-9.
PubMed
2) Yin M, Pu T, Wang L, et al. Astroglial water channel aquaporin 4-mediated glymphatic clearance function : A determined factor for time-sensitive treatment of aerobic exercise in patients with Alzheimer's disease. Med Hypotheses. 2018 ; 119 : 18-21.
PubMed
3) Aselli G. De Lactibus, sive lacteis venis, quarto vasorum mesaraicorum genere, novo invento Gasparis Asellii,... dissertatio. (Alexander Tadinus et Senator Septalius ediderunt). Mediolani. apud J. B. Bidellium. 1627.
 
4) Bartholin T. Vasa lymphatica : nuper Hafniae in animantibus inventa, et hepatis exseqviae. Hafniae : Sumptibus Georgii Holst ... : Typis Petri Hakii. 1653.
 
5) Hosoyamada Y, Kurihara H, Sakai T. Ultrastructural localization and size distribution of collagen fibrils in Glisson's sheath of rat liver : implications for mechanical environment and possible producing cells. J Anat. 2000 ; 196 : 327-40.
 
6) Hosoyamada Y, Sakai T. Structural and mechanical architecture of the intestinal filli and crypts in the rat intestine : integrative reevaluation from ultrastructural analysis. Anat Embryol. 2005 ; 210 : 1-12.
 
7) Virchow R. Ueber die Erweiterung kleinerer Gefaesse. Archiv Pathol Anat Physiol Klin Med. 1851 ; 3 : 427-62.
 
8) Robin C. Recherches sur quelques particularite's de la structure des capillaires de l'encephale. J Physiol Homme Anim. 1859 ; 2 : 537-48.
 
9) Zhang ET, Inman CB, Weller RO. Interrelationship of the pia mater and the perivascular (Virchow-Robin) spaces in the human cerebrum. J Anat. 1990 ; 170 : 111-23.
PubMed
10) Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012 ; 4 : 147ra11.
 
11) Nedergaard M. Neuroscience. Garbage truck of the brain. Science. 2013 ; 340 : 1529-30.
PubMed
12) Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015 ; 11 : 457-70.
PubMed
13) Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013 ; 342 : 373-7.
PubMed
14) He XF, Liu DX, Zhang Q, et al. Voluntary exercise promotes glymphatic clearance of amyloid beta and reduces the activation of astrocytes and microglia in aged mice. Front Mol Neurosci. 2017 ; 10 : 144.
PubMed
15) Iliff JJ, Wang M, Zeppenfeld DM, et al. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J Neurosci. 2013 ; 33 : 18190-9.
 
16) Koh L, Zakharov A, Johnston M. Integration of the subarachnoid space and lymphatics : is it time to embrace a new concept of cerebrospinal fluid absorption? Cerebrospinal Fluid Res. 2005 ; 2 : 6.
PubMed
17) Aspelund A, Antila S, Proulx ST, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015 ; 212 : 991-9.
PubMed
18) Taoka T, Naganawa S. Gadolinium-based Contrast Media, Cerebrospinal fluid and the glymphatic system : Possible mechanisms for the deposition of gadolinium in the brain. Magn Reson Med Sci. 2018 ; 17 : 111-9.
PubMed
19) Eide PK, Ringstad G. MRI with intrathecal MRI gadolinium contrast medium administration : a possible method to assess glymphatic function in human brain. Acta Radiol Open. 2015 ; 4 : 2058460115609635.
PubMed
20) Taoka T, Masutani Y, Kawai H, et al. Evaluation of glymphatic system activity with the diffusion MR technique : diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Alzheimer's disease cases. Jpn J Radiol. 2017 ; 35 : 172-8.
PubMed
P.30 掲載の参考文献
1) Suzuki N, Aoki M, Mori-Yoshimura M, et al. Increase in number of sporadic inclusion body myositis (sIBM) in Japan. J Neurol. 2012 ; 259 : 554-6.
PubMed
2) Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995 ; 38 : 705-13.
PubMed
3) Shibata S, Izumi R, Hara T, et al. Five-year history of dysphagia as a sole initial symptom in inclusion body myositis. J Neurol Sci. 2017 ; 381 : 325-7.
PubMed
4) Suzuki N, Mori-Yoshimura M, Yamashita S, et al. Multicenter questionnaire survey for sporadic inclusion body myositis in Japan. Orphanet J Rare Dis. 2016 ; 11 : 146.
 
5) Paltiel AD, Ingvarsson E, Lee DK, et al. Demographic and clinical features of inclusion body myositis in North America. Muscle Nerve. 2015 ; 52 : 527-33.
PubMed
6) Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011 ; 134 : 3176-84.
PubMed
7) Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis : an end stage with major disabilities. Brain. 2011 ; 134 : 3167-75.
PubMed
8) Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975 ; 292 : 403-7.
PubMed
9) Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 ; 292 : 344-7.
PubMed
10) Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014 ; 83 : 426-33.
PubMed
11) Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve. 2009 ; 40 : 19-31.
 
12) Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2008 ; 79 : 1186-9.
PubMed
13) Olive M, Janue A, Moreno D, et al. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol. 2009 ; 68 : 262-73.
PubMed
14) Kusters B, van Hoeve BJ, Schelhaas HJ, et al. TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol. 2009 ; 117 : 209-11.
PubMed
15) D'Agostino C, Nogalska A, Engel WK, et al. In sporadic inclusion body myositis muscle fibres TDP-43-positive inclusions are less frequent and robust than p62 inclusions, and are not associated with paired helical filaments. Neuropathol Appl Neurobiol. 2011 ; 37 : 315-20.
 
16) Hiniker A, Daniels BH, Lee HS, et al. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun. 2013 ; 1 : 29.
PubMed
17) Hokkoku K, Sonoo M, Higashihara M, et al. Electromyographs of the flexor digitorum profundus muscle are useful for the diagnosis of inclusion body myositis. Muscle Nerve. 2012 ; 46 : 181-6.
PubMed
18) Cox FM, Reijnierse M, van Rijswijk CS, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology. 2011 ; 50 : 1153-61.
PubMed
19) Noto Y, Shiga K, Tsuji Y, et al. Contrasting echogenicity in flexor digitorum profundus-flexor carpi ulnaris : a diagnostic ultrasound pattern in sporadic inclusion body myositis. Muscle Nerve. 2014 ; 49 : 745-8.
PubMed
20) Nodera H, Takamatsu N, Matsui N, et al. Intramuscular dissociation of echogenicity in the triceps surae characterizes sporadic inclusion body myositis. Eur J Neurol. 2016 ; 23 : 588-96.
PubMed
21) Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013 ; 73 : 408-18.
PubMed
22) Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013 ; 73 : 397-407.
PubMed
23) Greenberg SA. Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis : Isotypes and diagnostic utility. Muscle Nerve. 2014 ; 50 : 488-92.
PubMed
24) Herbert MK, Pruijn GJ. Novel serology testing for sporadic inclusion body myositis : disease-specificity and diagnostic utility. Curr Opin Rheumatol. 2015 ; 27 : 595-600.
PubMed
25) Muro Y, Nakanishi H, Katsuno M, et al. Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts. Clin Chim Acta. 2017 ; 472 : 1-4.
PubMed
26) Tawara N, Yamashita S, Zhang X, et al. Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis. Ann Neurol. 2017 ; 81 : 512-25.
PubMed
27) Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2016 ; 75 : 696-701.
PubMed
28) Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Care Res. 2016 ; 68 : 66-71.
PubMed
29) Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve. 1998 ; 21 : 115-7.
PubMed
30) Sakai K, Ikeda Y, Ishida C, et al. Inclusion body myositis with granuloma formation in muscle tissue. Neuromuscul Disord. 2015 ; 25 : 706-12.
PubMed
31) Sanmaneechai O, Swenson A, Gerke AK, et al. Inclusion body myositis and sarcoid myopathy : coincidental occurrence or associated diseases. Neuromuscul Disord. 2015 ; 25 : 297-300.
PubMed
32) Orimo S, Koga R, Goto K, et al. Immunohistochemical analysis of perforin and granzyme A in inflammatory myopathies. Neuromuscul Disord. 1994 ; 4 : 219-26.
PubMed
33) Fyhr IM, Moslemi AR, Lindberg C, et al. T cell receptor beta-chain repertoire in inclusion body myositis. J Neuroimmunol. 1998 ; 91 : 129-34.
PubMed
34) Dimitri D, Benveniste O, Dubourg O, et al. Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain. 2006 ; 129 : 986-95.
PubMed
35) Greenberg SA, Pinkus JL, Amato AA, et al. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain. 2016 ; 139 : 1348-60.
 
36) Rothwell S, Cooper RG, Lundberg IE, et al. Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum. Arthritis Rheumatol. 2017 ; 69 : 1090-9.
PubMed
37) Goyal NA, Cash TM, Alam U, et al. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J Neurol Neurosurg Psychiatry. 2016 ; 87 : 373-8.
PubMed
38) Lilleker JB, Rietveld A, Pye SR, et al. Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Ann Rheum Dis. 2017 ; 76 : 862-8.
PubMed
39) Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis : explanation for poor response to immunosuppressive therapy. Neurology. 1995 ; 45 : 1302-4.
PubMed
40) Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg : a double-blind, placebo-controlled study. Neurology. 1997 ; 48 : 712-6.
PubMed
41) Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002 ; 58 : 326.
PubMed
42) Chou SM. Myxovirus-like structures in a case of human chronic polymyositis. Science. 1967 ; 158 : 1453-5.
 
43) Nakano S, Oki M, Kusaka H. The role of p62/SQSTM1 in sporadic inclusion body myositis. Neuromuscul Disord. 2017 ; 27 : 363-9.
PubMed
44) Pinkus JL, Amato AA, Taylor JP, et al. Abnormal distribution of heterogeneous nuclear ribonucleoproteins in sporadic inclusion body myositis. Neuromuscul Disord. 2014 ; 24 : 611-6.
PubMed
45) Nogalska A, Engel WK, McFerrin J, et al. Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers. J Neurochem. 2006 ; 96 : 1491-9.
PubMed
46) Kitajima Y, Tashiro Y, Suzuki N, et al. Proteasome dysfunction induces muscle growth defects and protein aggregation. J Cell Sci. 2014 ; 127 : 5204-17.
PubMed
47) Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA. 2000 ; 97 : 9209-14.
PubMed
48) Sugarman MC, Kitazawa M, Baker M, et al. Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol Aging. 2006 ; 27 : 423-32.
 
49) Sugarman MC, Yamasaki TR, Oddo S, et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci USA. 2002 ; 99 : 6334-9.
PubMed
50) Gang Q, Bettencourt C, Machado PM, et al. The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiol Aging. 2015 ; 36 : 1766 e1-e3.
 
51) Guttsches AK, Brady S, Krause K, et al. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol. 2017 ; 81 : 227-39.
PubMed
52) Gang Q, Bettencourt C, Machado PM, et al. Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. Neurobiol Aging. 2016 ; 47 : 218 e1-e9.
 
53) Wanschitz JV, Dubourg O, Lacene E, et al. Expression of myogenic regulatory factors and myo-endothelial remodeling in sporadic inclusion body myositis. Neuromuscul Disord. 2013 ; 23 : 75-83.
PubMed
54) Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014 ; 83 : 2239-46.
PubMed
P.38 掲載の参考文献
1) Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med. 2018 ; 378 : 321-30.
PubMed
2) Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016 ; 8 : 595-608.
PubMed
3) Kaneko N, Nakamura A, Washimi Y, et al. Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B Phys Biol Sci. 2014 ; 90 : 353-64.
PubMed
4) Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017 ; 13 : 841-9.
PubMed
5) Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-beta biomarkers for Alzheimer's disease. Nature. 2018 ; 554 : 249-54.
PubMed
6) Gonzalez-Dominguez R, Garcia-Barrera T, Gomez-Ariza JL. Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer's disease. J Proteomics. 2014 ; 104 : 37-47.
 
7) Li NJ, Liu WT, Li W, et al. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin Biochem. 2010 ; 43 : 992-7.
PubMed
8) Cui Y, Liu X, Wang M, et al. Lysophosphatidylcholine and amide as metabolites for detecting alzheimer disease using ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabonomics. J Neuropathol Exp Neurol. 2014 ; 73 : 954-63.
 
9) Ciavardelli D, Piras F, Consalvo A, et al. Medium-chain plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy elderly, mildly cognitively impaired, or Alzheimer's disease subjects. Neurobiol Aging. 2016 ; 43 : 1-12.
 
10) Toledo JB, Arnold M, Kastenmuller G, et al. Metabolic network failures in Alzheimer's disease : A biochemical road map. Alzheimers Dement. 2017 ; 13 : 965-84.
PubMed
11) Gonzalez-Dominguez R, Ruperez FJ, Garcia-Barrera T, et al. Metabolomic-driven elucidation of serum disturbances associated with Alzheimer's disease and mild cognitive impairment. Curr Alzheimer Res. 2016 ; 13 : 641-53.
PubMed
12) Chouraki V, Preis SR, Yang Q, et al. Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study. Alzheimers Dement. 2017 ; 13 : 1327-36.
PubMed
13) Santiago JA, Littlefield AM, Potashkin JA. Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease. Sci Rep. 2016 ; 6 : 34579.
 
14) Santiago JA, Bottero V, Potashkin JA. Evaluation of RNA blood biomarkers in the Parkinson's disease biomarkers program. Front Aging Neurosci. 2018 ; 10 : 157.
PubMed
15) Schondorf DC, Ivanyuk D, Baden P, et al. The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of parkinson's disease. Cell Rep. 2018 ; 23 : 2976-88.
PubMed
16) Fan Y, Xiao S. Progression rate associated peripheral blood biomarkers of parkinson's disease. J Mol Neurosci. 2018 ; 65 : 312-8.
PubMed
17) Saiki S, Hatano T, Fujimaki M, et al. Decreased longchain acylcarnitines from insufficient beta-oxidation as potential early diagnostic markers for Parkinson's disease. Sci Rep. 2017 ; 7 : 7328.
PubMed
18) Gustafsson H, Aasly J, Strahle S, et al. Low muscle strength in late adolescence and Parkinson disease later in life. Neurology. 2015 ; 84 : 1862-9.
PubMed
19) Ma W, Li Y, Wang C, et al. Serum miR-221 serves as a biomarker for Parkinson's disease. Cell Biochem Funct. 2016 ; 34 : 511-5.
 
20) Dong H, Wang C, Lu S, et al. A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson's disease. Biomarkers. 2016 ; 21 : 129-37.
 
21) Botta-Orfila T, Morato X, Compta Y, et al. Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease. J Neurosci Res. 2014 ; 92 : 1071-7.
PubMed
22) Cao XY, Lu JM, Zhao ZQ, et al. MicroRNA biomarkers of Parkinson's disease in serum exosome-like microvesicles. Neurosci Lett. 2017 ; 644 : 94-9.
PubMed
23) Chi J, Xie Q, Jia J, et al. Integrated analysis and Identification of novel biomarkers in Parkinson's disease. Front Aging Neurosci. 2018 ; 10 : 178.
PubMed
24) Zhao N, Jin L, Fei G, et al. Serum microRNA-133b is associated with low ceruloplasmin levels in Parkinson's disease. Parkinsonism Relat Disord. 2014 ; 20 : 1177-80.
PubMed
25) Zhang X, Yang R, Hu BL, et al. Reduced circulating levels of miR-433 and miR-133b are potential biomarkers for parkinson's disease. Front Cell Neurosci. 2017 ; 11 : 170.
 
26) Petkau G, Kawano Y, Wolf I, et al. MiR221 promotes precursor B-cell retention in the bone marrow by amplifying the PI3K-signaling pathway in mice. Eur J Immunol. 2018 ; 48 : 975-89.
PubMed
27) Wang R, Wang X, Zhuang L. Gene expression profiling reveals key genes and pathways related to the development of non-alcoholic fatty liver disease. Ann Hepatol. 2016 ; 15 : 190-9.
 
28) Wu Y, Xu J, Xu J, et al. Lower serum levels of miR-29c-3p and miR-19b-3p as biomarkers for Alzheimer's disease. Tohoku J Exp Med. 2017 ; 242 : 129-36.
PubMed
29) Kim J, Inoue K, Ishii J, et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science. 2007 ; 317 : 1220-4.
PubMed
30) Schlaudraff F, Grundemann J, Fauler M, et al. Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease. Neurobiol Aging. 2014 ; 35 : 2302-15.
 
31) Heyer MP, Pani AK, Smeyne RJ, et al. Normal midbrain dopaminergic neuron development and function in miR-133b mutant mice. J Neurosci. 2012 ; 32 : 10887-94.
PubMed
32) Havelund JF, Heegaard NHH, Faergeman NJK, et al. Biomarker research in Parkinson's disease using metabolite profiling. Metabolites. 2017 ; 7.
PubMed
33) Fujimaki M, Saiki S, Li Y, et al. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology. 2018 ; 90 : e404-e11.
PubMed
34) Ohmichi T, Kasai T, Kosaka T, et al. Biomarker repurposing : Therapeutic drug monitoring of serum theophylline offers a potential diagnostic biomarker of Parkinson's disease. PLoS One. 2018 ; 13 : e0201260.
PubMed
35) Hatano T, Saiki S, Okuzumi A, et al. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. J Neurol Neurosurg Psychiatry. 2016 ; 87 : 295-301.
PubMed
36) Han W, Sapkota S, Camicioli R, et al. Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis. Mov Disord. 2017 ; 32 : 1720-8.
PubMed
37) Laurens B, Constantinescu R, Freeman R, et al. Fluid biomarkers in multiple system atrophy : A review of the MSA Biomarker Initiative. Neurobiol Dis. 2015 ; 80 : 29-41.
PubMed
38) Oropesa-Ruiz JM, Huertas-Fernandez I, Jesus S, et al. Low serum uric acid levels in progressive supranuclear palsy. Mov Disord. 2016 ; 31 : 402-5.
PubMed
39) Chen X, Guo X, Huang R, et al. Serum uric acid levels in patients with Alzheimer's disease : a meta-analysis. PLoS One. 2014 ; 9 : e94084.
 
40) Wilke C, Preische O, Deuschle C, et al. Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry. 2016 ; 87 : 1270-2.
PubMed
41) Wilke C, Bender F, Hayer SN, et al. Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias : a pilot study. J Neurol. 2018 ; 265 : 1618-24.
 
42) Mitsui J, Matsukawa T, Yasuda T, et al. Plasma coenzyme Q10 levels in patients with multiple system atrophy. JAMA Neurol. 2016 ; 73 : 977-80.
PubMed
43) Du J, Wang T, Huang P, et al. Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy. 2018, Parkinsonism Relat Disord.
PubMed
44) Cardo LF, Coto E, de Mena L, et al. Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. J Neurol. 2013 ; 260 : 1420-2.
PubMed
45) Khoo SK, Petillo D, Kang UJ, et al. Plasma-based circulating MicroRNA biomarkers for Parkinson's disease. J Parkinsons Dis. 2012 ; 2 : 321-31.
PubMed
46) Li N, Pan X, Zhang J, et al. Plasma levels of miR-137 and miR-124 are associated with Parkinson's disease but not with Parkinson's disease with depression. Neurol Sci. 2017 ; 38 : 761-7.
 
47) Burgos K, Malenica I, Metpally R, et al. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PLoS One. 2014 ; 9 : e94839.
PubMed
48) Ding H, Huang Z, Chen M, et al. Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease. Parkinsonism Relat Disord. 2016 ; 22 : 68-73.
PubMed
49) Vallelunga A, Ragusa M, Di Mauro S, et al. Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and multiple system atrophy. Front Cell Neurosci. 2014 ; 8 : 156.
PubMed
50) Margis R, Margis R, Rieder CR. Identification of blood microRNAs associated to Parkinsonis disease. J Biotechnol. 2011 ; 152 : 96-101.
 
51) Serafin A, Foco L, Zanigni S, et al. Overexpression of blood microRNAs 103a, 30b, and 29a in L-dopa-treated patients with PD. Neurology. 2015 ; 84 : 645-53.
 
P.47 掲載の参考文献
1) Altman J, Das GD. Autoradiographic and histological avidence of postnatal neurogenesis in rats. J Comp Neurol. 1965 ; 124 : 319-35.
 
2) van Praag H, Schinder AF, Christie BR, et al. Functional neurogenesis in the adult hippocampus. Nature. 2002 ; 415 : 1030-4.
PubMed
3) Ming G li, Song H. Adult neurogenesis in the mammalian brain : significant answers and significant questions. Neuron. 2011 ; 70 : 687-702.
 
4) Sakamoto M, Imayoshi I, Ohtsuka T, et al. Continuous neurogenesis in the adult forebrain is required for innate olfactory responses. Proc Natl Acad Sci USA. 2011 ; 108 : 8479-84.
PubMed
5) Muthusamy N, Zhang X, Johnson CA, et al. Developmentally defined forebrain circuits regulate appetitive and aversive olfactory learning. Nat Publ Gr. doi : 10.1038/nn.2016 ; 4452.
 
6) Clelland CD, Choi M, Romberg C, et al. A functional role for adult hippocampal neurogenesis in spatial pattern separation. Science. 2009 ; 325 : 210-3.
PubMed
7) Anacker C, Luna VM, Stevens GS, et al. By inhibiting the ventral dentate gyrus. Nature. 2018 ; doi : 10.1038/s41586-018-0262-4.
 
8) Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998 ; 4 : 1313-7.
PubMed
9) Ernst A, Alkass K, Bernard S, et al. Neurogenesis in the striatum of the adult human brain. Cell. 2014 ; 156 : 1072-83.
PubMed
10) Sorrells SF, Paredes MF, Cebrian-Silla A, et al. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature. 2018 ; 555 : 377-81.
PubMed
11) Boldrini M, Fulmore CA, Tartt AN, et al. Short article human hippocampal neurogenesis persists throughout aging. Cell Stem Cell. 2018 ; 589-99.
 
12) Kempermann G, Gage FH, Aigner L, et al. Human adult neurogenesis : Evidence and remaining questions. Cell Stem Cell. 2018 ; 0 : 1-6.
 
13) Llorens-Bobadilla E, Zhao S, Baser A, et al. Single-cell transcriptomics reveals a population of dormant neural stem cells that become activated upon brain injury. Cell Stem Cell. 2015 ; 17 : 329-40.
PubMed
14) Dulken BW, Leeman DS, Phane S, et al. Single-cell transcriptomic analysis defines heterogeneity and transcriptional dynamics in the adult neural stem cell lineage. Cell Rep. 2017 ; 18 : 777-90.
 
15) Shin J, Berg DA, Zhu Y, et al. Single-cell RNA-Seq with waterfall reveals molecular cascades underlying adult neurogenesis. Cell Stem Cell. 2015 ; 17 : 360-72.
PubMed
16) Artegiani B, Lyubimova A, Muraro M, et al. A single-cell RNA sequencing study reveals cellular and molecular dynamics of the hippocampal neurogenic niche. Cell Rep. 2017 ; 21 : 3271-84.
 
17) Bond AM, Ming GL, Song H. Adult mammalian neural stem cells and neurogenesis : Five decades later. Cell Stem Cell. 2015 ; 17 : 385-95.
PubMed
18) Miller FD, Gauthier-Fisher A. Home at last : Neural stem cell niches defined. Cell Stem Cell. 2009 ; 4 : 507-10.
PubMed
19) Song J, Zhong C, Bonaguidi MA, et al. Neuronal circuitry mechanism regulating adult quiescent neural stem-cell fate decision. Nature. 2012 ; 489 : 150-4.
 
20) Bao H, Asrican B, Li W, et al. Long-range GABAergic inputs regulate neural stem cell quiescence and control adult hippocampal neurogenesis. Cell Stem Cell. 2017 ; 21 : 604-17.e5.
 
21) Yeh CY, Asrican B, Moss J, et al. Mossy cells control adult neural stem cell quiescence and maintenance through a dynamic balance between direct and indirect pathways. Neuron. 2018 ; 1-18.
 
22) Paul A, Paul A, Chaker Z, et al. Hypothalamic regulation of regionally distinct adult neural stem cells and neurogenesis. Science. 2017 ; 3839 : 1-8.
 
23) Kerever A, Schnack J, Vellinga D, et al. Novel extracellular matrix structures in the neural stem cell niche capture the neurogenic factor fibroblast growth factor 2 from the extracellular milieu. Stem Cells. 2007 ; 25 : 2146-57.
PubMed
24) Nascimento MA, Sorokin L, Coelho-Sampaio T. Fractone bulbs derive from ependymal cells and their laminin composition influence the stem cell niche in the subventricular zone. Journal of Neuroscience. 2018 ; 3064-17.
 
25) Mercier F, Cho-Kwon Y, Kodama R. Meningeal/vascular alterations and loss of extracellular matrix in the neurogenic zone of adult BTBR T?tf/J mice, animal model for autism. Neurosci Lett. 2011 ; 498 : 173-8.
PubMed
26) Campos-Ordonez T, Herranz-Perez V, Chaichana KL, et al. Long-term hydrocephalus alters the cytoarchitecture of the adult subventricular zone. Exp Neurol. 2014 ; 261 : 236-44.
PubMed
27) Merkle FT, Tramontin AD, Garcia-Verdugo JM, et al. Radial glia give rise to adult neural stem cells in the subventricular zone. Proc Natl Acad Sci USA. 2004 ; 101 : 17528-32.
PubMed
28) Furutachi S, Matsumoto A, Nakayama KI, et al. p57 controls adult neural stem cell quiescence and modulates the pace of lifelong neurogenesis. EMBO J. 2013 ; 32 : 970-81.
PubMed
29) Furutachi S, Miya H, Watanabe T, et al. Slowly dividing neural progenitors are an embryonic origin of adult neural stem cells. Nat Neurosci. 2015 ; 18 : 657-65.
PubMed
30) Fuentealba LC, Rompani SB, Parraguez JI, et al. Embryonic origin of postnatal neural stem cells. Cell. 2015 ; 161 : 1644-55.
PubMed
P.54 掲載の参考文献
1) Soderlund TA, Dickson JC, Prvulovich E, et al. Value of semiquantitative analysis for clinical reporting of 123I-2-β-carbomethoxy-3β- (4-iodophenyl) -N- (3-fluoropropyl) nortropane SPECT studies. J Nucl Med. 2013 ; 54 : 714-22.
 
2) Lavalaye J, Booij J, Reneman L, et al. Effect of age and gender on dopamine transporter imaging with [123I] FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000 ; 27 : 867-9.
PubMed
3) Varrone A, Dickson JC, Tossici-Bolt L, et al. European multicentre database of healthy controls for [123I] FPCIT SPECT (ENC-DAT) : age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013 ; 40 : 213-27.
PubMed
4) Albert NL, Unterrainer M, Diemling M, et al. Implementation of the European multicentre database of healthy controls for [(123) I] FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. Eur J Nucl Med Mol Imaging. 2016 ; 43 : 1315-22.
PubMed
5) Matsuda H, Murata M, Mukai Y, et al. Japanese multicenter database of healthy controls for [123I] FP-CIT SPECT. Eur J Nucl Med Mol Imaging. 2018 ; 45 : 1405-16.
PubMed
6) McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology. 2017 ; 89 : 88-100.
PubMed
7) Walker Z, Costa DC, Walker RW, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002 ; 73 : 134-40.
PubMed
8) Tossici-Bolt L, Hoffmann SM, Kemp PM, et al. Quantification of [123I] FP-CIT SPECT brain images : an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006 ; 33 : 1491-9.
PubMed
9) Tossici-Bolt L, Dickson JC, Sera T, et al. Calibration of gamma camera systems for a multicentre European 123I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging. 2011 ; 38 : 1529-40.
PubMed
10) Yokoyama K, Imabayashi E, Sumida K, et al. Computed-tomography-guided anatomic standardization for quantitative assessment of dopamine transporter SPECT. Eur J Nucl Med Mol Imaging. 2017 ; 44 : 366-72.
PubMed
P.63 掲載の参考文献
1) 青木茂樹, 阿部修, 増谷佳孝, 編著. 新版これでわかる拡散MRI : 東京 : 学研メディカル秀潤社 ; 2006.
 
2) 荒木力. 拡散MRI-ブラウン運動. 拡散テンソルからq空間へ, 東京 : 学研メディカル秀潤社 ; 2006.
 
3) Barkhof F. MRI in multiple sclerosis : correlation with expanded disability status scale (EDSS). Mult Scler. 1999 ; 5 : 283-6.
PubMed
4) Callaghan PT, Coy A, Macgowan D, et al. Diffraction-like effects in nmr diffusion studies of fluids in porous solids. Nature. 1991 ; 351 : 467-9.
 
5) 藤吉兼浩, 疋島啓吾, 岡野栄之, 他. 拡散テンソルイメージングの有用性・中枢伝導路の画像. 特集 脊椎脊髄の科学-基礎と臨床の進歩. 脊椎脊髄ジャーナル. 2014 ; 27 : 319-27.
 
6) 藤吉兼浩, 疋島啓吾, 中原仁, 他. q-space imagingを用いたニューロイメージング. 特集 脊椎・脊髄外傷診療の最前線. 臨床雑誌整形外科. 2016 ; 67 : 712-8.
 
7) 藤吉兼浩, 疋島啓吾, 中原仁, 他. q-Space imagingによる髄鞘イメージングの開発. 特集 脊椎脊髄イメージングの進歩と話題の疾患. 脊椎脊髄ジャーナル. 2016 ; 29 : 861-9.
 
8) Fujiyoshi K, Hikisima K, Nakahara J, et al. Application of q-Space diffusion MRI for the visualization of white matter. J Neurosci. 2016 ; 36 : 2796-808.
 
9) Fujiyoshi K, Konomi T, Yamada M, et al. Diffusion tensor imaging and tractography of the spinal cord : from experimental studies to clinical application. Exp Neurol. 2013 ; 242 : 74-82.
PubMed
10) Fujiyoshi K, Yamada M, Nakamura M, et al. In vivo Tracing of neural tracts in the intact and injured spinal cord of marmosets by diffusion tensor tractography. J Neurosci. 2007 ; 27 : 11991-8.
PubMed
11) Uchida K, Nakamura M, Ozawa H, et al. Editors. Sptinger. Neuroprotection and Regeneration of the spinal cord.
 
12) Tuch DS, Reese TG, Wiegell MR, et al. Diffusion MRI of complex neural architecture. Neuron. 2003 ; 40 : 885-95.
PubMed
13) 藤吉兼浩, 畑純一, 疋島啓吾, 他. 脊髄における拡散MRIの進歩-拡散テンソルトラクトグラフィからq-Space imagingへ-. 脊椎・脊髄疾患のニューロサイエンス-神経所見の診かたから再生医療まで. 脊椎脊髄ジャーナル. 整形災害外科2017年臨時増刊号. 2012.
 
14) Tanikawa M, Nakahara J, Hata J, et al. q-Space Myelin Map imaging for longitudinal analysis of demyelination and remyelination in multiple sclerosis patients treated with fingolimod : A preliminary study. J Neurol Sci. 2017 ; 373 : 352-7.
PubMed

II. 本年の動向

P.70 掲載の参考文献
1) Gitler AD, Tsuiji H. There has been an awakening : Emerging mechanisms of C9orf72 mutations in FTD/ALS. Brain Res. 2016 ; 1647 : 19-29.
 
2) Kenna KP, van Doormaal PT, Dekker AM, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet. 2016 ; 48 : 1037-42.
PubMed
3) Smith BN, Topp SD, Fallini C, et al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci Transl Med. 2017 ; 9 : 388.
PubMed
4) Nicolas A, Kenna KP, Renton AE, et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018 ; 97 : 1268-83.
PubMed
5) Sances S, Bruijn LI, Chandran S, et al. Modeling ALS with motor neurons derived from human induced pluripotent stem cells. Nat Neurosci. 2016 ; 19 : 542-53.
 
6) Kiskinis E, Kralj JM, Zou P, et al. All-optical electrophysiology for high-throughput functional characterization of a human iPSC-derived motor neuron model of ALS. Stem Cell Reports. 2018 ; 10 : 1991-2004.
PubMed
7) Imamura K, Izumi Y, Watanabe A, et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 2017 ; 9 : 391.
PubMed
8) Egawa N, Kitaoka S, Tsukita K, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med. 2012 ; 4 : 145ra104.
PubMed
9) Imaizumi K, Sone T, Ibata K, et al. Controlling the regional identity of hpsc-derived neurons to uncover neuronal subtype specificity of neurological disease phenotypes. Stem Cell Reports. 2015 ; 5 : 1010-22.
PubMed
10) Ichiyanagi N, Fujimori K, Yano M, et al. Establishment of In vitro FUS-associated familial amyotrophic lateral sclerosis model using human induced pluripotent stem cells. Stem Cell Reports. 2016 ; 6 : 496-510.
PubMed
11) Imaizumi K, Fujimori K, Ishii S, et al. Rostrocaudal areal patterning of human psc-derived cortical neurons by FGF8 signaling. eNeuro. 2018 ; 5 : 2.
PubMed
12) Fujimori K, Ishikawa M, Otomo A, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med. 2018.
PubMed
13) Kramer NJ, Haney MS, Morgens DW, et al. CRISPRCas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity. Nat Genet. 2018 ; 50 : 603-12.
PubMed
14) Chai N, Gitler AD. Yeast screen for modifiers of C9orf72 poly (glycine-arginine) dipeptide repeat toxicity. FEMS Yeast Res. 2018 ; 18 : 4.
PubMed
15) Corrionero A, Horvitz HR. A C9orf72 ALS/FTD Ortholog acts in endolysosomal degradation and lysosomal homeostasis. Curr Biol. 2018 ; 28 : 1522-35.
PubMed
16) Xu W, Xu J. C9orf72 dipeptide repeats cause selective neurodegeneration and cell-autonomous excitotoxicity in drosophila glutamatergic neurons. J Neurosci. 2018 ; 38 : 7741-52.
 
17) Yuva-Aydemir Y, Almeida S, Gao FB. Insights into C9ORF72-Related ALS/FTD from drosophila and iPSC models. Trends Neurosci. 2018 ; 41 : 457-69.
PubMed
18) Bakthavachalu B, Huelsmeier J, Sudhakaran IP, et al. RNP-Granule assembly via ataxin-2 disordered domains is required for long-term memory and neurodegeneration. Neuron. 2018 ; 98 : 754-66.
PubMed
19) Morrice JR, Gregory-Evans CY, Shaw CA. Modeling environmentally-induced motor neuron degeneration in zebrafish. Sci Rep. 2018 ; 8 : 4890.
PubMed
20) Swinnen B, Bento-Abreu A, Gendron TF, et al. A zebrafish model for C9orf72 ALS reveals RNA toxicity as a pathogenic mechanism. Acta Neuropathol. 2018 ; 135 : 427-43.
PubMed
21) Becker LA, Huang B, Bieri G, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017 ; 544 : 367-71.
PubMed
22) Chen S, Sayana P, Zhang X, et al. Genetics of amyotrophic lateral sclerosis : an update. Mol Neurodegener. 2013 ; 8 : 28.
PubMed
23) Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS : from genes to mechanism. Nature. 2016 ; 539 : 197-206.
PubMed
24) Kato M, Han TW, Xie S, et al. Cell-free formation of RNA granules : low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012 ; 149 : 753-67.
PubMed
25) Lin Y, Protter DS, Rosen MK, et al. Formation and maturation of phase-separated liquid droplets by RNA-binding proteins. Mol Cell. 2015 ; 60 : 208-19.
PubMed
26) Mackenzie IR, Nicholson AM, Sarkar M, et al. TIA1 Mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. Neuron. 2017 ; 95 : 808-16.
PubMed
27) Yoshizawa T, Ali R, Jiou J, et al. Nuclear import receptor inhibits phase separation of FUS through binding to multiple sites. Cell. 2018 ; 173 : 693-705.
PubMed
28) Molliex A, Temirov J, Lee J, et al. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015 ; 163 : 123-33.
PubMed
29) Patel A, Lee HO, Jawerth L, et al. A liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation. Cell. 2015 ; 162 : 1066-77.
PubMed
30) Murray DT, Kato M, Lin Y, et al. Structure of FUS protein fibrils and its relevance to self-assembly and phase separation of low-complexity domains. Cell. 2017 ; 171 : 615-27.
PubMed
31) Monahan Z, Ryan VH, Janke AM, et al. Phosphorylation of the FUS low-complexity domain disrupts phase separation, aggregation, and toxicity. EMBO J. 2017 ; 36 : 2951-67.
PubMed
32) Wainger BJ, Kiskinis E, Mellin C, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014 ; 7 : 1-11.
PubMed
33) 米国国立医学図書館 (clinicaltrials.gov) ホームページ <https://clinicaltrials.gov/ct2/show/NCT02450552>
 
34) 米国ALS協会ホームページ <http://www.alsa.org/news/media/press-releases/trial-collaboration.html>
 
35) Dormann D, Haass C. TDP-43 and FUS : a nuclear affair. Trends Neurosci. 2011 ; 34 : 339-48.
 
P.80 掲載の参考文献
1) Dalmau J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse : The 2016 Cotzias Lecture. Neurology. 2016 ; 87 : 2471-82.
PubMed
2) Graus F, Titulaer JM, Balu R, et al. Clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 ; 15 : 391-404.
 
3) Rosenfeld MR, Titulaer MJ, Dalmau J. Paraneoplastic syndromes and autoimmune encephalitis : Five new things. Neurol Clin Pract. 2012 ; 2 : 215-23.
PubMed
4) Mitoma H, Manto M, Hampe CS. Pathogenic roles of glutamic acid decarboxylase 65 autoantibodies in cerebellar ataxias. J Immunol Res. 2017 ; 2017 : 2913297.
PubMed
5) Kishitani T, Matsunaga A, Ikawa M, et al. Limbic encephalitis associated with anti-NH2-terminal of α-enolase antibodies : A clinical subtype of Hashimoto encephalopathy. Medicine (Baltimore). 2017 ; 96 : e6181.
 
6) Kaneko J, Kanazawa N, Tominaga N, et al. Practical issues in measuring autoantibodies to neuronal cell-surface antigens in autoimmune neurological disorders : 190 cases. J Neurol Sci. 2018 ; 390 ; 26-32.
 
7) Chatzikonstantinou A, Gass A, Forster A, et al. Features of acute DWI abnormalities related to status epilepticus. Epilepsy Res. 2011 ; 97 : 45-51.
PubMed
8) Chevret L, Husson B, Nguefack S, et al. Prolonged refractory status epilepticus with early and persistent restricted hippocampal signal MRI abnormality. J Neurol. 2008 ; 255 : 112-6.
PubMed
9) Meletti S, Slonkova J, Mareckova I, et al. Claustrum damage and refractory status epilepticus following febrile illness. Neurology. 2015 ; 85 : 1224-32.
PubMed
10) Mikaeloff Y, Jambaque I, Hertz-Pannier L, et al. Devastating epileptic encephalopathy in school-aged children (DESC) : a pseudo encephalitis. Epilepsy Res. 2006 ; 69 : 67-79.
PubMed
11) Van Baalen A, Hausler M, Boor R, et al. Febrile infection-related epilepsy syndrome (FIRES) : a nonencephalitic encephalopathy in childhood. Epilepsia. 2010 ; 51 : 1323-8.
PubMed
12) Sakuma H, Awaya Y, Shiomi M, et al. Acute encephalitis with refractory, repetitive partial seizures (AERRPS) : a peculiar form of childhood encephalitis. Acta Neurol Scand. 2010 ; 121 : 251-6.
PubMed
13) Wilder-Smith EP, Lim EC, Teoh HL, et al. The NORSE (new-onset refractory status epilepticus) syndrome : defining a disease entity. Ann Acad Med Singapore. 2005 ; 34 : 417-20.
PubMed
14) Nabbout R, Vezzani A, Dulac O, et al. Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurol. 2011 ; 10 : 99-108.
PubMed
15) Illingworth MA, Hanrahan D, Anderson CE, et al. Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-age children (FIRES). Dev Med Child Neurol. 2011 ; 53 : 1053-7.
 
16) Hainsworth JB, Shishido A, Theeler BJ, et al. Treatment responsive GABA (B) -receptor limbic encephalitis presenting as new-onset super-refractory status epilepticus (NORSE) in a deployed U.S. soldier. Epileptic Disord. 2014 ; 16 : 486-93.
 
17) Gaspard N, Foreman BP, Alvarez V, et al. New-onset refractory status epilepticus : etiology, clinical features, and outcome. Neurology. 2015 ; 85 : 1604-13.
PubMed
18) Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018 ; 59 : 739-44.
 
19) Gaspard N, Hirsch LJ, Sculier C, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES) : State of the art and perspectives. Epilepsia. 2018 ; 59 : 745-52.
PubMed
20) Iizuka T, Kanazawa N, Kaneko J, et al. Cryptogenic NORSE : its distinctive clinical features and response to immunotherapy. Neurol Neuroimmunol Neuroinflamm. 2017 ; 4 : e396.
PubMed
21) Specchio N, Claps D, Vigevano F, et al. Refractory focal epilepsy following acute encephalopathy with inflammation-mediated status epilepticus. Seizure. 2011 ; 20 : 824-5.
PubMed
22) Gall CR, Jumma O, Mohanraj R. Five cases of new onset refractory status epilepticus (NORSE) syndrome : outcomes with early immunotherapy. Seizure. 2013 ; 22 : 217-20.
PubMed
23) Kaneko J, Iizuka T, Asari H, et al. Retrospective review of 6 patients with new-onset refractory status epilepticus (NORSE) syndrome : early intervention with intravenous cyclophosphamide may improve outcome. Neurology. 2013 ; 80 : P07. 171. (Abstract).
 
24) Iizuka T, Kaneko J, Tominaga N, et al. Association of progressive cerebellar atrophy with long-term outcome in patients with anti-NMDA receptor encephalitis. JAMA Neurol. 2016 ; 73 : 706-13.
PubMed
25) Tominaga N, Kanazawa N, Kaneko A, et al. Prodromal headache in anti-NMDAR encephalitis : epiphenomenon of NMDAR autoimmunity. Brain and Behavior (in press).
 
26) Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis : an observational cohort study. Lancet Neurol. 2013 ; 12 : 157-65.
PubMed
27) Kaneko A, Kaneko J, Tominaga N, et al. Pitfalls in clinical diagnosis of anti-NMDA receptor encephalitis. J Neurol. 2018 ; 265 : 586-96.
PubMed
28) Viaccoz A, Desestret V, Ducray F, et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology. Neurology. 2014 ; 82 : 556-63.
PubMed
29) Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis : a retrospective study. Lancet Neurol. 2014 ; 13 : 167-77.
PubMed
30) Lennox BR, Palmer-Cooper EC, Pollak T. Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis : a case-control study. Lancet Psychiatry. 2017 ; 4 : 42-8.
PubMed
31) Doss S, Wandinger KP, Hyman BT. High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. Ann Clin Transl Neurol. 2014 ; 1 : 822-32.
PubMed
32) Hara M, Martinez-Hernandez E, Arino H, et al. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology. 2018 ; 90 : e1386-e94.
PubMed
33) Titulaer MJ, Hoftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014 ; 75 : 411-28.
PubMed
34) Armangue T, Moris G, Cantarin-Extremera V, et al. Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology. 2015 ; 85 : 1736-43.
PubMed
35) Armangue T, Martinez-Hernandez E, Graus F, et al. Brain autoimmunity following HSV encephalitis : 100 cases. Neurology. 2017 ; 88 : Supplement S30.004 (abstr).
 
36) Lang B, Makuch M, Moloney, et al. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. J Neurol Neurosurg Psychiatry. 2017 ; 88 : 353-61.
PubMed
37) Patterson KR, Dalmau J, Lancaster E. Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia. Ann Neurol. 2018 ; 83 : 40-51.
PubMed
38) Spatola M, Petit-Pedrol M, Simabukuro MM, et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology. 2017 ; 88 : 1012-20.
PubMed
39) Hara M, Arino H, Petit-Pedrol M, et al. DPPX antibody-associated encephalitis : Main syndrome and antibody effects. Neurology. 2017 ; 88 : 1340-8.
PubMed
40) Spatola M, Sabater L, Planaguma J, et al. Encephalitis with mGluR5 antibodies : Symptoms and antibody effects. Neurology. 2018 ; 90 : e1964-72.
PubMed
P.88 掲載の参考文献
1) Ueda A, Ueda M, Nagatoshi A, et al. Genotypic and phenotypic spectrum of CADASIL in Japan : the experience at a referral center in Kumamoto University from 1997 to 2014. J Neurol. 2015 ; 262 : 1828-36.
 
2) Davous P. CADASIL : a review with proposed diagnostic criteria. Eur J Neurol. 1998 ; 5 : 219-33.
PubMed
3) Mizuta I, Watanabe-Hosomi A, Koizumi T, et al. New diagnostic criteria for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukocencephalopathy in Japan. J Neurol Sci. 2017 ; 381 : 62-7.
PubMed
4) 水野敏樹. CADASILの診断, 病態, 治療の進歩. 臨床神経. 2012 ; 52 : 303-13.
 
5) Fukutake T, Hirayama K. Familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension. Eur Neurol. 1995 ; 35 : 69-79.
 
6) Hara K, Shiga A, Fukutake T, et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med. 2009 ; 360 : 1729-39.
PubMed
7) Nozaki H, Sekine Y, Fukutake T, et al. Characteristic features and progression of abnormalities on MRI for CARASIL. Neurology. 2015 ; 85 : 459-63.
PubMed
8) Nozaki H, Kato T, Nihonmatsu M, et al. Distinct molecular mechanisms of HTRA1 mutants in manifesting heterozygotes with CARASIL. Neurology. 2016 ; 86 : 1964-74.
PubMed
9) Konno T, Yoshida K, Mizuno T, et al. Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation. Eur J Neurol. 2017 ; 24 : 37-45.
PubMed
10) Konno T, Broderick DF, Mezaki N, et al. Diagnostic value of brain calcifications in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. AJNR Am J Neuroradiol. 2017 ; 38 : 77-83.
PubMed
11) Konno T, Yoshida K, Mizuta I, et al. Diagnostic criteria for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia due to CSF1R mutation. Eur J Neurol. 2018 ; 25 : 142-7.
PubMed
12) Yoshida T, Sasaki M, Yoshida M, et al. Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis. J Neurol. 2011 ; 258 : 1998-2008.
PubMed
13) Finnsson J, Sundblom J, Dahl N, et al. LMNB1-related autosomal-dominant leukodystrophy : Clinical and radiological course. Ann Neurol. 2015 ; 78 : 412-25.
PubMed
14) Sundblom J, Melberg A, Kalimo H, et al. MR imaging characteristics and neuropathology of the spinal cord in adult-onset autosomal dominant leukodystrophy with autonomic symptoms. AJNR Am J Neuroradiol. 2009 ; 30 : 328-35.
PubMed
15) Sone J, Mori K, Inagaki T, et al. Clinicopathological features of adult-onset neuronal intranuclear inclusion disease. Brain. 2016 ; 139 (Pt 12) : 3170-86.
 
16) Sone J, Kitagawa N, Sugawara E, et al. Neuronal intranuclear inclusion disease cases with leukoencephalopathy diagnosed via skin biopsy. J Neurol Neurosurg Psychiatry. 2014 ; 85 : 354-6.
PubMed
17) Lynch DS, Zhang WJ, Lakshmanan R, et al. Analysis of mutations in AARS2 in a series of CSF1R-Negative Patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. JAMA Neurol. 2016 ; 73 : 1433-9.
 
18) Dallabona C, Diodato D, Kevelam SH, et al. Novel (ovario) leukodystrophy related to AARS2 mutations. Neurology. 2014 ; 82 : 2063-71.
PubMed
P.95 掲載の参考文献
1) WHO. World Health Organization. Manual for immunization program managers on activities related to polio eradication. 1989.
 
2) Quadros CAD, Andrus JK, Olive JM, et al. Eradication of poliomyelitis : Progress in the Americas. Pediatr Infect Dis J. 1991 ; 10 : 222-9.
 
3) WHO. World Health Assembly. Global eradication of polio myelitis by the year 2000. 1988 (Resolution WHA41, 28).
 
4) Midgley CM, Watson JT, Nix WA, et al. Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014) : a descriptive epidemiological investigation. Lancet Respir Med. 2015 ; 3 : 879-87.
PubMed
5) Messacar K, Schreiner TL, Maloney JA, et al. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet. 2015 ; 385 : 1662-71.
PubMed
6) Nelson GR, Bonkowsky JL, Doll E, et al. Recognition and management of acute flaccid myelitis in children. Pediatric Neurol. 2016 ; 55 : 17-21.
PubMed
7) Van Haren K, Ayscue P, Waubant E, et al. Acute flaccid myelitis of unknown etiology in California, 2012-2015. JAMA. 2015 ; 314 : 2663-71.
PubMed
8) Sejvar JJ, Lopez AS, Cortese MM, et al. Acute flaccid myelitis in the United States, August-december 2014 : Results of nationwide surveillance. Clin Infect Dis. 2016 ; 63 : 737-45.
PubMed
9) Greninger AL, Naccache SN, Messacar K, et al. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14) : a retrospective cohort study. Lancet Infect Dis. 2015 ; 15 : 671-82.
PubMed
10) Centers for Disease Control and Prevention. Acute flaccid myelitis : interim considerations for clinical management. 2014. <https://www.cdc.gov/acute-flaccid-myelitis/downloads/Interim-Considerations-AFM.pdf> Accessed August 31, 2018.
 
11) Chong PF, Kira R, Mori H, et al. Clinical features of acute flaccid myelitis temporally associated with an enterovirus D68 outbreak : Results of a nationwide survey of acute flaccid paralysis in Japan, August-December 2015. Clin Infect Dis. 2018 ; 66 : 653-64.
PubMed
12) Knoester M, Helfferich J, Poelman R, et al. Twenty-nine cases of enterovirus-D68 associated acute flaccid myelitis in Europe 2016 ; a case series and epidemiologic overview. Pediatr Infect Dis J. 2018 Sep 18. doi:10.1097/INF.0000000000002188. [Epub ahead of print]
 
13) Ruggieri V, Paz MI, Peretti MG, et al. Enterovirus D68 infection in a cluster of children with acute flaccid myelitis, Buenos aires, Argentina, 2016. Eur J Paediatr Neurol. 2017 ; 21 : 884-90.
 
14) Council of State and Territorial Epidemiologists. Standardized case definition for acute flaccid myelitis, 2017. <https://c.ymcdn.com/sites/www.cste.org/resource/resmgr/2017PS/2017PSFinal/17-ID-01.pdf> Accessed August 31, 2018.
 
15) Messacar K, Schreiner TL, Van Haren K, et al. Acute flaccid myelitis : A clinical review of US cases 2012-2015. Ann Neurol. 2016 ; 80 : 326-38.
PubMed
16) Maloney JA, Mirsky DM, Messacar K, et al. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. AJNR Am J Neuroradiol. 2015 ; 36 : 245-50.
PubMed
17) Hovden IA, Pfeiffer HC. Electrodiagnostic findings in acute flaccid myelitis related to enterovirus D68. Muscle Nerve. 2015 ; 52 : 909-10.
PubMed
18) Hixon AM, Clarke P, Tyler KL. Evaluating treatment efficacy in a mouse model of enterovirus D68-associated paralytic myelitis. J Infect Dis. 2017 ; 216 : 1245-53.
 
19) Martin JA, Messacar K, Yang ML, et al. Outcomes of Colorado children with acute flaccid myelitis at 1 year. Neurology. 2017 ; 89 : 129-37.
PubMed
20) Holm-Hansen CC, Midgley SE, Fischer TK. Global emergence of enterovirus D68 : a systematic review. Lancet Infect Dis. 2016 ; 16 : e64-e75.
PubMed
21) Ikeda T, Mizuta K, Abiko C, et al. Acute respiratory infections due to enterovirus 68 in Yamagata, Japan between 2005 and 2010. Microbiol Immunol. 2012 ; 56 : 139-43.
PubMed
22) Imamura T, Oshitani H. Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections. Rev Med Virol. 2015 ; 25 : 102-14.
PubMed
23) Kaida A, Iritani N, Yamamoto SP, et al. Distinct genetic clades of enterovirus D68 detected in 2010, 2013, and 2015 in Osaka City, Japan. PLoS One. 2017 ; 12 : e0184335.
PubMed
24) Korematsu S, Nagashima K, Sato Y, et al. 'Spike' in acute asthma exacerbations during enterovirus D68 epidemic in Japan : A nation-wide survey. Allergol Int. 2018 ; 67 : 55-60.
PubMed
25) Sun S, Gao F, Hu Y, et al. A cross-sectional seroepidemiology study of EV-D68 in China. Emerg Microbes Infect. 2018 ; 7 : 99.
 
26) Kimura K, Fukushima T, Katada N, et al. Adult case of acute flaccid paralysis with enterovirus D68 detected in the CSF. Neurol Clin Pract. 2017 ; 7 : 390-3.
PubMed
27) Bitnun A, Yeh EA. Acute flaccid paralysis and enteroviral infections. Curr Infect Dis Rep. 2018 ; 20 : 34.
PubMed
28) Messacar K, Asturias EJ, Hixon AM, et al. Enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality. Lancet Infect Dis. 2018 ; 18 : e239-47.
PubMed
29) Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010 ; 10 : 778-90.
PubMed
30) Centers for Disease Control and Prevention. AFM Investigation. <https://www.cdc.gov/acute-flaccid-myelitis/afm-surveillance.html>. Assessed October 19, 2018.
 
31) 「エンテロウイルス等感染症を含む急性弛緩性麻痺・急性脳炎・脳症の原因究明に資する臨床疫学研究」研究班. 急性弛緩性麻痺を認める疾患のサーベイランス・診断・検査・治療に関する手引き. <https://www.niid.go.jp/niid/images/idsc/disease/AFP/AFP-guide.pdf> Accessed August 31, 2018.
 
P.104 掲載の参考文献
1) EuroCJDのホームぺージ. <https://www.eurocjd.ed.ac.uk/>
 
2) 米国NPDPSCのホームページ. <https://case.edu/medicine/pathology/divisions/prion-center/resourcesfor-professionals/tables-of-cases-examined/>
 
3) 厚生労働科学研究費補助金難治性疾患克服研究事業「プリオン病のサーベイランスと感染予防に関する調査研究班」. プリオン病のサーベイランス結果. 2018年3月27日.
 
4) Gambetti P, Dong Z, Yuan J, et al. A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol. 2008 ; 63 : 697-708.
 
5) Zo W-Q, Puot G, Xiao X, et al. Variably protease-sensitive prionopathy : A new sporadic disease of the prion protein. Ann Neurol. 2010 ; 68 : 162-72.
 
6) Peden AH, Sarode DP, Mulholland CR, et al. The prion protein protease sensitivity, stability and seeding activity in variably protease sensitive prionopathy brain tissue suggests molecular overlaps with sporadic Creutzfeldt-Jakob disease. Acta Neuropathol Commun. 2014 ; 2 : 152.
PubMed
7) Diack AB, Ritchie DL, Peden AH, et al. Variably protease-sensitive prionopathy, a unique prion variant with inefficient transmission properties. Emerg Infect Dis. 2014 ; 20 : 1969-79.
PubMed
8) Mead S, Reilly MM. A new prion disease : relationship with central and peripheral amyloidosis. Nat Rev Neurol. 2015 ; 11 : 90-7.
PubMed
9) Mead S, Gandhi S, Beck J, et al. A novel prion disease associated with diarrhea and autonomic neuropathy. N Engl J Med. 2013 ; 369 : 1904-14.
 
10) Matsumoto K, Ikeda Y, Liu W, et al. A novel familial prion disease causing pan-autonomic-sensory neuropathy and cognitive impairment. Eur J Neurol. 2013 ; 20 : e67-e9.
 
11) Nomura E, Harada T, Kurokawa K, et al. Creutzfeldt-Jakob disease associated with autonomic nervous system dysfunction in the early stage. Intern Med. 1997 ; 36 : 492-6.
PubMed
12) Honda H, Matsuzono K, Fushimi S, et al. C-Terminal-Deleted prion protein fragment is a major accumulated compoment of systemic PrP deposits in hereditary prion disease with a 2-Bp (CT) deletion in PRNP codon 178. J Neuropathol Exp Neurol. 2016 ; 75 : 1008-19.
 
13) プリオン病感染予防ガイドライン (2008年版).
 
14) Matsuzono K, Morihara R, Sato K, et al. Single photon emission computed tomography (SPECT) findings of a patient with a novel prion mutation. Intern Med. 2015 ; 54 : 79-82.
PubMed
15) 米国農務省 (USDA) ホームページ <https://www.aphis.usda.gov/aphis/ourfocus/animalealth/animal-diseaseinformation/sa_alternate_livestock/sa_cervid_health/sa_cwd/ct_cwd_index>
 
16) Kim TY, Shon HJ, Joo YS, et al. Additional cases of chromic wasting disease in imported deer in Korea. J Vet Med Sci. 2005 ; 67 : 753-9.
 
17) Stokstad E. Norway seeks to stamp out prion disease. Science. 2017 ; 356 : 12-3.
PubMed
18) 岩丸祥史. 平成29年度プリオン病のサーベイランスと政策に関する全国担当者会議「8. シカの慢性消耗病 (CWD) の拡大とその対策」. 東京 : 2018.
 
19) 食品安全委員会. 鹿慢性消耗性疾患 (CWD) ファクトシート <www.fsc.go.jp/fsciis/meetingMaterial/show/kai2017017pr1>
 
20) Marsh RF, Kincaid AE, Bessen RA, et al. Interspecies transmission of chronic wasting disease prions to squirrel monkeys (Saimiri sciureus). J Virol. 2005 ; 79 : 13794-6.
PubMed
21) Meade-White KD, Phillips K, Race B, et al. Chronic wasting disease agents in nonhuman primates. Emerg Infect Dis. 2014 ; 20 : 833-7.
PubMed
22) Wilson R, Plinston C, Hunter N, et al. Chronic Wasting Disease and Atypical forms of BSE and scrapie are not transmissible to mice expressing wild-type levels of human PrP. J Gen Virol. 2012 ; 93 : 1624-9.
 
23) Hamir AN, Cutlip RC, Miller JM, et al. Preliminary findings on the experimental transmission of chronic wasting disease agent of mule deer to cattle. J Vet Diagn Invest. 2001 ; 13 : 91-6.
 
24) Hamir AN, Kehrli ME Jr, Kunkle RA, et al. Experimental interspecies transmission studies of the transmissible spongiform encephalopathies to cattle : comparison to bovine spongiform encephalopathy in cattle. J Vet Disgn Invest. 2011 ; 23 : 407-20.
 
25) Czub S, et al. First evidence of intracranial and peroral transmission of Chronic Wasting Disease (CWD) into Cynomolgus macaques : a work in progress. CSTE/NASPHV WEBINAR, July 10 2017 <from PDF : https://www.cste2.org/Webinars/files/CWD_Slides_FINAL.pdf>
 
P.112 掲載の参考文献
1) Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995 ; 80 : 155-65.
PubMed
2) Lorson CL, Hahnen E, Androphy EJ, et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA. 1999 ; 96 : 6307-11.
PubMed
3) Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999 ; 8 : 1177-83.
PubMed
4) Kashima T, Rao N, Manley JL. An intronic element contributes to splicing repression in spinal muscular atrophy. Proc Natl Acad Sci USA. 2007 ; 104 : 3426-31.
PubMed
5) Wirth B, Brichta L, Schrank B, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006 ; 119 : 422-8.
PubMed
6) Kubo Y, Nishio H, Saito K. A new method for SMN1 and hybrid SMN gene analysis in spinal muscular atrophy using long-range PCR followed by sequencing. J Hum Genet. 2015 ; 60 : 233-9.
 
7) Hua Y, Vickers TA, Okunola HL, et al. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet. 2008 ; 82 : 834-48.
PubMed
8) Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010 ; 24 : 1634-44.
 
9) Finkel RS, Mercuri E, Darras BT, et al. ENDEAR Study Group. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017 ; 377 : 1723-32.
 
10) Mercuri E, Darras BT, Chiriboga CA, et al. CHERISH Study Group. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med. 2018 ; 378 : 625-35.
 
11) Otsuki N, Arakawa R, Kaneko K, et al. A new biomarker candidate for spinal muscular atrophy : identification of a peripheral blood cell population capable of monitoring the level of survival motor neuron protein. PLoS One. 2018 ; 13 : e0201764.
PubMed
P.121 掲載の参考文献
1) Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004 ; 350 : 552-9.
PubMed
2) Legendre C, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013 ; 368 : 2169-81.
PubMed
3) Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN) : a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017 ; 16 : 976-86.
PubMed
4) Thurman JM, Frazer-Abel A, Holers VM. The evolving landscape for complement therapeutics in rheumatic and autoimmune diseases. Arthritis Rheumatol. 2017 ; 69 : 2102-13.
PubMed
5) 慢性炎症性脱髄性多発根ニューロパチー，多巣性運動ニューロパチー診療ガイドライン作成委員会，編．慢性炎症性脱髄性多発根ニューロパチー，多巣性運動ニューロパチー診療ガイドライン 2013．東京 : 南江堂 ; 2013.
 
6) Susuki K, Baba H, Tohyama K, et al. Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia. 2007 ; 55 : 746-57.
PubMed
7) Susuki K, Rasband MN, Tohyama K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci. 2007 ; 27 : 3956-67.
PubMed
8) Greenshields KN, Halstead SK, Zitman FM, et al. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest. 2009 ; 3 : 595-610.
PubMed
9) Fitzpatrick AM, Mann CA, Barry S, et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011 ; 16 : 84-91.
PubMed
10) 本村政勝. 自己免疫性神経筋接合部疾患の病態と治療. 臨床神経学. 2011 ; 51 : 872-6.
 
11) Higuchi O, Hamuro J, Motomura M, et al. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011; 69 : 418-22.
PubMed
12) Liu A, Lin H, Liu Y. Correlation of C3 level with severity of generalized myasthenia gravis. Muscle Nerve. 2009 ; 40 : 801-8.
PubMed
13) Zhou Y, Gong B, Lin F. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol. 2007 ; 179 : 8562-7.
PubMed
14) Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013 ; 48 : 76-84.
PubMed
15) Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN) : a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017 ; 16 : 976-86.
PubMed
16) 藤原一男．視神経脊髄炎の病態と治療 疾患概念と診断基準．吉良潤一，編．最新アプローチ 多発性硬化症と視神経脊髄炎．東京 : 中山書店 ; 2012. p.304-13.
 
17) Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet. 2004 ; 364 : 2106-12.
PubMed
18) 宮本勝一．視神経脊髄炎（NMO）の病態 : 多発性硬化症（MS）の診断のすべて．診断と治療社．2012 ; 164-9.
 
19) Kuroda H, Fujihara K, Takano R, et al. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol. 2013 ; 254 : 178-82.
PubMed
20) Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders : an open-label pilot study. Lancet Neurol. 2013 ; 12 : 554-62.
PubMed
21) ギラン・バレー症候群，フィッシャー症候群診療ガイドライン作成委員会，編．ギラン・バレー症候群，フィッシャー症候群診療ガイドライン 2013, 東京 : 南江堂; 2013.
 
22) Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008 ; 131 : 1197-208.
 
23) Davidson AI, Halstead SK, Goodfellow JA, et al. Inhibition of complement in Guillain-Barre syndrome : the ICA-GBS study. J Peripher Nerv Syst. 2017 ; 22 : 4-12.
PubMed
24） Misawa S, Kuwabara S, Sato Y, et al. Safety and efficacy of eculizumab in Guillain-Barre syndrome : a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018 ; 17 : 519-29.
PubMed
25） Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014 ; 370 : 632-9.
PubMed
P.130 掲載の参考文献
1) Hamill R. Report of a case of melanosis of the brain, cord and meninges. J Nerv Ment Dis. 1908 ; 35 : 594.
 
2) Levy M, Turtzo C, Llinas RH. Superficial siderosis : a case report and review of the literature. Nat Clin Pract Neurol. 2007 ; 3 : 54-8 ; quiz 59.
PubMed
3) Fearnley JM, Stevens JM, Rudge P. Superficial siderosis of the central nervous system. Brain. 1995 ; 118 (Pt 4) : 1051-66.
 
4) 高尾昌樹. 厚生労働科学研究費補助金 難治性疾患克服研究事業 脳表ヘモシデリン沈着症の診断基準の構築と調査に関する研究班 平成23年度 総括・分担報告書. 2012.
 
5) 高尾昌樹. 厚生労働科学研究費補助金 難治性疾患克服研究事業 脳表ヘモシデリン沈着症の診断基準の構築と調査に関する研究班 平成23年度 総合研究報告書. 2012.
 
6) 高尾昌樹. 鉄と神経疾患 脳表ヘモシデリン沈着症とNeuroferritinopathyの神経病理. 臨床神経学. 2012 ; 52 : 959-61.
 
7) 高尾昌樹. 指定難病最前線 (Volume 65) 脳表ヘモジデリン沈着症 (古典型). 新薬と臨牀. 2018 ; 67 : 982-6.
 
8) 高尾昌樹, 美原盤, 吉田洋二. 臨床医のための神経病理 脳表ヘモシデリン沈着症. Clin Neurosci. 2013 ; 31 : 136-7.
 
9) Ohira M, Takao M. [Superficial Siderosis]. Brain Nerve. 2018 ; 70 : 1107-13.
PubMed
10) 難病情報センター. 脳表ヘモジデリン沈着症 (指定難病 122) [online]. <http://www.nanbyou.or.jp/entry/4811>. 2018.
 
11) Vernooij MW, Ikram MA, Hofman A, et al. Superficial siderosis in the general population. Neurology. 2009 ; 73 : 202-5.
PubMed
12) Shams S, Martola J, Charidimou A, et al. Cortical superficial siderosis : Prevalence and biomarker profile in a memory clinic population. Neurology. 2016 ; 87 : 1110-7.
 
13) Wilson D, Chatterjee F, Farmer SF, et al. Infratentorial superficial siderosis : Classification, diagnostic criteria, and rational investigation pathway. Ann Neurol. 2017 ; 81 : 333-43.
PubMed
14) Anderson NE, Sheffield S, Hope JK. Superficial siderosis of the central nervous system : a late complication of cerebellar tumors. Neurology. 1999 ; 52 : 163-9.
PubMed
15) Takao M, Murayama S, Yoshida Y, et al. Superficial siderosis associated with abundant tau and alpha-synuclein accumulation. BMJ Case Rep. 2011 ; 2011.
PubMed
16) Stabile A, Di Lazzaro V, Colosimo C, et al. Idiopathic infratentorial superficial siderosis of the central nervous system : case report and review of literature. Neurol Neurochir Pol. 2018 ; 52 : 102-6.
PubMed
17) Koeppen AH, Dickson AC, Chu RC, et al. The pathogenesis of superficial siderosis of the central nervous system. Ann Neurol. 1993 ; 34 : 646-53.
PubMed
18) Moulin S, Casolla B, Kuchcinski G, et al. Cortical superficial siderosis : A prospective observational cohort study. Neurology. 2018 ; 91 : e132-e8.
PubMed
19) Pichler M, Vemuri P, Rabinstein AA, et al. Prevalence and natural history of superficial siderosis : A population-based study. Stroke. 2017 ; 48 : 3210-4.
PubMed
20) Lummel N, Bernau C, Thon N, et al. Prevalence of superficial siderosis following singular, acute aneurysmal subarachnoid hemorrhage. Neuroradiology. 2015 ; 57 : 349-56.
PubMed
21) Kumar N. Beyond superficial siderosis : introducing "duropathies". Neurology. 2012 ; 78 : 1992-9.
PubMed
22) Kumar N, Miller GM, Piepgras DG, et al. A unifying hypothesis for a patient with superficial siderosis, low-pressure headache, intraspinal cyst, back pain, and prominent vascularity. J Neurosurg. 2010 ; 113 : 97-101.
PubMed
23) Arishima H, Higashino Y, Yamada S, et al. Spinal endoscopy combined with selective CT myelography for dural closure of the spinal dural defect with superficial siderosis : technical note. J Neurosurg Spine. 2018 ; 28 : 96-102.
PubMed
24) Kumar N, Lindell EP, Wilden JA, et al. Role of dynamic CT myelography in identifying the etiology of superficial siderosis. Neurology. 2005 ; 65 : 486-8.
PubMed
25) Koeppen AH, Michael SC, Li D, et al. The pathology of superficial siderosis of the central nervous system. Acta Neuropathol. 2008 ; 116 : 371-82.
PubMed
26) Ikeda T, Noto D, Noguchi-Shinohara M, et al. CSF tau protein is a useful marker for effective treatment of superficial siderosis of the central nervous system : two case reports. Clin Neurol Neurosurg. 2010 ; 112 : 62-4.
PubMed
27) Kondziella D, Zetterberg H. Hyperphosphorylation of tau protein in superficial CNS siderosis. J Neurol Sci. 2008 ; 273 : 130-2.
PubMed
28) Revesz T, Earl CJ, Barnard RO. Superficial siderosis of the central nervous system presenting with longstanding deafness. J R Soc Med. 1988 ; 81 : 479-81.
PubMed
29) Kellermier H, Wang G, Wiley C. Iron localization in superficial siderosis of the central nervous system. Neuropathology. 2009 ; 29 : 187-95.
PubMed
30) Torii Y, Iritani S, Fujishiro H, et al. An autopsy case of cortical superficial siderosis with persistent abnormal behavior. Neuropathology. 2016 ; 36 : 544-50.
PubMed
31) Koeppen AH, Barron KD. Superficial siderosis of the central nervous system. A histological, histochemical and chemical study. J Neuropathol Exp Neurol. 1971 ; 30 : 448-69.
PubMed
32) Koeppen AH, Dentinger MP. Brain hemosiderin and superficial siderosis of the central nervous system. J Neuropathol Exp Neurol. 1988 ; 47 : 249-70.
PubMed
33) 豊島靖子, 柿田明美. 臨床医のための神経病理 脳表ヘモジデリン沈着症. Clinical Neuroscience. 2016 ; 34 : 956-7.
 
34) 豊島靖子, 高橋均. 鉄と神経疾患 : 脳表ヘモジデリン沈着症の病理組織学的所見. 神経内科. 2013 ; 79 : 482-90.
 
35) 長谷川章. 病理解剖マニュアル : 私の1例 脳表ヘモシデリン沈着症. 病理と臨床. 1998 ; 16 : 406-7.
 
36) Kondziella D, Lindelof M, Haziri D, et al. Diagnostic and therapeutic challenges in superficial CNS siderosis. Dan Med J. 2015 ; 62.
PubMed
37) Shih P, Yang BP, Batjer HH, et al. Surgical management of superficial siderosis. Spine J. 2009 ; 9 : e16-9.
 
38) Payer M, Sottas C, Bonvin C. Superficial siderosis of the central nervous system : secondary progression despite successful surgical treatment, mimicking amyotrophic lateral sclerosis. Case report and review. Acta Neurochir (Wien). 2010 ; 152 : 1411-6.
PubMed
39) 南里悠介, 薬師寺祐介, 雪竹基弘, 他. 止血剤の点滴および内服加療で改善をみとめた脳表ヘモジデリン沈着症の1例. 臨床神経学. 2013 ; 53 : 470-3.
 
40) 田中佑佳, 永田倫之, 秋山拓也, 他. 1年間無症候で経過した後, 急速に進行した特発性脳表ヘモジデリン沈着症の1例. 神経内科. 2015 ; 82 : 438-41.
 
41) Angstwurm K, Schielke E, Zimmer C, et al. Superficial siderosis of the central nervous system : response to steroid therapy. J Neurol. 2002 ; 249 : 1223-5.
PubMed
42) Levy M, Llinas RH. Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis. AJNR Am J Neuroradiol. 2011 ; 32 : E1-2.
PubMed
43) Levy M, Llinas R. Pilot safety trial of deferiprone in 10 subjects with superficial siderosis. Stroke. 2012 ; 43 : 120-4.
PubMed
44) Kessler RA, Li X, Schwartz K, et al. Two-year observational study of deferiprone in superficial siderosis. CNS Neurosci Ther. 2018 ; 24 : 187-92.
PubMed
45) 川口友里加, 青木光広, 棚橋重聡, 他. 人工内耳が有効であった脳表ヘモジデリン沈着症例. 耳鼻咽喉科臨床. 2015 ; 108 : 763-6.
 
46) 佐藤啓, 大井長和, 正崎泰作, 他. 人工内耳挿入により聴力改善を認め, 長期的臨床評価を行った脳表ヘモジデリン沈着症の1症例. BRAIN and NERVE. 神経研究の進歩. 2018 ; 70 : 73-80.
 
47) Modest MC, Carlson ML, Wanna GB, et al. Cochlear implantation in patients with superficial siderosis : Seven cases and systematic review of the literature. Otol Neurotol. 2015 ; 36 : 1191-6.
PubMed
P.139 掲載の参考文献
1) Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018 ; 378 : 11-21.
PubMed
2) Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018 ; 378 : 708-18.
PubMed
3) Barber PA, Demchuk AM, Zhang J, et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000 ; 355 : 1670-4.
 
4) Astrup J, Siesjo BK, Symon L. Threshold in cerebral ischemia : T hischemic penumbra. Stroke. 1981 ; 12 : 723-5.
 
5) Leigh R, Krakauer JW. MRI-guided selection of patients for treatment of acute ischemic stroke. Curr Opin Neurol. 2014 ; 27 : 425-33.
PubMed
6) Inoue M, Mlynash M, Straka M, et al. Patients with the malignant profile within 3 hours of symptom onset have very poor outcomes after intravenous tissue-type plasminogen activator therapy. Stroke. 2012 ; 43 : 2494-6.
PubMed
7) Inoue M, Mlynash M, Christensen S, et al. Early diffusion-weighted imaging reversal after endovascular reperfusion is typically transient in patients 3 to 6 hours after onset. Stroke. 2014 ; 45 : 1024-8.
PubMed
8) Hirai T, Sasaki M, Maeda M, et al. Diffusion-weighted imaging in ischemic stroke : Effect of display method on observers' diagnostic performance. Acad Radiol. 2009 ; 16 : 305-12.
PubMed
9) Nezu T, Koga M, Kimura K, et al. Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA : SAMURAI rt-PA Registry. Neurology. 2010 ; 75 : 555-61.
PubMed
10) Kawano H, Hirano T, Nakajima M, et al. Modified ASPECTS for DWI including deep white matter lesions predicts subsequent intracranial hemorrhage. J Neurol. 2012 ; 259 : 2045-52.
PubMed
11) Kawano H, Hirano T, Inatomi Y, et al. Presence of deep white matter lesions on diffusion-weighted imaging is a negative predictor of early dramatic improvement after intravenous tissue plasminogen activator thrombolysis. Cerebrovasc Dis. 2010 ; 30 : 230-6.
PubMed
12) Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018 ; 49 : e46-e99.
PubMed
13) Terasawa Y, Kimura K, Iguchi Y, et al. Could clinical diffusion-mismatch determined using DWI ASPECTS predict neurological improvement after thrombolysis before 3 h after acute stroke? J Neurol Neurosurg Psychiatry. 2010 ; 81 : 864-8.
PubMed
14) Lin K, Lee SA, Zink WE. What ASPECTS value best predicts the 100-mL threshold on diffusion weighted imaging? Study of 150 patients with middle cerebral artery stroke. J Neuroimaging. 2011 ; 21 : 229-31.
PubMed
15) de Margerie-Mellon C, Turc G, Tisserand M, et al. Can DWI-ASPECTS substitute for lesion volume in acute stroke? Stroke. 2013 ; 44 : 3565-7.
PubMed
16) Schroder J, Cheng B, Ebinger M, et al. Validity of acute stroke lesion volume estimation by Diffusion-Weighted Imaging-Alberta Stroke Program Early Computed Tomographic Score depends on lesion location in 496 patients with middle cerebral artery stroke. Stroke. 2014 ; 45 : 3583-8.
PubMed
17) Demeestere J, Garcia-Esperon C, Garcia-Bermejo P, et al. Evaluation of hyoeracute infarct volume using ASPECTS and brain CT perfusion core volume. Neurology. 2017 ; 88 : 2248-53.
 
18) http://jns.umin.ac.jp/jns_wp/wp-content/uploads/2018/05/20180510.pdf (2018年8月31日アクセス)
 
19) Bouslama M, Bowen MT, Haussen DC, et al. Selection paradigms for large vessel occlusion acute ischemic stroke endovascular therapy. Cerebrovasc Dis. 2017 ; 44 : 277-84.
PubMed
20) Albers GW. Late window paradox. Stroke. 2018 ; 49 : 768-71.
PubMed
21) Saver JL, Goyal M, Bonafe A, et al. Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke. N Engl J Med. 2015 ; 372 : 2285-95.
PubMed
22) Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015 ; 372 : 1009-18.
PubMed
23) Wheeler HM, Mlynash M, Inoue M, et al. The growth rate of early DWI lesions is highly variable and associated with penumbral salvage and clinical outcome following endovascular reperfusion. Int J Stroke. 2015 ; 10 : 723-9.
PubMed
P.148 掲載の参考文献
1) Belykh E, George L, Zhao X, et al. Microvascular anastomosis under 3D exoscope or endoscope magnification : A proof-of-concept study. Surgical Neurolo Int. 2018 ; 9 : 115-8.
PubMed
2) Beez T, Munoz-Bendix C, Beseoglu K, et al. First Clinical Applications of a High-Definition Three-Dimensional Exoscope in Pediatric Neurosurgery. Cureus. 2018 ; 10 : 1-8.
PubMed
3) Kwan K, Schneider JR, Du V, et al. Lessons Leaned Using a High-Definition 3-Dimensional Exoscope for Spinal Surgery. Operataive Neurosurgery. 2018 ; 0 : 1-7.
 
4) Takahashi S, Toda M, Nishimoto M, et al. Pros and cons of using ORBEYE for microneurosurgery. Clin Neurol Neurosurg. 2018 ; 17 : 57-62.
 
5) Raabe A, Beck J, Gerlach R, et al. Near-infrared indocyanine green video angiography : a new method for intraoperative assessment of vascular flow. Neurosurgery. 2003 ; 52 : 132-9.
PubMed
6) Sato T, Suzuki K, Sakuma J, et al. Development of a new high-resolution intraoperative imaging system (dual-image videoangiography, DIVA) to simultaneously visualize light and near-infrared fluorescence images of indocyaninge gree angiography. Acta Neurochir. 2015 ; 157 : 1295-301.
 
7) Feletti A, Wang X, Tanaka R, et al. Dural-Image videoangiography during intracranial microvascular surgery. World Neurosurgery. 2016 ; 99 : 572-9.
 
8) 吉岡秀幸, 西山義久, 金丸和也, 他. 脳動脈瘤手術における内視鏡下蛍光血管造影の有用性. 脳卒中の外科. 2014 ; 42 : 31-6.
Medical*Online
9) Akimoto J. Photodynamic therapy for malignant brain tumors. Neurol Med Chir. 2016 ; 56 : 151-7.
PubMed
10) 山本哲哉, 上月暎浩, 鶴淵隆夫, 他. 悪性脳腫瘍に対する光線力学的療法 (PDT) の基礎. Jpn J Neurosurg. 2016 ; 25 : 905-11.
 
11) 丸山隆志, 村垣善浩, 新田雅之, 他. 原発性悪性脳腫瘍に対する光線力学療法 (PDTの臨床). Jpn J Neurosurg. 2016 ; 25 : 895-904.
 
12) (一社) 日本脳神経外科学会新医療機器使用要件等基準策定事業 (MRガイド下集束超音波治療器) 委員会. 平成28年度 新医療機器使用要件等基準策定事業 (MRガイド下集束超音波治療器) 事業報告書. 2017.
 
13) Sperling SA, Shah BB, Barrett MJ, et al. Focused ultrasound thalamotomy in Parkinson disease : Nonmotor outcomes and quality of life. Neurology. 2018 ; 1-10.
 
14) Fomenko A, Neudorfer C, Dallapiazza RF, et al. Low-intensity ultrasound neuromodulation : An overview of mechanisms and emerging human applications. Brain Stimul. 2018 ; 1-9.
 
15) Legon W, Bansal P, Tyshynsky R, et al. Transcranial focused ultrlasound neuromodulation of the human primary motor cortex. Sci Rep. 2018 ; 8 : 1007.
 
16) 中川敦寛, 遠藤俊毅, 川口奉洋, 他. パルスウォータージェットメスを用いた精密手術用治療機器. 精密工学会誌. 2015 ; 81 : 293-7.
 
17) Nakayashiki A, Kawaguchi T, Nakagawa A, et al. Water veil effect of control splashing from the pused water jet device : Minimizing the potential risk of dissemination using surgical aspirators. J Neuro Surg A Cent Eur Neurosurg. 2018 ; 79 : 309-15.
 
18) Okamoto J, Masamune K, Iseki H, et al. Development concepts of a Smart Cyber Operating Theater (SCOT) using ORiN technology. Biomed Tech. 2018 ; 23 : 31-7.
 

III. 各種疾患

P.153 掲載の参考文献
1) Bangham CR, Araujo A, Yamano Y, et al. HTLV-I-associated myelopathy/ tropical spastic paraparesis. Nat Rev Dis Primers. 2015 ; 1 : 15012.
PubMed
2) Tanaka A, Matsuoka M. HTLV-1 alters T cells for viral persistence and transmission. Front Microbiol. 2018 ; 9 : 461.
PubMed
3) Yamagishi M, Fujikawa D, Watanabe T, et al. HTLV-1-mediated epigenetic pathway to adult T-cell leukemia-lymphoma. Front Microbiol. 2018 ; 9 : 1686.
PubMed
4) Matsuoka E, Takenouchi N, Hasgimoto K, et al. Perivascular T cells are infected with HTLV-I in the spinal cord lesions with HTLV-I-associated myelopathy/tropical spastic paraparesis : double staining of immunohistochemistry and polymerase chain reaction in situ hybridization. Acta Neuropathol. 1998 ; 4 : 340-6.
 
5) Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers : High proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998 ; 6 : 586-93.
PubMed
6) Ando H, Sato T, Tomaru U, et al. Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy. Brain. 2013 ; 136 : 2876-87.
PubMed
7) Coler-Reilly AL, Yagishita N, Suzuki H, et al. Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net). Orphanet J Rare Dis. 2016 ; 11 : 69.
PubMed
8) Sato T, Yagishita N, Tamaki K, et al. Proposal of classification criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis disease activity. Front Microbiol. 2018 ; 9 : 1651.
PubMed
9) Sato T, Coler-Reilly A, Utsunomiya A, et al. CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/Tropical spastic paraparesis. PLoS Negl Trop Dis. 2013 ; 7 : e2479.
PubMed
10) Olindo S, Lezin A, Cabre P, et al. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients : a marker of disease progression. J Neurol Sci. 2005 ; 237 : 53-9.
PubMed
11) Coler-Reilly ALG, Sato T, Matsuzaki T, et al. Effectiveness of daily prednisolone to slow progression of human T-Lymphotropic virus type 1-associated myelopathy/Tropical spastic paraparesis : A multicenter retrospective cohort study. 2017 ; 14 : 1084-94.
PubMed
12) Yamano Y, Araya N, Sato T, et al. Abnormally high levels of virus-infected IFN-γ+CCR4+CD4+CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS One. 2009 ; 4 : e6517.
 
13) Araya N, Sato T, Ando H, et al. HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. J Clin Invest. 2014 ; 124 : 3431-42.
 
14) Yamauchi J, Coler-Reilly A, Sato T, et al. Anti-CCR4 antibody mogamulizumab targets human T-lymphotropic virus type I-infected CD8+ as well as CD4+ T cells to treat associated myelopathy. J Infect Dis. 2015 ; 211 : 238-48.
 
15) Sato T, Coler-Reilly ALG, Yagishita N, et al. Mogamulizumab (Anti-CCR4) in HTLV-1-associated myelopathy. N Engl J Med. 2018 ; 378 : 529-38.
PubMed
16) Kobayashi S, Nakano K, Watanabe E, et al. CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma. Clin Cancer Res. 2014 ; 20 : 2851-61.
PubMed
P.161 掲載の参考文献
1) Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation. 2011 ; 124 : 314-23.
PubMed
2) Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010 : findings from the Global Burden of Disease Study 2010. Lancet Glob Health. 2013 ; 1 : e259-e81.
PubMed
3) Zeng XT, Leng WD, Lam YY, et al. Periodontal disease and carotid atherosclerosis : A meta-analysis of 17,330 participants. Int J Cardiol. 2016 ; 203 : 1044-51.
PubMed
4) Kudo C, Shin WS, Sasaki N, et al. Effects of periodontal treatment on carotid intima-media thickness in patients with lifestyle-related diseases : Japanese prospective multicentre observational study. Odontology. 2018 ; 106 : 316-27.
PubMed
5) Van Dyke TE, Starr JR. Unravelling the link between periodontitis and cardiovascular disease. J Am Heart Assoc. 2013 ; 2 : e000657.
PubMed
6) Seldin MM, Meng Y, Qi H, et al. Trimethylamine N-Oxide Promotes Vascular Inflammation Through Signaling of Mitogen-Activated Protein Kinase and Nuclear Factor-κB. J Am Heart Assoc. 2016 ; 5 : e002767.
 
7) Haghikia A, Li XS, Liman TG, et al. Gut microbiota-dependent trimethylamine N-Oxide predicts risk of cardiovascular events in patients with stroke and Is related to proinflammatory monocytes. Arterioscler Thromb Vasc Biol. 2018 [Epub ahead of print].
 
8) Ohira H, Tsutsui W, Fujioka Y. Are short chain fatty acids in gut microbiota defensive players for inflammation and atherosclerosis? J Atheroscler Thromb. 2017 ; 24 : 660-72.
PubMed
9) Michelsen KS, Wong MH, Shah PK, et al. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004 ; 101 : 10679-84.
PubMed
10) Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest. 2005 ; 115 : 3149-56.
PubMed
11) Wu RQ, Zhang DF, Tu E, et al. The mucosal immune system in the oral cavity-an orchestra of T cell diversity. Int J Oral Sci. 2014 ; 6 : 125-32.
PubMed
12) Moutsopoulos NM, Konkel JE. Tissue-specific immunity at the oral mucosal barrier. Trends Immunol. 2018 ; 39 : 276-87.
PubMed
13) Lockhart PB, Brennan MT, Sasser HC, et al. Bacteremia associated with toothbrushing and dental extraction. Circulation. 2008 ; 117 : 3118-25.
PubMed
14) Fernandes CP, Oliveira FA, Silva PG, et al. Molecular analysis of oral bacteria in dental biofilm and atherosclerotic plaques of patients with vascular disease. Int J Cardiol. 2014 ; 174 : 710-2.
PubMed
15) Koren O, Spor A, Felin J, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA. 2011 ; 108 : 4592-8.
PubMed
16) Werdan K, Dietz S, Loffler B, et al. Mechanisms of infective endocarditis : pathogen-host interaction and risk states. Nat Rev Cardiol. 2014 ; 11 : 35-50.
PubMed
17) Song L, Wang W, Conrads G, et al. Genetic variability of mutans streptococci revealed by wide whole-genome sequencing. BMC Genomics. 2013 ; 14 : 430.
PubMed
18) Sato Y, Okamoto K, Kagami A, et al. Application of in vitro mutagenesis to identify the gene responsible for cold agglutination phenotype of Streptococcus mutans. Microbiol Immunol. 2004 ; 48 : 449-56.
PubMed
19) Nakano K, Hokamura K, Taniguchi N, et al. The collagen-binding protein of Streptococcus mutans is involved in haemorrhagic stroke. Nat Commun. 2011 ; 2 : 485.
PubMed
20) Cornejo OE, Lefebure T, Bitar PD, et al. Evolutionary and population genomics of the cavity causing bacteria Streptococcus mutans. Mol Biol Evol. 2013 ; 30 : 881-93.
PubMed
21) Nakano K, Nomura R, Taniguchi N, et al. Molecular characterization of Streptococcus mutans strains containing the cnm gene encoding a collagen-binding adhesin. Arch Oral Biol. 2010 ; 55 : 34-9.
PubMed
22) Aviles-Reyes A, Miller JH, Lemos JA. The collagen binding proteins of Streptococcus mutans and related streptococci. Mol Oral Microbiol. 2017 ; 32 : 89-106.
PubMed
23) Nomura R, Naka S, Nemoto H, et al. Potential involvement of collagen-binding proteins of Streptococcus mutans in infective endocarditis. Oral Dis. 2013 ; 19 : 387.
 
24) Miyatani F, Kuriyama N, Watanabe I, et al. Relationship between Cnm-positive Streptococcus mutans and cerebral microbleeds in humans. Oral Dis. 2015 ; 21 : 886-93.
PubMed
25) Watanabe I, Kuriyama N, Miyatani F, et al. Oral cnm-positive Streptococcus mutans expressing collagen binding activity is a risk factor for cerebral microbleeds and cognitive impairment. Sci Rep. 2016 ; 6 : 38561.
PubMed
26) Tonomura S, Ihara M, Kawano T, et al. Intracerebral hemorrhage and deep microbleeds associated with cnm-positive Streptococcus mutans ; a hospital cohort study. Sci Rep. 2016 ; 6 : 20074.
PubMed
27) Inenaga C, Hokamura K, Nakano K, et al. A potential new risk factor for stroke : Streptococcus mutans with collagen binding protein. World Neurosurg. 2018 ; 113 : e77-81.
PubMed
28) Ihara M, Yamamoto Y. Emerging evidence for pathogenesis of sporadic cerebral small vessel disease. Stroke. 2016 ; 47 : 554-60.
PubMed
29) Ito S, Nagasawa T, Abe M, et al. Strain vessel hypothesis : a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res. 2009 ; 32 : 115-21.
PubMed
30) Bouvy WH, Geurts LJ, Kuijf HJ, et al. Assessment of blood flow velocity and pulsatility in cerebral perforating arteries with 7-T quantitative flow MRI. NMR Biomed. 2016 ; 29 : 1295-304.
PubMed
31) Schnerr RS, Jansen JFA, Uludag K, et al. Pulsatility of lenticulostriate arteries assessed by 7 tesla flow MRI-measurement, reproducibility, and applicability to aging effect. Front Physiol. 2017 ; 8 : 961.
PubMed
32) Simpson JE, Wharton SB, Cooper J, et al. Alterations of the blood-brain barrier in cerebral white matter lesions in the ageing brain. Neurosci Lett. 2010 ; 486 : 246-51.
PubMed
33) Zhang WW, Olsson Y. The angiopathy of subcortical arteriosclerotic encephalopathy (Binswanger's disease) : immunohistochemical studies using markers for components of extracellular matrix, smooth muscle actin and endothelial cells. Acta Neuropathol. 1997 ; 93 : 219-24.
PubMed
34) Aviles-Reyes A, Miller JH, Simpson-Haidaris PJ, et al. Cnm is a major virulence factor of invasive Streptococcus mutans and part of a conserved three-gene locus. Mol Oral Microbiol. 2014 ; 29 : 11-23.
 
P.172 掲載の参考文献
1) Lander ES, Schork NJ. Genetic dissection of complex traits. Science. 1994 ; 265 : 2037.
PubMed
2) Brass LM, Isaacsohn JL, Merikangas KR, et al. A study of twins and stroke. Stroke. 1992 ; 23 : 221-3.
PubMed
3) Bak S, Gaist D, Sindrup SH, et al. Genetic liability in stroke. Stroke. 2002 ; 33 : 769-74.
PubMed
4) Tournier-Lasserve E, Joutel A, Melki J, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet. 1993 ; 3 : 256-9.
PubMed
5) Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996 ; 383 : 707-10.
PubMed
6) Altmuller J, Palmer LJ, Fischer G, et al. Genomewide scans of complex human diseases : True linkage is hard to find. Am J Hum Genet. 2001 ; 69 : 936-50.
PubMed
7) Kubo M, Hata J, Ninomiya T, et al. A nonsynonymous SNP in PRKCH (protein kinase Cη) increases the risk of cerebral infarction. Nat Genet. 2007 ; 39 : 212-7.
 
8) Ikram MA, Seshadri S, Bis JC, et al. Genomewide association studies of stroke. N Engl J Med. 2009 ; 360 : 1718-28.
PubMed
9) Holliday EG, Maguire JM, Evans T-J, et al. Common variants at 6p21.1 are associated with large artery atherosclerotic stroke. Nat Genet. 2012 ; 44 : 1147-51.
PubMed
10) Bellenguez C, Bevan S, Gschwendtner A, et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet. 2012 ; 44 : 328-33.
PubMed
11) Gretarsdottir S, Thorleifsson G, Manolescu A, et al. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. Ann Neurol. 2008 ; 64 : 402-9.
PubMed
12) Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence variant in ZFHX3 on 16q22 associates with a trial fibrillation and ischemic stroke. Nat Genet. 2009 ; 41 : 876-8.
 
13) Traylor M, Farrall M, Holliday EG, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration) : a meta-analysis of genome-wide association studies. Lancet Neurol. 2012 ; 11 : 951-62.
 
14) Debette S, Kamatani Y, Metso TM, et al. Common variation in PHACTR1 is associated with susceptibility to cervical artery dissection. Nat Genet. 2014 ; 47 : 78-83.
PubMed
15) Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associate variation in regulatorty DNA. Science (80-). 2012 ; 337 : 1190-5.
 
16) Gupta RM, Hadaya J, Trehan A, et al. A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression. Cell. 2017 ; 170 : 522-33. e15.
 
17) Woo D, Falcone GJ, Devan WJ, et al. Meta-analysis of genome-wide association studies identifies 1q22 as a susceptibility locus for intracerebral hemorrhage. Am J Hum Genet. 2014 ; 94 : 511-21.
PubMed
18) Chauhan G, Arnold CR, Chu AY, et al. Identification of additional risk loci for stroke and small vessel disease : a meta-analysis of genome-wide association studies. Lancet Neurol. 2016 ; 15 : 695-707.
PubMed
19) Rosand J, Mitchell BD, Ay H, et al. Loci associated with ischaemic stroke and its subtypes (SiGN) : A genome-wide association study. Lancet Neurol. 2016 ; 15 : 174-84.
PubMed
20) Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2013 ; 506 : 376-81.
PubMed
21) Morris AP. Transethnic meta-analysis of genomewide association studies. Genet Epidemiol. 2011 ; 35 : 809-22.
PubMed
22) Bevan S, Traylor M, Adib-Samii P, et al. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke. 2012 ; 43 : 3161-7.
PubMed
23) Hyde CL, Nagle MW, Tian C, et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nat Genet. 2016 ; 48 : 1031-6.
PubMed
24) Lee JJ, Wedow R, Okbay A, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat Genet. 2018 ; 50 : 1112-21.
PubMed
25) Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018 ; 50 : 1219-24.
PubMed
26) Martin AR, Gignoux CR, Walters RK, et al. Human demographic history impacts genetic risk prediction across diverse populations. Am J Hum Genet. 2017 ; 100 : 635-49.
PubMed
P.180 掲載の参考文献
1) Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015 ; 372 : 11-20.
PubMed
2) Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015 ; 372 : 1019-30.
PubMed
3) Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015 ; 372 : 1009-18.
PubMed
4) Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015 ; 372 : 2285-95.
PubMed
5) Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015 ; 372 : 2296-306.
PubMed
6) Powers WJ, Derdeyn CP, Biller J, et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment : A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015 ; 46 : 3020-35.
PubMed
7) Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke : a meta-analysis of individual patient data from five randomised trials. Lancet. 2016 ; 387 : 1723-31.
PubMed
8) Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018 ; 378 : 11-21.
PubMed
9) Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018 ; 378 : 708-18.
PubMed
10) Yoshimura S, Sakai N, Uchida K, et al. Endovascular Therapy in Ischemic Stroke With Acute Large-Vessel Occlusion : Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism Japan Registry 2. J Am Heart Association. 2018 ; 7.
 
11) Turk AS, Frei D, Fiorella D, et al. ADAPT FAST study : a direct aspiration first pass technique for acute stroke thrombectomy. J Neurointerv Surg. 2014 ; 6 : 260-4.
PubMed
12) Lapergue B, Blanc R, Gory B, et al. Effect of endovascular contact aspiration contact aspiration vs stent retriever on revascularization in patients with acute ischemic stroke and large vessel occlusion : The ASTER randomized clinical trial. JAMA. 2017 ; 318 : 10.
PubMed
13) Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013 ; 368 : 893-903.
PubMed
14) Ciccone A, Valvassori L, Nichelatti M, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013 ; 368 : 904-13.
PubMed
15) Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013 ; 368 : 914-23.
 
16) Yoshimura S, Shirakawa M, Uchida K, et al. Endovascular treatment of acute ischemic stroke : Honolulu shock and thereafter. J Stroke Cerebrovasc Dis. 2014 ; 23 : e295-8.
PubMed
17) Saver JL, Goyal M, van der Lugt A, et al. Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke : A Meta-analysis. JAMA. 2016 ; 316 : 1279-88.
PubMed
18) van den Berg LA, Dijkgraaf MG, Berkhemer OA, et al. Two-year outcome after endovascular treatment for acute ischemic stroke. N Engl J Med. 2017 ; 376 : 1341-9.
PubMed
19) Son S, Kim YW, Oh MK, et al. Initial factors affecting the clinical outcome after successful recanalization via MR-based mechanical thrombectomy in patients with acute ischemic stroke due to basilar artery occlusion. J Neurointerv Surg. 2016 ; 8 : 889-93.
PubMed
20) Rebello LC, Bouslama M, Haussen DC, et al. Endovascular treatment for patients with acute stroke who have a large ischemic core and large mismatch imaging profile. JAMA Neurol. 2017 ; 74 : 34-40.
PubMed
21) Mistry EA, Mistry AM, Nakawah MO, et al. Mechanical thrombectomy outcomes with and without intravenous thrombolysis in stroke patients : A Meta-Analysis. Stroke. 2017 ; 48 : 2450-6.
PubMed
P.188 掲載の参考文献
1) Korja M, Kaprio J. Controversies in epidemiology of intracranial aneurysms and sah. Nature reviews. Neurology. 2016 ; 12 : 50-5.
PubMed
2) Malhotra A, Wu X, Forman HP, et al. Management of tiny unruptured intracranial aneurysms : A comparative effectiveness analysis. JAMA Neurol. 2018 ; 75 : 27-34.
PubMed
3) Nomura S, Kunitsugu I, Ishihara H, et al. Relationship between aging and enlargement of intracranial aneurysms. J Stroke Cerebrovase Dis. 2015 ; 24 : 2049-53.
 
4) Takashima N, Arima H, Kita Y, et al. Incidence, management and short-term outcome of stroke in a general population of 1.4 million Japanese- Shiga stroke registry. Circ J. 2017 ; 81 : 1636-46.
 
5) Korja M, Lehto H, Juvela S, et al. Incidence of subarachnoid hemorrhage is decreasing together with decreasing smoking rates. Neurology. 2016 ; 87 : 1118-23.
PubMed
6) Jalbert JJ, Isaacs AJ, Kamel H, et al. Clipping and coiling of unruptured intracranial aneurysms among medicare beneficiaries, 2000 to 2010. Stroke. 2015 ; 46 : 2452-7.
PubMed
7) de Rooij NK, Linn FH, van der Plas JA, et al. Incidence of subarachnoid haemorrhage : A systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007 ; 78 : 1365-72.
PubMed
8) Froelich JJ, Neilson S, Peters-Wilke J, et al. Size and location of ruptured intracranial aneurysms : A 5-year clinical survey. World Neurosurg. 2016 ; 91 : 260-5.
PubMed
9) Lee GJ, Eom KS, Lee C, et al. Rupture of very small intracranial aneurysms : Incidence and clinical characteristics. J Cerebrovasc Endovasc Neurosurg. 2015 ; 17 : 217-22.
PubMed
10) Dolati P, Pittman D, Morrish WF, et al. The frequency of subarachnoid hemorrhage from very small cerebral aneurysms (< 5 mm) : A population-based study. Cureus. 2015 ; 7 : e279.
 
11) Bender MT, Wendt H, Monarch T, et al. Small aneurysms account for the majority and increasing percentage of aneurysmal subarachnoid hemorrhage : A 25-year, single institution study. Neurosurgery. 2018 ; 83 : 692-9.
 
12) Korja M, Kivisaari R, Rezai Jahromi B, et al. Size of ruptured intracranial aneurysms is decreasing : Twenty-year long consecutive series of hospitalized patients. Stroke. 2018 ; 49 : 746-9.
PubMed
13) Rajah G, Narayanan S, Rangel-Castilla L. Update on flow diverters for the endovascular management of cerebral aneurysms. Neurosurg Focus. 2017 ; 42 : E2.
 
14) Lindgren A, Vergouwen MD, van der Schaaf I, et al. Endovascular coiling versus neurosurgical clipping for people with aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2018 ; 8 : CD003085.
PubMed
15) Xia ZW, Liu XM, Wang JY, et al. Coiling is not superior to clipping in patients with high-grade aneurysmal subarachnoid hemorrhage : Systematic review and meta-analysis. World Neurosurg. 2017 ; 98 : 411-20.
 
16) Spetzler RF, Zabramski JM, McDougall CG, et al. Analysis of saccular aneurysms in the barrow ruptured aneurysm trial. J Neurosurg. 2017 ; 1-6.
 
17) Kurogi R, Kada A, Nishimura K, et al. Effect of treatment modality on in-hospital outcome in patients with subarachnoid hemorrhage : A nationwide study in Japan (j-aspect study). J Neurosurg. 2017 ; 1-9.
PubMed
18) Ikawa F, Abiko M, Ishii D, et al. Analysis of outcome at discharge after aneurysmal subarachnoid hemorrhage in japan according to the japanese stroke databank. Neurosurg Rev. 2017.
 
19) Ikawa F, Abiko M, Ishii D, et al. Effect of actual age on outcome at discharge in patients by surgical clipping and endovascular coiling for ruptured cerebral aneurysm in Japan. Neurosurg Rev. 2018.
PubMed
20) Bekelis K, Gottlieb DJ, Su Y, et al. Medicare expenditures for elderly patients undergoing surgical clipping or endovascular intervention for subarachnoid hemorrhage. J Neurosurg. 2017 ; 126 : 805-10.
PubMed
21) Zhang X, Li L, Hong B, et al. A systematic review and meta-analysis on economic comparison between endovascular coiling versus neurosurgical clipping for ruptured intracranial aneurysms. World Neurosurg. 2018 ; 113 : 269-75.
 
22) Vlak MH, Algra A, Brandenburg R, et al. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period : A systematic review and meta-analysis. Lancet Neurol. 2011 ; 10 : 626-36.
PubMed
23) Imaizumi Y, Mizutani T, Shimizu K, et al. Detection rates and sites of unruptured intracranial aneurysms according to sex and age : An analysis of mr angiography-based brain examinations of 4070 healthy Japanese adults. J Neurosurg. 2018 ; 1-6.
PubMed
24) Chan DY, Abrigo JM, Cheung TC, et al. Screening for intracranial aneurysms? Prevalence of unruptured intracranial aneurysms in hong kong chinese. J Neurosurg. 2016 ; 124 : 1245-9.
 
25) Serrone JC, Tackla RD, Gozal YM, et al. Aneurysm growth and de novo aneurysms during aneurysm surveillance. J Neurosurg. 2016 ; 125 : 1374-82.
PubMed
26) Giordan E, Lanzino G, Rangel-Castilla L, et al. Risk of de novo aneurysm formation in patients with a prior diagnosis of ruptured or unruptured aneurysm : Systematic review and meta-analysis. J Neurosurg. 2018 ; 1-11.
PubMed
27) Hu S, Yu N, Li Y, et al. A meta-analysis of risk factors for the formation of de novo intracranial aneurysms. Neurosurgery. 2018.
 
28) Backes D, Rinkel GJ, Laban KG, et al. Patient- and aneurysm-specific risk factors for intracranial aneurysm growth : A systematic review and meta-analysis. Stroke. 2016 ; 47 : 951-7.
PubMed
29) Mocco J, Brown RD Jr, Torner JC, et al. Aneurysm morphology and prediction of rupture : An international study of unruptured intracranial aneurysms analysis. Neurosurgery. 2017.
 
30) Murayama Y, Takao H, Ishibashi T, et al. Risk analysis of unruptured intracranial aneurysms : Prospective 10-year cohort study. Stroke. 2016 ; 47 : 365-71.
PubMed
31) Lindgren AE, Koivisto T, Bjorkman J, et al. Irregular shape of intracranial aneurysm indicates rupture risk irrespective of size in a population-based cohort. Stroke. 2016 ; 47 : 1219-26.
 
32) Suzuki T, Takao H, Suzuki T, et al. Determining the presence of thin-walled regions at high-pressure areas in unruptured cerebral aneurysms by using computational fluid dynamics. Neurosurgery. 2016 ; 79 : 589-95.
PubMed
33) Can A, Du R. Association of hemodynamic factors with intracranial aneurysm formation and rupture : Systematic review and meta-analysis. Neurosurgery. 2016 ; 78 : 510-20.
 
34) Kubo Y, Koji T, Kashimura H, et al. Female sex as a risk factor for the growth of asymptomatic unruptured cerebral saccular aneurysms in elderly patients. J Neurosurg. 2014 ; 121 : 599-604.
PubMed
35) Greving JP, Wermer MJ, Brown RD Jr, et al. Development of the phases score for prediction of risk of rupture of intracranial aneurysms : A pooled analysis of six prospective cohort studies. Lancet Neurol. 2014 ; 13 : 59-66.
PubMed
36) Tominari S, Morita A, Ishibashi T, et al. Prediction model for 3-year rupture risk of unruptured cerebral aneurysms in japanese patients. Ann Neurol. 2015 ; 77 : 1050-9.
PubMed
37) Sonobe M, Yamazaki T, Yonekura M, et al. Small unruptured intracranial aneurysm verification study : Suave study, Japan. Stroke. 2010 ; 41 : 1969-77.
PubMed
38) Guresir E, Vatter H, Schuss P, et al. Natural history of small unruptured anterior circulation aneurysms : A prospective cohort study. Stroke. 2013 ; 44 : 3027-31.
PubMed
39) Ikawa F, Morita A, Tominari S, et al. Rupture risk of small unruptured cerebral aneurysms. J Neurosurg. 2019 ; DOI : 10.3171/2018.9. JNS181736.
 
40) Bekelis K, Gottlieb DJ, Su Y, et al. Comparison of clipping and coiling in elderly patients with unruptured cerebral aneurysms. J Neurosurg. 2017 ; 126 : 811-8.
PubMed
41) Silva NA, Shao B, Sylvester MJ, et al. Unruptured aneurysms in the elderly : Perioperative outcomes and cost analysis of endovascular coiling and surgical clipping. Neurosurg Focus. 2018 ; 44 : E4.
PubMed
42) Dasenbrock HH, Smith TR, Rudy RF, et al. Reoperation and readmission after clipping of an unruptured intracranial aneurysm : A national surgical quality improvement program analysis. J Neurosurg. 2018 ; 128 : 756-67.
PubMed
43) Zhang X, Tang H, Huang Q, et al. Total hospital costs and length of stay of endovascular coiling versus neurosurgical clipping for unruptured intracranial aneurysms : Systematic review and meta-analysis. World Neurosurg. 2018 ; 115 : 393-9.
PubMed
44) Mori K, Wada K, Otani N, et al. Validation of effectiveness of keyhole clipping in nonfrail elderly patients with unruptured intracranial aneurysms. J Neurosurg. 2017 ; 127 : 1307-14.
PubMed
45) Mori K, Wada K, Otani N, et al. Keyhole strategy aiming at minimizing hospital stay for surgical clipping of unruptured middle cerebral artery aneurysms. J Neurosurg. 2018 : 1-8.
PubMed
46) Mori K, Wada K, Otani N, et al. Long-term neurological and radiological results of consecutive 63 unruptured anterior communicating artery aneurysms clipped via lateral supraorbital keyhole minicraniotomy. Oper Neurosurg. 2018 ; 14 : 95-103.
PubMed
47) Bonares MJ, Egeto P, de Oliveira Manoel AL, et al. Unruptured intracranial aneurysm treatment effects on cognitive function : A meta-analysis. J Neurosurg. 2016 ; 124 : 784-90.
PubMed
48) Rinaldo L, McCutcheon BA, Murphy ME, et al. Quantitative analysis of the effect of institutional case volume on complications after surgical clipping of unruptured aneurysms. J Neurosurg. 2017 ; 127 : 1297-306.
PubMed
49) Aishima K, Shimizu T, Aihara M, et al. Lifetime effects of small unruptured intracranial aneurysms. World Neurosurg. 2016 ; 95 : 434-40.
PubMed
50) Pawlowska E, Szczepanska J, Wisniewski K, et al. Nf-kappa b-mediated inflammation in the pathogenesis of intracranial aneurysm and subarachnoid hemorrhage. Does autophagy play a role? Int J Mol Sci. 2018 ; 19.
 
51) Pyysalo MJ, Pyysalo LM, Pessi T, et al. Bacterial DNA findings in ruptured and unruptured intracranial aneurysms. Acta Odontol Scand. 2016 ; 74 : 315-20.
PubMed
52) Pyysalo MJ, Pyysalo LM, Hiltunen J, et al. The dental infections in patients undergoing preoperative dental examination before surgical treatment of saccular intracranial aneurysm. BMC Res Notes. 2018 ; 11 : 600.
PubMed
P.195 掲載の参考文献
1) Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme : prognosis, extent of resection, and survival. J Neurosurg. 2001 ; 95 : 190-8.
PubMed
2) Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011 ; 115 : 3-8.
PubMed
3) Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008 ; 26 : 1338-45.
 
4) Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma : a randomised controlled multicentre phase III trial. Lancet Oncol. 2006 ; 7 : 392-401.
PubMed
5) Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995 ; 345 : 1008-12.
PubMed
6) Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003 ; 5 : 79-88.
 
7) Akimoto J. Photodynamic therapy for malignant brain tumors. Neurol Med Chir. 2016 ; 56 : 151-7.
PubMed
8) Muragaki Y, Akimoto J, Maruyama T, et al. Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors. J Neurosurg. 2013 ; 119 : 845-52.
PubMed
9) Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma : a randomized clinical trial. JAMA. 2015 ; 314 : 2535-43.
PubMed
10) Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma : A randomized clinical trial. JAMA. 2017 ; 318 : 2306-16.
PubMed
11) Mrugala MM, Engelhard HH, Dinh Tran D, et al. Clinical practice experience with NovoTTF-100A system for glioblastoma : The Patient Registry Dataset (PRiDe). Semin Oncol. 2014 ; 41 Suppl 6 : S4-S13.
 
12) Wick W. TTFields : where does all the skepticism come from?. Neuro Oncol. 2016 ; 18 : 303-5.
PubMed
13) Rick J, Chandra A, Aghi MK. Tumor treating fields : a new approach to glioblastoma therapy. J Neurooncol. 2018 ; 137 : 447-53.
 
14) Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 ; 370 : 709-22.
PubMed
15) Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 ; 370 : 699-708.
PubMed
16) Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017 ; 377 : 1954-63.
PubMed
17) Sandmann T, Bourgon R, Garcia J, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide : Retrospective analysis of the AVAglio Trial. J Clin Oncol. 2015 ; 33 : 2735-44.
 
18) Chinot OL, Nishikawa R, Mason W, et al. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy : an exploratory analysis of AVAglio. Neuro Oncol. 2016 ; 18 : 1313-8.
 
19) Tamura R, Tanaka T, Miyake K, et al. Bevacizumab for malignant gliomas : current indications, mechanisms of action and resistance, and markers of response. Brain Tumor Pathol. 2017 ; 34 : 62-77.
PubMed
20) Arita H, Narita Y, Fukushima S, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013 ; 126 : 267-76.
PubMed
21) Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of selfrenewal. Proc Natl Acad Sci USA. 2013 ; 110 : 6021-6.
 
22) Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 ; 360 : 765-73.
PubMed
23) Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme Science. 2008 ; 321 : 1807-12.
 
24) Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013 ; 340 : 626-30.
PubMed
25) Shankar GM, Kirtane AR, Miller JJ, et al. Genotype-targeted local therapy of glioma. Proc Natl Acad Sci USA. 2018 ; 115 : E8388-E94.
PubMed
26) Tateishi K, Wakimoto H, Iafrate AJ, et al. Extreme vulnerability of IDH1 mutant cancers to NAD+ Depletion. Cancer Cell. 2015 ; 28 : 773-84.
PubMed
27) Aihara K, Mukasa A, Gotoh K, et al. H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro Oncol. 2014 ; 16 : 140-6.
PubMed
28) Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012 ; 482 : 226-31.
PubMed
29) Lewis PW, Muller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013 ; 340 : 857-61.
PubMed
30) Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012 ; 22 : 425-37.
PubMed
31) Hashizume R, Andor N, Ihara Y, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 2014 ; 20 : 1394-6.
PubMed
32) Grasso CS, Tang Y, Truffaux N, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 2015 ; 21 : 555-9.
PubMed
33) Piunti A, Hashizume R, Morgan MA, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017.
PubMed
34) Mohammad F, Weissmann S, Leblanc B, et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med. 2017.
PubMed
35) Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008 ; 68 : 8673-7.
PubMed
36) Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011 ; 121 : 397-405.
PubMed
37) Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer. 2014 ; 14 : 258.
PubMed
38) Le DT, Uram JN, Wang H, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 ; 372 : 2509-20.
PubMed
39) Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 ; 363 : 711-23.
PubMed
40) Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 ; 366 : 2443-54.
PubMed
41) Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016 ; 18 : 195-205.
PubMed
42) Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015 ; 17 : 1064-75.
PubMed
43) Garber ST, Hashimoto Y, Weathers SP, et al. Immune checkpoint blockade as a potential therapeutic target : surveying CNS malignancies. Neuro Oncol. 2016 ; 18 : 1357-66.
PubMed
44) Maxwell R, Jackson CM, Lim M. Clinical trials investigating immune checkpoint blockade in glioblastoma. Curr Treat Options Oncol. 2017 ; 18 : 51.
PubMed
45) Kurz SC, Cabrera LP, Hastie D, et al. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018.
PubMed
46) Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143 : the game is not over yet. Oncotarget. 2017 ; 8 : 91779-94.
 
47) Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015 ; 350 : 207-11.
PubMed
48) Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 ; 348 : 124-8.
 
49) Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013 ; 500 : 415-21.
PubMed
50) Bouffet E, Larouche V, Campbell BB, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016 ; 34 : 2206-11.
PubMed
51) Sinnadurai M, McDonald KL. Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma. J Neurooncol. 2017 ; 132 : 359-72.
PubMed
52) Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011 ; 365 : 725-33.
PubMed
53) Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 ; 371 : 1507-17.
PubMed
54) Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-Cell Therapy. N Engl J Med. 2016 ; 375 : 2561-9.
PubMed
55) O'Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017 ; 9.
 
56) Chistiakov DA, Chekhonin IV, Chekhonin VP. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. Eur J Pharmacol. 2017 ; 810 : 70-82.
PubMed
57) Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV) : a randomised, double-blind, international phase 3 trial. The Lancet Oncology. 2017 ; 18 : 1373-85.
 
58) Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014 ; 512 : 324-7.
PubMed
59) Chheda ZS, Kohanbash G, Okada K, et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med. 2018 ; 215 : 141-57.
PubMed
60) Vogelbaum MA, Aghi MK. Convection-enhanced delivery for the treatment of glioblastoma. Neuro Oncol. 2015 ; 17 Suppl 2 : ii3-ii8.
 
61) Desjardins A, Gromeier M, Herndon JE, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018 ; 379 : 150-61.
PubMed
P.202 掲載の参考文献
1) Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004 ; 22 : 2865-72.
PubMed
2) Brain Tumor Registry of Japan (2005-2008). Neurol Med Chir (Tokyo). 2017 ; 57 (Suppl) : 9-102.
 
3) Arita H, Narita Y, Miyakita Y, et al. Risk factors for early death after surgery in patients with brain metastases : reevaluation of the indications for and role of surgery. J Neurooncol. 2014 ; 116 : 145-52.
PubMed
4) Narita Y, Shibui S. Strategy of surgery and radiation therapy for brain metastases. Int J Clin Oncol. 2009 ; 14 : 275-80.
PubMed
5) Serizawa T, Higuchi Y, Ono J, et al. Gamma Knife surgery for metastatic brain tumors without prophylactic whole-brain radiotherapy : results in 1000 consecutive cases. J Neurosurg. 2006 ; 105 (Suppl) : 86-90.
 
6) DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989 ; 39 : 789-96.
PubMed
7) Ueki K, Matsutani M, Nakamura O, et al. Comparison of whole brain radiation therapy and locally limited radiation therapy in the treatment of solitary brain metastases from non-small cell lung cancer. Neurol Med Chir (Tokyo). 1996 ; 36 : 364-9.
PubMed
8) Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases : phase III results of the RTOG 9508 randomised trial. The Lancet. 2004 ; 363 : 1665-72.
PubMed
9) Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007 ; 68 : 1388-95.
PubMed
10) Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997 ; 37 : 745-51.
PubMed
11) Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment : an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012 ; 30 : 419-25.
PubMed
12) Horton J, Baxter DH, Olson KB. The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med. 1971 ; 111 : 334-6.
 
13) Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases : phase III results of the RTOG 9508 randomised trial. Lancet. 2004 ; 363 : 1665-72.
PubMed
14) Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases : a randomized controlled trial. JAMA. 2006 ; 295 : 2483-91.
PubMed
15) Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990 ; 322 : 494-500.
 
16) Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis : radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993 ; 33 : 583-90.
 
17) Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain : a randomized trial. JAMA. 1998 ; 280 : 1485-9.
 
18) Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases : A randomized clinical trial. JAMA. 2016 ; 316 : 401-9.
PubMed
19) Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3) : a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 ; 18 : 1049-60.
PubMed
20) Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases : a single-centre, randomised, controlled, phase 3 trial. The lancet Oncology. 2017 ; 18 : 1040-8.
PubMed
21) Kayama T, Sato S, Sakurada K, et al. Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504) : A phase III, noninferiority, randomized controlled trial. J Clin Oncol. 2018 : JCO2018786186.
PubMed
22) Olson R, Tyldesley S, Carolan H, et al. Prospective comparison of the prognostic utility of the mini mental state examination and the Montreal cognitive assessment in patients with brain metastases. Support Care Cancer. 2011 ; 19 : 1849-55.
 
23) Magnuson WJ, Lester-Coll NH, Wu AJ, et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer : A retrospective multiinstitutional analysis. J Clin Oncol. 2017 : JCO2016 697144.
 
24) Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 : JCO2018783118.
PubMed
25) Chen L, Douglass J, Kleinberg L, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2018 ; 100 : 916-25.
PubMed
P.209 掲載の参考文献
1) 内閣府. 平成29年版高齢社会白書. 2018. <http://www8.cao.go.jp/kourei/whitepaper/w-2017/zenbun/29pdf_index.html (2018年11月)>
 
2) Toyoda K, Yasaka M, Nagata K, et al. Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage. The Bleeding with antithrombotic therapy (BAT) retrospective study. Cerebrovasc Dis. 2009 ; 27 : 151-9.
PubMed
3) Uccella L, Zoia C, Bongetta D, et al. Are antiplatelet and anticoagulants drugs a risk factor for bleeding in mild traumatic brain injury? World Neurosurg. 2018 ; 110 : e339-e45.
PubMed
4) Van den Brand CL, Tolido T, Rambach AH, et al. Systematic review and meta-analysis : is pre-injury antiplatelet therapy associated with traumatic intracranial hemorrhage? J Neurotrauma. 2017 ; 34 : 1-7.
PubMed
5) Akamatsu Y, Sasaki T, Kanamori M, et al. Factors contributing to surgical intervention for subacute subdural hematoma enlargement in patients with mild head injuries. No Shinkei Geka. 2017 ; 45 : 771-9.
PubMed
6) Shabani S, Nguyen HS, Doan N, et al. Case report and review of literature of delayed acute subdural hematoma. World Neurosurg. 2016 ; 96 : 66-71.
PubMed
7) Chenoweth JA, Gaona SD, Faul M, et al. Incidence of delayed intracranial hemorrhage in older patients after blunt head trauma. JAMA Surg. 2018 ; 153 : 570-5.
PubMed
8) Cohn B, Keim SM, Sanders AB. Can anticoagulated patients be discharged home safely from the emergency department after minor head injury? J Emerg Med. 2014 ; 46 : 410-7.
PubMed
9) Chauny JM, Marquis M, Bernard F, et al. Risk of delayed intracranial hemorrhage in anticoagulated patients with mild traumatic brain injury : Systematic review and meta-analysis. J Emerg Med. 2016 ; 51 : 519-28.
PubMed
10) Campiglio L, Bianchi F, Cattalini C, et al. Mild brain injury and anticoagulants : Less is enough. Neurol Clin Pract. 2017 ; 7 : 296-305.
PubMed
11) Verschoof MA, Zuurbier CCM, de Beer F, et al. Evaluation of the yield of 24-h close observation in patients with mild traumatic brain injury on anticoagulation therapy : a retrospective multicenter study and meta-analysis. J Neurol. 2018 ; 265 : 315-21.
PubMed
12) Watson VL, Louis N, Seminara BV, et al. Proposal for the rapid reversal of coagulopathy in patients with nonoperative head injuries on anticoagulants and/or antiplatelet agents : A case study and literature review. Neurosurgery. 2017 ; 81 : 899-909.
PubMed
13) 日本脳卒中学会 脳卒中ガイドライン [追補2017] 委員会, 編. 脳卒中治療ガイドライン 2015 [追補2017]. 東京 : 協和企画 ; 2017.
 
14) Bershad EM, Farhadi S, Suri MF, et al. Coagulopathy and inhospital deaths in patients with acute subdural hematoma. J Neurosurg. 2008 ; 109 : 664-9.
PubMed
15) Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH) : a randomized trial. Lancet Neurol. 2016 ; 15 : 566-73.
 
16) Yanamadala V, Walcott BP, Fecci PE, et al. Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage. J Clin Neurosci. 2014 ; 21 : 1881-4.
PubMed
17) Suzuki Y, Kitahara T, Soma K, et al. Impact of platelet transfusion on survival of patients with intracerebral hemorrhage after administration of anti-platelet agents at a tertiary emergency center. PLoS One. 2014 ; 9 : e97328.
 
18) Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH) : a randomized, open-label, phase 3 trial. Lancet. 2016 ; 387 : 2605-13.
 
19) Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage : a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit Care. 2016 ; 24 : 6-46.
PubMed
P.214 掲載の参考文献
1) Almenawer SA, Farrokhyar F, Hong C, et al. Chronic subdural hematoma management : a systematic review and meta-analysis of 34,829 patients. Ann Surg. 2014 ; 259 : 449-57.
PubMed
2) Liu W, Bakker NA, Groen RJ. Chronic subdural hematoma : a systematic review and meta-analysis of surgical procedures. J Neurosurg. 2014 ; 121 : 665-3.
PubMed
3) Alcala-Cerra G, Young AM, Moscote-Salazar LR, et al. Efficacy and safety of subdural drains after burr-hole evacuation of chronic subdural hematomas : systematic review and meta-analysis of randomized controlled trials. World Neurosurg. 2014 ; 82 : 1148-57.
PubMed
4) Ivamoto HS, Lemos HP Jr, Atallah AN. Surgical treatments for chronic subdural hematomas : A comprehensive systematic review. World Neurosurg. 2016 ; 86 : 399-418.
PubMed
5) Peng D, Zhu Y. External drains versus no drains after burr-hole evacuation for the treatment of chronic subdural haematoma in adults. Cochrane Database Syst Rev. 2016 ; 31 : CD011402.
PubMed
6) 登坂雅彦, 好本裕平. 慢性硬膜下血腫手術のガイドライン構築のために. Geriatric Neurosurgery. 2018 ; 30 : 59-63.
 
7) Santarius T, Kirkpatrick PJ, Ganesan D, et al. Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma : a randomised controlled trial. Lancet. 2009 ; 374 : 1067-73.
PubMed
8) Wang Y, Wang C, Liu Y. Chronic subdural haematoma evolving from traumatic subdural hydroma. Brain Injury. 2015 ; 29 : 462-5.
 
9) Olivero WC, Wang H, Farahvar A, et al. Predictive (subtle or overlooked) initial head CT findings in patients who develop delayed chronic subdural hematoma. J Clin Neurosci. 2017 ; 42 : 129-33.
PubMed
10) Tosaka M, Sakamoto K, Watanabe S, et al. Critical classification of craniostomy for chronic subdural hematoma ; safer technique for hematoma aspiration. Neurol Med Chir. 2013 ; 53 : 273-8.
PubMed
11) Smith MD, Kishikova L, Norris JM. Surgical management of chronic subdural haematoma : one hole or two? Int J Surg. 2012 ; 10 : 450-2.
PubMed
12) Yuan Y, Wang QP, Cao YL, et al. Burr hole drainage and burr hole drainage with irrigation to treat chronic subdural hematoma : A systematic review and meta-analysis. Medicine. 2018 ; 97 : e11827.
 
13) Nathan S, Goodarzi Z, Jette N, et al. Anticoagulant and antiplatelet use in seniors with chronic subdural hematoma : systematic review. Neurology. 2017 ; 88 : 1889-93.
PubMed
14) Rust T, Kiemer N, Erasmus A. Chronic subdural haematomas and anticoagulantion or anti-thrombotic therapy. J Clin Neurosci. 2006 ; 13 : 823-7.
PubMed
15) Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015 ; 373 : 823-33.
PubMed
16) Arai N, Mine Y, Kagami H, et al. Safe burr hole surgery for chronic subdural hematoma using dabigatran with Idarucizumab. World Neurosurg. 2018 ; 109 : 432-5.
PubMed
17) Uno M, Toi H, Hirai S. Chronic subdural hematoma in elderly patients : is this disease benign? Neurol Med Chir. 2017 ; 57 : 402-9.
PubMed
18) Toi H, Kinoshita K, Hirai S, et al. Present epidemiology of chronic subdural hematoma in Japan : analysis of 63,358 cases recorded in a national administrative database. J Neurosurg. 2018 ; 128 : 222-8.
 
19) Lee L, Ker J, Ng HY, et al. Outcomes of chronic subdural hematoma drainage in nonagenarians and centenarians : a multicenter study. J Neurosurg. 2016 ; 124 : 546-51.
PubMed
20) Bartek J Jr, Sjavik K, Stahl F, et al. Surgery for chronic subdural hematoma in nonagenarians : A Scandinavian population-based multicenter study. Acta Neurol Scand. 2017 ; 136 : 516-20.
PubMed
21) Mandai S, Sakurai M, Matsumoto Y. Middle meningeal artery embolization for refractory chronic subdural hematoma. Case report. J Neurosurg. 2000 ; 93 : 686-8.
PubMed
22) Hashimoto T, Ohashi T, Watanabe D, et al. Usefulness of embolization of the middle meningeal artery for refractory chronic subdural hematomas. Surg Neurol Int. 2013 ; 19 : 104.
 
23) Ban SP, Hwang G, Byoun HS, et al. Middle meningeal artery embolization for chronic subdural hematoma. Radiology. 2018 ; 286 : 992-9.
PubMed
24) Hellwig D, Kuhn TJ, Bauer BL, et al. Endoscopic treatment of septated chronic subdural hematoma. Surg Neurol. 1996 ; 45 : 272-7.
PubMed
25) Zhang J, Liu X, Fan X, et al. The use of endoscopic-assisted burr-hole craniostomy for septated chronic subdural haematoma : A retrospective cohort comparison study. Brain Res. 2018 ; 1678 : 245-53.
 
26) Majovsky M, Masopust V, Netuka D, et al. Flexible endoscope-assisted evacuation of chronic subdural hematomas. Acta Neurochir. 2016 ; 158 : 1987-92.
PubMed
27) 登坂雅彦, 齋藤延人. 低髄液圧症候群 (脳脊髄液減少症) に関する最新動向 脳神経外科の立場から. 脊髄脊椎ジャーナル. 2006 ; 19 : 356-61.
 
28) Tanaka Y, Tosaka M, Fujimaki H, et al. Sex- and age-related differences in the clinical and neuroimaging characteristics of patients With Spontaneous intracranial hypotension : a records review. Headache. 2016 ; 56 : 1310-6.
PubMed
29) Beck J, Gralla J, Fung C, et al. Spinal cerebrospinal fluid leak as the cause of chronic subdural hematomas in nongeriatric patients. J Neurosurg. 2014 ; 121 : 1380-7.
PubMed
30) Kelley GR, Johnson PL. Sinking brain syndrome : craniotomy can precipitate brainstem herniation in CSF hypovolemia. Neurology. 2004 ; 62 : 157.
PubMed
31) Liu JKC. Neurologic Deterioration Due to brain sag after bilateral craniotomy for subdural hematoma evacuation. World Neurosurg. 2018 ; 114 : 90-3.
PubMed
32) Haku T, Motoyama Y, Takamura Y, et al. Central Herniation Induced by Craniotomy Prompting Air Replacement for Subdural Fluid Collection Due to Cerebrospinal Fluid Hypovolemia. World Neurosurg. 2018 ; 117 : 182-5.
PubMed
33) Yao Z, Hu X, Ma L, et al. Dexamethasone for chronic subdural haematoma : a systematic review and meta-analysis. Acta Neurochir. 2017 ; 159 : 2037-44.
PubMed
34) Goto S, Kato K, Yamamoto T, et al. Effectiveness of goreisan in preventing recurrence of chronic subdural hematoma. Asian J Neurosurg. 2018 ; 13 : 370-4.
PubMed
35) Shimamura N, Ogasawara Y, Naraoka M, et al. Irrigation with thrombin solution reduces recurrence of chronic subdural hematoma in high-risk patients: preliminary report. J Neurotrauma. 2009 ; 26 : 1929-33.
PubMed
36) Toi H, Fujii Y, Iwama T, et al. Does artificial cerebrospinal fluid prevent recurrence of chronic subdural hematoma? A multi-center prospective randomized clinical trial. J Neurotrauma. 2018 (in press).
 
37) 登坂雅彦. 慢性硬膜下血腫 標準治療, 内視鏡, 薬物療法. In 菊田健一郎, 他, 編. 新NS NOW No.14 脳脊髄外傷の治療. 東京 : メジカルビュー社 ; 2018. p.72-9.
 
P.223 掲載の参考文献
1) 平山恵造. 神経症候学II. 改訂第2版. 東京 : 文光堂 ; 2010. p.538-55.
 
2) 三苫博. 小脳症候の病態生理. 臨床神経. 2009 ; 49 : 401-6.
 
3) Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia : development of a new clinical scale. Neurology. 2006 ; 66 : 1717-20.
PubMed
4) Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004 ; 19 : 1391-402.
 
5) Jacobi H, Bauer P, Giunti P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6 : a 2-year follow-up study. Neurology. 2011 ; 77 : 1035-41.
PubMed
6) Schmitz-Hubsch T, Fimmers R, Rakowicz M, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology. 2010 ; 74 : 678-84.
PubMed
7) Koziol LF, Budding D, Andreasen N, et al. Consensus paper : the cerebellum's role in movement and cognition. Cerebellum. 2014 ; 13 : 151-77.
PubMed
8) Buhusi CV, Meck WH. What makes us tick? Functional and neural mechanisms of interval timing. Nat Rev Neurosci. 2005 ; 6 : 755-65.
PubMed
9) Teki S, Grube M, Griffiths TD. A unified model of time perception accounts for duration-based and beatbased timing mechanisms. Front Integr Neurosci. 2012 ; 5 : 90.
PubMed
10) Spencer RM, Zelaznik HN, Diedrichsen J, et al. Disrupted timing of discontinuous but not continuous movements by cerebellar lesions. Science. 2003 ; 300 : 1437-9.
 
11) Ilg W, Golla H, Thier P, et al. Specific influences of cerebellar dysfunctions on gait. Brain. 2007 ; 130 : 786-98.
PubMed
12) Wolpert D, Miall C, Kawato M. Internal models in the cerebellum. Trends in Cog Sci. 1998 ; 2 : 338-47.
 
13) Ito M. Control of mental activities by internal models in the cerebellum. Nat Rev Neurosci. 2008 ; 9 : 304-13.
PubMed
14) Wolpert D, Kawato M. Multiple paired forward and inverse models for motor control. Neural Networks. 1998 ; 11 : 1317-29.
 
15) Tada M, Nishizawa M, Onodera O. Redefining cerebellar ataxia in degenerative ataxias : lessons from recent research on cerebellar systems. J Neurol Neurosurg Psychiatry. 2015 ; 86 : 922-8.
PubMed
16) Kitazawa S, Kimura T, Uka T. Prism adaptation of reaching movements : specificity for the velocity of reaching. J Neurosci. 1997 ; 17 : 1481-92.
PubMed
17) Hanajima R, Shadmehr R, Ohminami S, et al. Modulation of error-sensitivity during a prism adaptation task in people with cerebellar degeneration. J Neurophysiol. 2015 ; 114 : 2460-71.
PubMed
18) Hashimoto Y, Honda T, Matsumura K, et al. Quantitative evaluation of human cerebellum-dependent motor learning through prism adaptation of hand-reaching movement. PLoS One. 2015 ; 10:e0119376.
PubMed
19) 徳重真一. 神経生理検査update : 大脳基底核疾患・小脳疾患における最新知見 時間認知とタッピング課題. 神経内科. 2017 ; 86 : 295-300.
 
20) Matsuda S, Matsumoto H, Furubayashi T, et al. The 3-second rule in hereditary pure cerebellar ataxia : a synchronized tapping study. PLoS One. 2015 ; 10 : e0118592.
PubMed
21) Lee J, Kagamihara Y, Kakei S. A new method for functional evaluation of motor commands in patients with cerebellar ataxia. PLoS One. 2015 ; 10 : e0132983.
PubMed
22) 筧慎治, 李鍾昊. 小脳症状の解析-predictive control and feedback control. Annual Review神経. 2014 ; 11-7.
Medical*Online
23) Tada M, Tokunaga J, Nagai T, et al. iPatax : A new method for quantitative assessment for motor coordination of ataxia. 2014 Annual Meeting of AAN. P6.059 (Abstract).
 
P.230 掲載の参考文献
1) Rosborough K, Patel N, Kalia LV. α-Synuclein and Parkinsonism : Updates and future perspectives. Curr Neurol Neurosci Rep. 2017 ; 17 : 31.
 
2) Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease : a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 ; 55 : 181-4.
 
3) Saeed U, Compagnone J, Aviv RI, et al. Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes : current and emerging concepts. Transl Neurodegener. 2017 ; 6 : 8.
PubMed
4) Blazejewska AI, Schwarz ST, Pitiot A, et al. Visualization of nigrosome 1 and its loss in PD : pathoanatomical correlation and in vivo 7 T MRI. Neurology. 2013 ; 81 : 534-40.
PubMed
5) Massey LA, Micallef C, Paviour DC, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2012 ; 27 : 1754-62.
PubMed
6) Suwijn SR, van Boheemen CJ, de Haan RJ, et al. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism : a systematic review. EJNMMI Res. 2015 ; 5 : 12.
PubMed
7) Perju-Dumbrava LD, Kovacs GG, Pirker S, et al. Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy. Mov Disord. 2012 ; 27 : 65-71.
PubMed
8) Shimada H, Ono M, Tagai K, et al. Preclinical and clinical characterization of 18F-PM-PBB3, a PET ligand for diverse tau pathologies. Alzheimer Dement. 2018 ; 14 (suppl) : P318-P9.
 
9) Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003 ; 24 : 197-211.
PubMed
10) Angot E, Steiner JA, Hansen C, et al. Are synucleinopathies prion-like disorders? Lancet Neurol. 2010 ; 9 : 1128-38.
PubMed
11) Villemagne VL, Dore V, Burnham SC, et al. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018 ; 14 : 225-36.
 
12) Kikuchi A, Takeda A, Okamura N, et al. In vivo visualization of α-synuclein deposition by carbon-11-labelled 2- [2- (2-dimethylaminothiazol-5-yl) ethenyl] -6- [2- (fluoro) ethoxy] benzoxazole positron emission tomography in multiple system atrophy. Brain. 2010 ; 133 : 1772-8.
 
13) Kudo Y, Okamura N, Furumoto S, et al. 2- (2- [2-Dimethylaminothiazol-5-yl] ethenyl) -6- (2- [fluoro] ethoxy) benzoxazole : a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med. 2007 ; 48 : 553-61.
PubMed
14) Verdurand M, Levigoureux E, Lancelot S, et al. Amyloid-beta radiotracer [18F] BF-227 does not bind to cytoplasmic glial inclusions of postmortem multiple system atrophy brain tissue. Contrast Media Mol Imaging. 2018 ; 2018 : 9165458.
 
15) Chu W, Zhou D, Gaba V, et al. Design, Synthesis, and Characterization of 3- (Benzylidene) indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils. J Med Chem. 2015 ; 58 : 6002-17.
 
16) Hsieh CJ, Xu K, Lee I, et al. Chalcones and five-membered heterocyclic isosteres bind to alpha synuclein fibrils in vitro. ACS Omega. 2018 ; 3 : 4486-93.
PubMed
17) Tsika E, Davranche A, Molette J, et al. Novel PET Tracers of alpha-synuclein for the diagnosis of Parkinson' s disease. Mov Disord. 2016 ; 31 (suppl 2).
 
18) Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013 ; 79 : 1094-108.
 
19) Perez-Soriano A, Arena JE, Dinelle K, et al. PBB3 imaging in Parkinsonian disorders : Evidence for binding to tau and other proteins. Mov Disord. 2017 ; 32 : 1016-24.
PubMed
20) Koga S, Ono M, Sahara N, et al. Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology. Mov Disord. 2017 ; 32 : 884-92.
 
21) Masuda-Suzukake M, Nonaka T, Hosokawa M, et al. Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol Commun. 2014 ; 2 : 88.
PubMed
22) Shimozawa A, Ono M, Takahara D, et al. Propagation of pathological α-synuclein in marmoset brain. Acta Neuropathol Commun. 2017 ; 5 : 12.
 
23) Brundin P, Dave KD, Kordower JH. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017 ; 298 : 225-35.
PubMed
24) Kingwell K. Zeroing in on neurodegenerative α-synuclein. Nat Rev Drug Discov. 2017 ; 16 : 371-3.
 
P.236 掲載の参考文献
1) Norris FH Jr, Colella J, McFarlin D. EFFECT of diphenylhydantoin on neuromuscular synapse. Neurology. 1964 ; 14 : 869-76.
PubMed
2) Peterson H. Association of trimethadione therapy and myasthenia gravis. N Engl J Med. 1966 ; 274 : 506-7.
PubMed
3) McQuillen MP, Cantor HE, O'Rourke JR. Myasthenic syndrome associated with antibiotics. Arch Neurol. 1968 ; 18 : 402-15.
PubMed
4) Herishanu Y, Rosenberg P. Letter : beta-blockers and myasthenia gravis. Ann Intern Med. 1975 ; 83 : 834-5.
PubMed
5) Bucknall RC, Dixon ASJ, Glick EN, et al. Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. Br Med J. 1975 ; 1 : 600-2.
 
6) Neil JF, Himmelhoch JM, Licata SM. Emergence of myasthenia gravis during treatment with lithium carbonate. Arch General Psychiatry. 1976 ; 33 : 1090-2.
 
7) Sghirlanzoni A, Mantegazza R, Mora M, et al. Chloroquine myopathy and myasthenia-like syndrome. Muscle Nerve. 1988 ; 11 : 114-9.
PubMed
8) Bashuk RG, Krendel DA. Myasthenia gravis presenting as weakness after magnesium administration. Muscle Nerve. 1990 ; 13 : 708-12.
PubMed
9) Fujiyama J, Tokimura Y, Ijichi S, et al. Bucillamine may induce myasthenia gravis. Jap J Med. 1991 ; 30 : 101-2.
 
10) Batocchi AP, Evoli A, Servidei S, et al. Myasthenia gravis during interferon alfa therapy. Neurology. 1995 ; 45 : 382-3.
PubMed
11) Krishnan K, Trobe JD, Adams PT. Myasthenia gravis following iron chelation therapy with intravenous desferrioxamine. European journal of haematology. 1995 ; 55 : 138-9.
PubMed
12) Pijpers E, van Rijswijk RE, Takx-Kohlen B, et al. A clarithromycin-induced myasthenic syndrome. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1996 ; 22 : 175-6.
PubMed
13) Tarsy D, Bhattacharyya N, Borodic G. Myasthenia gravis after botulinum toxin A for meige syndrome. movement disorders : official journal of the Movement Disorder Society. 2000 ; 15 : 736-8.
PubMed
14) Parmar B, Francis PJ, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet. 2002 ; 360 : 717.
PubMed
15) Gunduz A, Turedi S, Kalkan A, et al. Levofloxacin induced myasthenia crisis. Emergency medicine journal. 2006 ; 23 : 662.
PubMed
16) Fee DB, Kasarskis EJ. Myasthenia gravis associated with etanercept therapy. Muscle & nerve. 2009 ; 39 : 866-70.
PubMed
17) Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. J j Clin oncol. 2016 ; 46 : 86-8.
 
18) Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European journal of cancer. 2016 ; 60 : 210-25.
PubMed
19) Makarious D, Horwood K, Coward JIG. Myasthenia gravis : An emerging toxicity of immune checkpoint inhibitors. Eur j cancer. 2017 ; 82 : 128-36.
PubMed
20) Takizawa T, Kojima M, Suzuki S, et al. New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin : A first case report and literature review. Medicine. 2017 ; 96 : e8757.
 
21) Oh SJ, Dhall R, Young A, et al. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008 ; 38 : 1101-7.
PubMed
22) Watanabe Y, Suzuki S, Nishimura H, et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies. An observational study in Japan. Medicine. 2015 ; 94 : e416.
PubMed
23) Albers JW, Hodach RJ, Kimmel DW, et al. Penicillamine-associated myasthenia gravis. Neurology. 1980 ; 30 : 1246-9.
PubMed
24) Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017 ; 89 : 1127-34.
PubMed
P.241 掲載の参考文献
1) Steinman L. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol. 2014 ; 32 : 257-81.
PubMed
2) Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. The Lancet Neurology. 2010 ; 9 : 520-32.
PubMed
3) McKay KA, Jahanfar S, Duggan T, et al. Factors associated with onset, relapses or progression in multiple sclerosis : a systematic review. Neurotoxicology. 2017 ; 61 : 189-212.
PubMed
4) Collaborators GO. Health effects of overweight and obesity in 195 countries over 25 years. N Egl J Med. 2017 ; 377 : 13-27.
 
5) Yokote H, Miyake S, Croxford JL, et al. NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol. 2008 ; 173 : 1714-23.
PubMed
6) Croxford JL, Miyake S, Huang YY, et al. Invariant V (alpha) 19i T cells regulate autoimmune inflammation. Nat Immunol. 2006 ; 7 : 987-94.
PubMed
7) Miyazaki Y, Miyake S, Chiba A, et al. Mucosal-associated invariant t cells regulate Th1 response in multiple sclerosis. Int Immunol. 2011 ; 23 : 529-35.
PubMed
8) Kadowaki A, Miyake S, Saga R, et al. Gut environment-induced intraepithelial autoreactive CD4+ T cells suppress central nervous system autoimmunity via LAG-3. Nature communications. 2016 ; 7.
PubMed
9) Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature. 2011 ; 479 : 538-41.
PubMed
10) Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009 ; 139 : 485-98.
PubMed
11) Atarashi K, Tanoue T, Ando M, et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell. 2015 ; 163 : 367-80.
PubMed
12) Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous clostridium species. Science. 2011 ; 331 : 337-41.
PubMed
13) Mizuno M, Noto D, Kaga N, et al. The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models. PloS one. 2017 ; 12 : e0173032.
PubMed
14) Haghikia A, Jorg S, Duscha A, et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity. 2015 ; 43 : 817-29.
PubMed
15) Miyake S, Kim S, Suda W, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters. PLoS One. 2015 ; 10 : e0137429.
PubMed
16) Chen J, Chia N, Kalari KR, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016 ; 6 : 28484.
PubMed
17) Jangi S, Gandhi R, Cox LM, et al. Alterations of the human gut microbiome in multiple sclerosis. Nature Communications. 2016 ; 7 : 12015.
PubMed
18) Nishijima S, Suda W, Oshima K, et al. The gut microbiome of healthy Japanese and its microbial and functional uniqueness. DNA Research. 2016 : dsw002.
PubMed
19) Tremlett H, Fadrosh DW, Faruqi AA, et al. Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls. BMC neurology. 2016 ; 16 : 182.
PubMed
20) Cekanaviciute E, Yoo BB, Runia TF, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. PNAS. 2017 ; 114 : 10713-8.
 
21) Berer K, Gerdes LA, Cekanaviciute E, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. PNAS. 2017 ; 114 : 10719-24.
PubMed
22) Kroemer G, Zitvogel L. Cancer immunotherapy in 2017 : The breakthrough of the microbiota. Nature Reviews Immunology. 2018 ; 18 : 87.
PubMed
23) Saresella M, Mendozzi L, Rossi V, et al. Immunological and clinical effect of diet modulation of the gut microbiome in multiple sclerosis patients : a Pilot study. Frontiers in Immunology. 2017 ; 8 : 1391.
PubMed
24) Tankou SK, Regev K, Healy BC, et al. A probiotic modulates the microbiome and immunity in multiple sclerosis. Ann Neurol. 2018 ; 83 : 1147-61.
PubMed
P.247 掲載の参考文献
1) Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012 ; 79 : 1273-7.
PubMed
2) Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies : a comparative study. JAMA Neurol. 2014 ; 71 : 276-83.
PubMed
3) Probstel AK, Rudolf G, Dornmair K, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015 ; 12 : 46.
 
4) Siritho S, Sato DK, Kaneko K, et al. The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients. Mult Scler. 2016 ; 22 : 964-8.
PubMed
5) Tanaka M, Tanaka K. Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J Neuroimmunol. 2014 ; 270 : 98-9.
PubMed
6) Ikeda K, Kiyota N, Kuroda H, et al. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. Mult Scler. 2015 ; 21 : 656-9.
PubMed
7) Rostasy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol. 2012 ; 69 : 752-6.
PubMed
8) Huppke P, Rostasy K, Karenfort M, et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler. 2013 ; 19 : 941-6.
PubMed
9) Chalmoukou K, Alexopoulos H, Akrivou S, et al. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2015 ; 2 : e131.
PubMed
10) Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014 ; 82 : 474-81.
PubMed
11) Akaishi T, Nakashima I, Takeshita T, et al. Different etiologies and prognoses of optic neuritis in demyelinating diseases. J Neuroimmunol. 2016 ; 299 : 152-7.
PubMed
12) O'Connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007 ; 13 : 211-7.
PubMed
13) Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 2009 ; 66 : 833-42.
PubMed
14) Lalive PH, Hausler MG, Maurey H, et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler. 2011 ; 17 : 297-302.
PubMed
15) Olsson T. White matter disease : Roles of anti-MOG antibodies in demyelinating diseases. Nat Rev Neurol. 2011 ; 7 : 248-9.
PubMed
16) Hino-Fukuyo N, Haginoya K, Nakashima I, et al. Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies. Brain Dev. 2015 ; 37 : 849-52.
PubMed
17) Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO : a clinical CSF biomarker study. Neurology. 2010 ; 75 : 208-16.
PubMed
18) Kaneko K, Sato DK, Nakashima I, et al. Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry. 2016 ; 87 : 1257-9.
PubMed
19) Kothur K, Wienholt L, Tantsis EM, et al. B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination. PLoS One. 2016 ; 11 : e0149411.
PubMed
20) Uzawa A, Mori M, Kuwabara S. Cytokines and chemokines in neuromyelitis optica : pathogenetic and therapeutic implications. Brain Pathol. 2014 ; 24 : 67-73.
PubMed
21) Waters P, Woodhall M, O'Connor KC, et al. MOG cellbased assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015 ; 2 : e89.
PubMed
22) Yamamoto D, Uchiyama T, Ohashi T, et al. Case of steroid-responsive unilateral encephalitis with anti-myelin oligodendrocyte glycoprotein antibodies. Neurology and Clinical Neuroscience. 2017 ; 5 : 101-2.
 
23) Spadaro M, Gerdes LA, Krumbholz M, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016 ; 3 : e257.
 
24) Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders : a multicenter study of 50 patients. Part 2 : Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016 ; 13 : 280.
PubMed
25) Rostasy K, Mader S, Hennes EM, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler. 2013 ; 19 : 1052-9.
 
26) Thulasirajah S, Pohl D, Davila-Acosta J, et al. Myelin oligodendrocyte glycoprotein-associated pediatric central nervous system demyelination : Clinical course, neuroimaging findings, and response to therapy. Neuropediatrics. 2016 ; 47 : 245-52.
PubMed
27) Nishiyama M, Nagase H, Matsumoto M, et al. Clinical features in very early-onset demyelinating disease with anti-MOG antibody. Brain Dev. 2017.
PubMed
P.255 掲載の参考文献
1) Boulton AJM, Freeman R, Vinik AJ, et al. Diabetic neuropathies. Diabetes care. 2005 ; 28 : 956-62.
 
2) Tesfaye S, Bulton AJM, Dyck PJ, et al. Diabetic neuropathies. Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 ; 33 : 2285-93.
 
3) 厚生労働省 : 糖尿病. 健康日本 21. 2016 ; p.7-1-7-14.
 
4) Busui RP, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy : A position statement by the American Diabetes Association. Diabetes Care. 2017 ; 40 : 136-54.
 
5) Feldman EL, Brown MB, Stevens MJ, et al. A practical two step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994 ; 17 : 1281-9.
 
6) Bril V, Perkins BA. Validation of the Tronto clinical scoring system for diabetic polyneuropathy. Diabetes Care. 2002 ; 25 : 2048-52.
 
7) 糖尿病性神経障害を考える会. 簡易診断基準をもとにした糖尿病性多発神経障害の病期分類の公表に当たって. 末梢神経. 2008 ; 19 : 118-9.
 
8) 馬場正之. 神経伝導検査による糖尿病性神経障害による重症度分類. 臨床神経生理学. 2013 ; 41 : 143-50.
 
9) 馬場正之, 鈴木千恵子, 小川吉司. 神経伝導検査による2型糖尿病神経障害の重症度分類 : 重症度別にみた足病変, 大血管障害および突然死の発生に関する5年間のまえむき研究. 臨床神経生理学. 2018 ; 46 : 71-7.
 
10) The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 ; 329 : 977-86.
 
11) Tesfaye S, Chaturvedi N, Eaton SE, et al. EURODIAB Prospective Complications Study Group : Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005 ; 352 : 341-50.
 
12) Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy : the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006 ; 29 : 1538-44.
PubMed
13) Hotta N, Kawamori R, Atsumi Y, et al. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med. 2008 ; 25 : 818-25.
PubMed
14) Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid : a meta-analysis. Diabetes Med. 2004 ; 21 : 114-21.
PubMed
15) Himeno T, Kamiya H, Naruse K, et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes. 2011 ; 60 : 2397-406.
PubMed
16) Jin HY, Liu WJ, Park JH, et al. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res. 2009 ; 40 : 536-44.
PubMed
17) Oskarsson P, ljunggren J-G, Lins P-E. Efficacy and safety of mexilitine in the treatment of painful diabetic neuropathy. The mexiletine study group. Diabetes Care. 1997 ; 20 : 1594-7.
 
18) 日本ペインクリニック学会, 編. 神経障害性疼痛薬物療法ガイドライン. 東京 : 真興交易医書出版部, 2011. p.11-38.
 
19) Tesfaye S, Vileikyre L, Rayman G, et al. Painful diabetic peripheral neuropathy : consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011 ; 27 : 629-38.
 
20) Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin : High-dose monotherapy or their combination? The "COMBO-DN study" -a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013 ; 154 : 2616-25.
 
21) Shun CT, Chang YC, Wu HP, et al. Skin denervation in type 2 diabetes : correlations with diabetic duration and functional impairments. Brain. 2004 ; 127 : 1593-605.
PubMed
22) Sumner CJ, Sheth S, Griffin JW, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003 ; 60 : 108-11.
PubMed
23) Hossain P, Sachdev A, Malik RA, et al. Early detection of diabetic peripheral neuropathy with corneal confocal microsopy. Lancet. 2005 ; 366 : 1340-3.
 
24) Petropoulos IN, Ponirakis G, Khan A, et al. Diagnosis diabetic neuropathy : Something old, something new. Diabetes Metab J. 2018 ; 42 : 255-69.
PubMed
25) Tavakoli M, Pretorian MM, Petropoulos IN, et al. Corneal confocal microscopy detects early nerve regeneration in diabetic neuropathy after simultaneous pancreas and kidney transplantation. Diabetes. 2013 ; 62 : 254-60.
 
26) Inui K, Kakigi R. Pain perception in humans : use of intraepidermal electrical stimulation. J Neurol Neurosurg Psychiatry. 2012 ; 83 : 551-6.
PubMed
27) Suzuki C, Kon T, Funamizu Y, et al. Elevated pain threshold in patients with asymptomatic diabetic neuropathy : an intraepidermal electrical stimulation study. Muscle Nerve. 2016 ; 54 : 146-9.
PubMed
28) Suzuki C, Kon T, Funamizu Y, et al. An electrophysiological severity classification system for diabetic polyneuropathy and small fiber dysfunction. Clinical Neurophysiology. 2017 ; 128 : e174.
 
P.260 掲載の参考文献
1) Petersen LR, Jamieson DJ, Powers AM, et al. Zika Virus. N Engl J Med. 2016 ; 374 : 1552-63.
PubMed
2) Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009 ; 360 : 2536-43.
PubMed
3) Zhang Q, Sun K, Chinazzi M, et al. Spread of Zika virus in the Americas. Proc Natl Acad Sci USA. 2017 ; 114 : E4334-43.
PubMed
4) Massad E, Tan SH, Khan K, et al. Estimated Zika virus importations to Europe by travellers from Brazil. Glob Health Action. 2016 ; 9 : 31669.
PubMed
5) Kutsuna S. Zika virus infection : Clinical overview with a summary of Japanese cases. Clin Exp Neuroimmunol. 2017 ; 8 : 192-8.
 
6) Malta JM, Vargas A, Leite PL, et al. Guillain-Barre syndrome and other neurological manifestations possibly related to Zika virus infection in municipalities from Bahia, Brazil, 2015. Epidemiol Serv Saude. 2017 ; 26 : 9-18.
PubMed
7) Carteaux G, Maquart M, Bedet A, et al. Zika virus associated with meningoencephalitis. N Engl J Med. 2016 ; 374 : 1595-6.
PubMed
8) Mecharles S, Herrmann C, Poullain P, et al. Acute myelitis due to Zika virus infection. Lancet. 2016 ; 387 : 1481.
PubMed
9) Niemeyer B, Niemeyer R, Borges R, et al. Acute disseminated encephalomyelitis following Zika virus infection. Eur Neurol. 2017 ; 77 : 45-6.
PubMed
11) Martinez ARM, Costa MCM, Novaes MAC, et al. A novel phenotype of Zika virus-related neurological disease : Sensory neuronopathy. Muscle Nerve. 2018 ; 57 : E100-1.
PubMed
12) de Paula Freitas B, Ventura CV, Maia M, et al. Zika virus and the eye. Curr Opin Ophthalmol. 2017 ; 28 : 595-9.
PubMed
13) Relich RF, Loeffelholz M. Zika Virus. Clin Lab Med. 2017 ; 37 : 253-67.
PubMed
14) Barzon L, Pacenti M, Berto A, et al. Isolation of infectious Zika virus from saliva and prolonged viral RNA shedding in a traveller returning from the Dominican Republic to Italy, January 2016. Euro Surveill. 2016 ; 21 : 30159.
 
15) Roze B, Najioullah F, Ferge JL, et al. Zika virus detection in urine from patients with Guillain-Barre syndrome on Martinique, January 2016. Euro Surveill. 2016 ; 21 : 30154.
PubMed
16) Liu Y, Liu J, Du S, et al. Evolutionary enhancement of Zika virus infectivity in Aedes aegypti mosquitoes. Nature. 2017 ; 545 : 482-6.
PubMed
17) Deng C, Liu S, Zhang Q, et al. Isolation and characterization of Zika virus imported to China using C6/36 mosquito cells. Virol Sin. 2016 ; 31 : 176-9.
PubMed
18) Deng YQ, Zhao H, Li XF, et al. Isolation, identification and genomic characterization of the Asian lineage Zika virus imported to China. Sci China Life Sci. 2016 ; 59 : 428-30.
 
19) Huang AS, Shu PY, Yang CH. A new reportable disease is born : Taiwan Centers for Disease Control's response to emerging Zika virus infection. J Formos Med Assoc. 2016 ; 115 : 223-5.
PubMed
20) Jang HC, Park WB, Kim UJ, et al. First imported case of Zika virus infection into Korea. J Korean Med Sci. 2016 ; 31 : 1173-7.
 
21) Oehler E, Watrin L, Larre P, et al. Zika virus infection complicated by Guillain-Barre syndrome-case report, French Polynesia, December 2013. Euro Surveill. 2014 ; 19. pii : 20720.
 
22) Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia : a case-control study. Lancet. 2016 ; 387 : 1531-9.
PubMed
23) Parra B, Lizarazo J, Jimenez-Arango JA, et al. Guillain-Barre syndrome associated with Zika virus infection in Colombia. N Engl J Med. 2016 ; 375 : 1513-23.
PubMed
24) da Silva IRF, Frontera JA, Bispo de Filippis AM, et al. Neurologic complications associated with the Zika virus in Brazilian adults. JAMA Neurol. 2017 ; 74 : 1190-8.
PubMed
25) Dos Santos T, Rodriguez A, Almiron M, et al. Zika virus and the Guillain-Barre syndrome - case series from seven countries. N Engl J Med. 2016 ; 375 : 1598-601.
PubMed
26) Joob B, Wiwanitkit V. Incidence of Guillain-Barre syndrome among Zika virus infected cases : a report from Thailand. Arq Neuropsiquiatr. 2018 ; 76 : 63.
 
27) Simon O, Acket B, Forfait C, et al. Zika virus outbreak in New Caledonia and Guillain-Barre syndrome : a case-control study. J Neurovirol. in press.
 
28) Arias A, Torres-Tobar L, Hernandez G, et al. Guillain-Barre syndrome in patients with a recent history of Zika in Cucuta, Colombia : A descriptive case series of 19 patients from December 2015 to March 2016. J Crit Care. 2017 ; 37 : 19-23.
 
29) Anaya JM, Rodriguez Y, Monsalve DM, et al. A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cucuta, Colombia. J Autoimmun. 2017 ; 77 : 123-38.
PubMed
30) Sebastian UU, Ricardo AVA, Alvarez BC, et al. Zika virus-induced neurological critical illness in Latin America : Severe Guillain-Barre Syndrome and encephalitis. J Crit Care. 2017 ; 42 : 275-81.
PubMed
31) Salinas JL, Walteros DM, Styczynski A, et al. Zika virus disease-associated Guillain-Barre syndrome-Barranquilla, Colombia 2015-2016. J Neurol Sci. 2017 ; 381 : 272-7.
PubMed
32) Dirlikov E, Major CG, Mayshack M, et al. Guillain-Barre Syndrome during ongoing Zika virus transmission-Puerto Rico, January 1-July 31, 2016. MMWR Morb Mortal Wkly Rep. 2016 ; 65 : 910-4.
PubMed
33) Fabrizius RG, Anderson K, Hendel-Paterson B, et al. Guillain-Barre syndrome associated with Zika virus infection in a traveler returning from Guyana. Am J Trop Med Hyg. 2016 ; 95 : 1161-5.
 
34) Langerak T, Yang H, Baptista M, et al. Zika virus infection and Guillain-Barre Syndrome in three patients from suriname. Front Neurol. 2016 ; 7 : 233.
PubMed
35) Siu R, Bukhari W, Todd A, et al. Acute Zika infection with concurrent onset of Guillain-Barre Syndrome. Neurology. 2016 ; 87 : 1623-4.
PubMed
36) Miller E, Becker Z, Shalev D, et al. Probable Zika virus-associated Guillain-Barre syndrome : challenges with clinico-laboratory diagnosis. J Neurol Sci. 2017 ; 375 : 367-70.
PubMed
37) Roze B, Najioullah F, Ferge JL, et al. Guillain-Barre syndrome associated with Zika virus infection in martinique in 2016 : A Prospective Study. Clin Infect Dis. 2017 ; 65 : 1462-8.
PubMed
38) Uncini A, Gonzalez-Bravo DC, Acosta-Ampudia YY, et al. Clinical and nerve conduction features in Guillain-Barre syndrome associated with Zika virus infection in Cucuta, Colombia. Eur J Neurol. 2018 ; 25 : 644-50.
PubMed
39) Resiere D, Ferge JL, Fabre J, et al. Cardiovascular complications in patients with Zika virus-induced Guillain-Barre syndrome. J Clin Virol. 2018 ; 98 : 8-9.
PubMed
40) Fontes CA, Dos Santos AA, Marchiori E. Magnetic resonance imaging findings in Guillain-Barre syndrome caused by Zika virus infection. Neuroradiology. 2016 ; 58 : 837-8.
PubMed
41) Nascimento OJM, da Silva IRF. Guillain-Barre syndrome and Zika virus outbreaks. Curr Opin Neurol. 2017 ; 30 : 500-7.
PubMed
42) Dirlikov E, Torres JV, Martines RB, et al. Postmortem findings in patient with Guillain-Barre syndrome and Zika Virus infection. Emerg Infect Dis. 2018 ; 24 : 114-7.
PubMed
43) Gonzalez-Escobar G, Valadere AM, Adams R, et al. Prolonged Zika virus viremia in a patient with Guillain-Barre syndrome in Trinidad and Tobago. Rev Panam Salud Publica. 2018 ; 41 : e136.
 
44) Nico D, Conde L, Rivera-Correa JL, et al. Prevalence of IgG autoantibodies against GD3 ganglioside in acute Zika virus infection. Front Med (Lausanne). 2018 ; 5 : 25.
 
45) Lucchese G, Kanduc D. Zika virus and autoimmunity : From microcephaly to Guillain-Barre syndrome, and beyond. Autoimmun Rev. 2016 ; 15 : 801-8.
PubMed
46) Sawai S, Satoh M, Mori M, et al. Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barre syndrome. Neurology. 2014 ; 83 : 113-7.
PubMed
47) Devakumar D, Bamford A, Ferreira MU, et al. Infectious causes of microcephaly : epidemiology, pathogenesis, diagnosis, and management. Lancet Infect Dis. 2018 ; 18 : e1-13.
PubMed
48) Lucchese G, Kanduc D. Minimal immune determinants connect Zika virus, human cytomegalovirus, and toxoplasma gondii to microcephaly-related human proteins. Am J Reprod Immunol. 2017 ; 77 : e12608.
 
49) Mori K, Hattori N, Sugiura M, et al. Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology. 2002 ; 58 : 979-82.
PubMed
50) Leonhard SE, Munts AG, van der Eijk AA, et al. Acute-onset chronic inflammatory demyelinating polyneuropathy after Zika virus infection. J Neurol Neurosurg Psychiatry. 2018 ; 89 : 1118-9.
PubMed
P.267 掲載の参考文献
1) Ohnuki Y, Suzuki S, Shiina T, et al. HLA-DRB1 alleles in immune-mediated necrotizing myopathy. Neurology. 2016 ; 87 : 1954-5.
PubMed
2) Allenbach Y, Benveniste O. Acquired necrotizing myopathies. Curr Opin Neurol. 2013 ; 26 : 554-60.
PubMed
3) Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016 ; 87 : 1038-44.
PubMed
4) Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci USA. 1986 ; 83 : 9507-11.
PubMed
5) Forman MS, Nakamura M, Mimori T, et al. Detection of antibodies to small nuclear ribonucleoproteins and small cytoplasmic ribonucleoproteins using unlabeled cell extracts. Arthritis Rheum. 1985 ; 28 : 1356-61.
PubMed
6) Hanaoka H, Kaneko Y, Suzuki S, et al. Anti-signal recognition particle antibody in patients without inflammatory myopathy : a survey of 6180 patients with connective tissue diseases. Scand J Rheumatol. 2016 ; 45 : 36-40.
PubMed
7) Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 2011 ; 63 : 1961-71.
PubMed
8) Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies : case series of 100 patients. Orphanet J Rare Dis. 2015 ; 10 : 61.
PubMed
9) Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010 ; 62 : 2757-66.
PubMed
10) Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011 ; 63 : 713-21.
PubMed
11) Mammen AL, Pak K, Williams EK, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken). 2012 ; 64 : 269-72.
PubMed
12) Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012 ; 64 : 4087-93.
PubMed
13) Watanabe Y, Suzuki S, Nishimura H, et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies : an observational study in Japan. Medicine (Baltimore). 2015 ; 94 : e416.
PubMed
14) Suzuki S, Hayashi YK, Kuwana M, et al. Myopathy associated with antibodies to signal recognition particle : disease progression and neurological outcome. Arch Neurol. 2012 ; 69 : 728-32.
PubMed
15) Liang WC, Uruha A, Suzuki S, et al. Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology. 2017 ; 56 : 287-93.
PubMed
16) 久留聡, 鈴木重明, 尾方克久, 他. 診断未確定慢性ミオパチーにおける壊死性ミオパチー関連抗体スクリーニング. 臨床神経. 2017 ; 57 : 562-6.
 
17) Tanaka T, Suzuki S, Nishino I, et al. What is the third serologic marker associated with immune-mediated necrotizing myopathy? Scan J Rheumatol. 2017 ; 46 : 416-8.
 
18) Allenbach Y, Arouche-Delaperche L, Preusse C, et al. Necrosis in anti-SRP+ and anti-HMGCR+myopathies : Role of autoantibodies and complement. Neurology (in press). 2018.
 
P.273 掲載の参考文献
1) Fujimoto M. Myositis-specific autoantobidies and skin manifestations. Clin Exp Neuroimmunol. 2012 ; 3 : 74-84.
 
2) Fujimoto M, Watanabe R, Ishitsuka R, et al. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016 ; 28 : 636-44.
 
3) Betteridge Z, McHugh N. Myositis-specific autoantibodies : an important tool to support diagnosis of myositis. J Intern Med. 2016 ; 280 : 8-23.
PubMed
4) Deakin CT, Yasin SA, Simou S, et al. Muscle biopsy findings in combination with myositis-specific auto-antibodies aid prediction of outcomes in juvenile dermatomyositis. Arthritis Rheumatol. 2016 ; 68 : 2806-16.
 
5) Fujimoto M, Murakami A, Kurei S, et al. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis. J Dermatol Sci. 2016 ; 84 : 272-81.
PubMed
6) Sato S, Murakami A, Kuwajima A, et al. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated Gene 5 autoantibodies. PLoS One. 2016 ; 11 : e0154285.
PubMed
7) Nakashima R, Imura Y, Hosono Y, et al. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One. 2014 ; 9 : e85062.
PubMed
8) Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis : an association with malignancy. Rheumatology. 2007 ; 46 : 25-8.
PubMed
9) Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006 ; 54 : 3682-9.
PubMed
10) Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcriptional intermediary factor 1 family proteins. Arthritis Rheum. 2012 ; 64 : 513-22.
PubMed
11) Ueda-Hayakawa I, Hamaguchi Y, Okiyama N, et al. Autoantibody to transcriptional intermediary factor-1beta as myositis-specific antibody : clinical correlation with CADM or DM with mild myopathy. Br J Dermatol. 2018.
PubMed
12) Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013 ; 92 : 223-43.
PubMed
13) Tansley SL, Simou S, Shaddick G, et al. Autoantibodies in juvenile-onset myositis : Their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun. 2017 ; 84 : 55-64.
 
14) Parkes JE, Rothwell S, Oldroyd A, et al. Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-gamma autoantibodies in adult patients with myositis. Arthritis Res Ther. 2018 ; 20 : 117.
 
15) Trallero-Araguas E, Rodrigo-Pendas J'A, Serva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis : a systematic review and meta-analysis. Arthritis Rheum. 2012 ; 64 : 523-32.
 
16) Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007 ; 66 : 1345-9.
PubMed
17) Venalis P, et al. Association of anti-transcription intermediary factor 1γ antibodies with paraneoplastic rheumatic syndromes other than dermatomyositis. Arthritis Care Res. 2017 ; 70 : 648-51.
 
18) Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology. 2018 ; 57 : 388-96.
PubMed
19) Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult japanese patients with dermatomyositis : A multicenter cross-sectional study. Arch Dermatol. 2011 ; 147 : 391-8.
PubMed
20) Mugii N, Hasegawa M, Matsushita T, et al. Oropharyngeal dysphagia in dermatomyositis : Associations with clinical and laboratory features including Autoantibodies. PLoS One. 2016 ; 11 : e0154746.
PubMed
21) Muro Y, Sugiura K, Akiyama M. Cutaneous manifestations in dermatomyositis : Key clinical and serological features-a comprehensive review. Clin Rev Allergy Immunol. 2016 ; 51 : 293-302.
PubMed
22) Fiorentino D, Casciola-Rosen L. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. Arthritis Rheum. 2012 ; 64 : 346-9.
PubMed
23) Gunawardena H, Wedderbum LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology. 2008 ; 47 : 324-8.
 
24) Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015 ; 72 : 449-55.
PubMed
25) Gunawardena H, Wedderbum LC, Chinog H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009 ; 60 : 1807-14.
 
26) Bernet LL, Lewis MA, Rieger KE, et al. Ovoid Palatal Patch in Dermatomyositis : A Novel Finding Associated With Anti-TIF1gamma (p155) Antibodies. JAMA Dermatol. 2016 ; 152 : 1049-51.
PubMed
27) Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005 ; 52 : 1571-6.
PubMed
28) Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis : Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009 ; 60 : 2193-200.
 
29) Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2010 ; 49 : 433-40.
PubMed
30) Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology. 2010 ; 49 : 1726-33.
PubMed
31) Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology. 2012 ; 51 : 1278-84.
PubMed
32) Sato S, Masui k, Nishina N, et al. Initial predictors of poor survival in myositis-associated interstitial lung disease : a multicentre cohort of 497 patients. Rheumatology. 2018.
PubMed
33) Muro Y, Sugiura K, Hoshino k, et al. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology. 2012 ; 51 : 800-4.
PubMed
34) Matsushita T, Mizumaki K, Kano M, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017 ; 176 : 395-402.
PubMed
35) Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology. 2012 ; 51 : 1563-70.
PubMed
36) Hosono Y, Nakashima R, Serada S, et al. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody. J Autoimmun. 2017 ; 77 : 116-22.
 
37) Kang EH, Nakashima R, Mimori T, et al. Myositis autoantibodies in Korean patients with inflammatory myositis : anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord. 2010 ; 11 : 223.
PubMed
38) Chen F, Wang D, Shu X, et al. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int. 2012 ; 32 : 3909-15.
 
39) Chen Z, Hu W, Wang Y, et al. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis. Clin Rheumatol. 2015 ; 34 : 1627-31.
PubMed
40) Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140) : A retrospective study. J Am Acad Dermatol. 2011 ; 65 : 25-34.
PubMed
41) Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis : expanding the clinical spectrum. Arthritis Care Res. 2013 ; 65 : 1307-15.
PubMed
42) Moghadam-Kia S, Oddis CV, Sato S, et al. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. Arthritis Care Res. 2016 ; 68 : 689-94.
PubMed
43) Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res. 2014 ; 290797.
 
44) Gono T, Kawaguchi Y, Kuwana M, et al. Association of HLA-DRB1*0101/*0405 is associated with susceptibility to Anti-MDA5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 2012.
 
45) Koguchi-Yoshioka H, Okiyama N, Iwamoto K, et al. Association ofIntravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules. Br J Dermatol. 2017 ; 177 : 1442-6.
 
46) Kobayashi I, Okura Y, Yamada M, et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 2011 ; 158 : 675-7.
PubMed
47) Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype : a prospective cohort study. Arthritis Res Ther. 2014 ; 16 : R138.
PubMed
48) Allenbach Y, Leroux G, Suarez-Calvet X, et al. Dermatomyositis with or without anti-melanoma differentiation-associated Gene 5 antibodies : Common interferon signature but distinct NOS2 expression. Am J Pathol. 2016 ; 186 : 691-700.
PubMed
49) Zhang SH, Zhao Y, Xie QB, et al. Aberrant activation of type I interferon system may contribute to the pathogenesis of anti-MDA5 dermatomyositis. Br J Dermatol. 2018.
 
50) Oddis CV, et al. Clinical and serological characterization of the anti-MJ antibody in childhood myositis [abstract]. Arthritis Rheum. 1997 ; 40 : S139.
 
51) Targoff IN, et al. Sera with autoantibodies to the MJ antigen react with NXP2 [abstract]. Arthritis Rheum. 2007 ; 56 : S787.
 
52) Espada G, MaldonadoCoco JA, Fertig N, et al. Clinical and serologic characterization of an Argentine pediatric myositis cohort : identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol. 2009 ; 36 : 2547-51.
 
53) Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies : possible association with malignancy. Ann Rheum Dis. 2012 ; 71 : 710-3.
PubMed
54) Ishikawa A, Muro Y, Sugiura K, et al. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology. 2012 ; 51 : 1181-7.
PubMed
55) Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum. 2013 ; 65 : 2954-62.
PubMed
56) Rogers A, Chung L, Li S, et al. Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res. 2017 ; 69 : 1909-14.
 
57) Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology. 2014 ; 53 : 2204-8.
PubMed
58) Betteridge Z, Gunawardena H, North J, et al. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 2007 ; 56 : 3132-7.
PubMed
59) Tarricone E, Chirardello A, Rampudda M, et al. Anti-SAE antibodies in autoimmune myositis : Identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods. 2012 ; 384 : 128-34.
 
60) Bodoki L, Nagy-Vincze M, Grigor Z, et al. Four dermatomyositis-specific autoantibodies-anti-TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev. 2014 ; 13 : 1211-9.
 
61) Fujimoto M, Matsushita T, Hamaguchi Y, et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis : comparison with a UK Caucasian cohort. Ann Rheum Dis. 2013 ; 72 : 151-3.
PubMed
62) Muro Y, Sugiura K, Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity. 2013 ; 46 : 279-84.
PubMed
63) Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep. 2017 ; 7 : 188.
PubMed
64) Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis. 2009 ; 68 : 1621-5.
PubMed
65) Inoue S, Okiyama N, Shobo M, et al. Diffuse erythema with 'angel wings' sign in Japanese patients with anti-small ubiquitin-like modifier activating enzyme antibody-associated dermatomyositis. Br J Dermatol. 2018.
PubMed
66) Mescam-Mancini L, Allenbach Y, Hervier B, et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain. 2015 ; 138 : 2485-92.
PubMed
67) Uruha A, Suzuki S, Suzuki N, et al. Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1. Brain. 2016 ; 139 : e50.
PubMed
68) Uruha A, Nishikawa A, Tsuburaya RS, et al. Sarcoplasmic MxA expression : A valuable marker of dermatomyositis. Neurology. 2017 ; 88 : 493-500.
 
P.282 掲載の参考文献
1) Sneddon LU. Pain in aquatic animals. J Exp Biol. 2015 ; 218 : 967-76.
PubMed
2) Patel R, Dickenson AH. Mechanisms of the gabapentinoids and α2δ-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect. 2016 ; 4 : e00205.
 
3) Denk F, McMahon SB, Tracey I. Pain vulnerability : a neurobiological perspective. Nat Neurosci. 2014 ; 17 : 192-200.
PubMed
4) Bushnell MC, Ceko M, Low L. Cognitive and emotional control of pain and its disruption in chronic pain. Nat Rev Neurosci. 2013 ; 14 : 502-11.
PubMed
5) Vachon-Presseau E, Centeno MV, Ren W, et al. The emotional brain as a predictor and amplifier of chronic pain. J Dent Res. 2016 ; 95 : 605-12.
PubMed
6) Peyron R, Laurent B, Garcia-Larrea L. Functional imaging of brain responses to pain. A review and meta-analysis (2000). Neurophysiol Clin. 2000 ; 30 : 263-88.
 
7) Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science. 2000 ; 288 : 1769-72.
PubMed
8) Rainville P, Rainville P, Duncan GH, et al. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science. 2008 ; 968 : 1997.
PubMed
9) Brooks J, Tracey I. From nociception to pain perception : imaging the spinal and supraspinal pathways. J Anat. 2005 ; 207 : 19-33.
 
10) Tracey I, Mantyh PW. The Cerebral Signature for Pain Perception and Its Modulation. Neuron. 2007 ; 377-91.
PubMed
11) Davis KD, Flor H, Greely HT, et al. Brain imaging tests for chronic pain : medical, legal and ethical issves and recommendations. Nat Rev Neurol. 2017 ; 13 : 624-38.
PubMed
12) Kulkarni B, Bentley DE, Elliott R, et al. Arthritic pain is processed in brain areas concerned with emotions and fear. Arthritis Rheum. 2007 ; 56 : 1345-54.
PubMed
13) Price DD. Central neural mechanisms that interrelate sensory and affective dimensions of pain. Mol Interv. 2002 ; 2 : 392-403.
PubMed
14) Hashmi JA, Baliki MN, Huang L, et al. Shape shifting pain : chronification of back pain shifts brain representation from nociceptive to emotional circuits. Brain. 2013 ; 136 : 2751-63.
PubMed
15) Vachon-Presseau E, Tetreault P, Petre B, et al. Corticolimbic anatomical characteristics predetermine risk for chronic pain. Brain. 2016 ; 139 : 1958-70.
PubMed
16) LeDoux JE, Brown R. A higher-order theory of emotional consciousness. Proc Natl Acad Sci. 2017 ; 114 : E2016-25.
 
17) Todd AJ. Neuronal circuitry for pain processing in the dorsal horn. Nat Neurosci. 2012 ; 11 : 823-36.
 
18) Gauriau C, Bernard JF. Pain pathways and parabrachial circuits in the rat. Exp Physiol. 2002 ; 87 : 251-8.
PubMed
19) Neugebauer V, Li W, Bird GC, et al. The amygdala and persistent pain. Neuroscientist. 2004 ; 10 : 221-34.
PubMed
20) Thompson JM, Neugebauer V. Amygdala plasticity and pain. Pain Res Manag. 2017 ; 2017.
PubMed
21) Sato M, Watabe AM, Kato F. Lateral parabrachial nucleus is involved in the acquisition of fear memory in mice. Mol Brain. 2015 ; 22.
PubMed
22) Han S, Soleiman MT, Soden ME, et al. Elucidating an Affective Pain Circuit that Creates a Threat Memory. Cell. 2015 ; 162 : 363-74.
PubMed
23) Sugimura YK, Takahashi Y, Watabe AM, et al. Synaptic and network consequences of monosynaptic nociceptive inputs of parabrachial nucleus origin in the central amygdala. J Neurophysiol. 2016 ; 81 : 2721-39.
 
24) Kato F, Sugimura YK, Takahashi Y. Pain-associated neural plasticity in the parabrachial to central amygdala circuit. Adv Exp Med Biol. 2018 ; 1099 : 157-66.
PubMed
25) Palmiter RD. The parabrachial nucleus : CGRP neurons function as a general alarm. Trends Neurosci. 2018 ; 41 : 280-93.
PubMed
26) Han JS, Neugebauer V. Synaptic plasticity in the amygdala in a visceral pain model in rats. Neurosci Lett. 2004 ; 361 : 254-7.
 
27) Nakao A, Takahashi Y, Nagase M, et al. Role of capsaicin-sensitive C-fiber afferents in neuropathic pain-induced synaptic potentiation in the nociceptive amygdala. Mol Pain. 2012 ; 8 : 51.
PubMed
28) Ikeda R, Takahashi Y, Inoue K, et al. NMDA receptor-independent synaptic plasticity in the central amygdala in the rat model of neuropathic pain. Pain. 2007 ; 127 : 161-72.
PubMed
29) Ochiai T, Takahashi Y, Asato M, et al. Bilateral potentiation of parabrachial, but not basolateral amygdala inputs, to central capsular amygdala neurons in neuropathic diabetic mice. Annu Meet Soc Neurosci. 2012 ; 703-85.
 
30) Adedoyin MO, Vicini S, Neale JH. Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model. Mol Pain. 2010 ; 6 : 60.
 
31) Miyazawa Y, Takahashi Y, Watabe AM, et al. Predominant synaptic potentiation and activation in the right central amygdala are independent of bilateral parabrachial activation in the hemilateral trigeminal inflammatory pain model of rats. Molecular Pain. 2018. 174480691880710.
PubMed
32) Shinohara K, Watabe AM, Nagase M, et al. Essential role of endogenous calcitonin gene-related peptide in pain-associated plasticity in the central amygdala. Eur J Neurosci. 2017 ; 46 : 2149-60.
PubMed
33) Watabe AM, Ochiai T, Nagase M, et al. Synaptic potentiation in the nociceptive amygdala following fear learning in mice. Mol Brain. 2013 ; 6 : 11.
PubMed
34) Bliss TVP, Collingridge GL, Kaang B-K, et al. Synaptic plasticity in the anterior cingulate cortex in acute and chronic pain. Nat Rev Neurosci. 2016 ; 17 : 485-96.
PubMed
35) Yalcin I, Barthas F, Barrot M. Emotional consequenes of neuropathic pain : Insight from preclinical studies. Neurosci Biobehav Rev. 2014 ; 47 : 154-64.
 
36) Sadler KE, McQuaid NA, Cox AC,et al. Divergent functions of the left and right central amygdala in visceral nociception. Pain. 2017 ; 158 : 747-59.
PubMed
37) Chang P-C, Pollema-Mays SL, Centeno MV, et al. Role of nucleus accumbens in neuropathic pain : linked multi-scale evidence in the rat transitioning to neuropathic pain. Pain. 2014 ; 155 : 1128-39.
PubMed
P.289 掲載の参考文献
1) Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors : a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998 ; 92 : 573-85.
 
2) de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins : hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998 ; 95 : 322-7.
PubMed
3) Sakurai T. The neural circuit of orexin (hypocretin) : maintaining sleep and wakefulness. Nat Rev Neurosci. 2007 ; 8 : 171-81.
PubMed
4) Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000 ; 27 : 469-74.
PubMed
5) Mileykovskiy B, Kiyashchenko L, Siegel J. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron. 2005 ; 46 : 787-98.
PubMed
6) Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice. molecular genetics of sleep regulation. Cell. 1999 ; 98 : 437-51.
PubMed
7) Nakamura A, Zhang W, Yanagisawa M, et al. Vigilance state-dependent attenuation of hypercapnic chemoreflex and exaggerated sleep apnea in orexin knockout mice. J Appl Physiol. 2007 ; 102 : 241-8.
PubMed
8) Deng BS, Nakamura A, Zhang W, et al. Contribution of orexin in hypercapnic chemoreflex : Evidence from genetic and pharmacological disruption and supplementation studies in mice. J Appl Physiol. 2007 ; 103 : 1772-9.
PubMed
9) Han F, Mignot E, Wei YC, et al. Ventilatory chemoresponsiveness, narcolepsy-cataplexy and human leukocyte antigen DQB1*0602 status. Eur Respir J. 2010 ; 36 : 577-83.
PubMed
10) Yamaguchi K, Futatsuki T, Ushikai J, et al. Intermittent but not sustained hypoxia activates orexin-containing neurons in mice. Resp Physiol Neurobiol. 2015 ; 206 : 11-4.
PubMed
11) Terada J, Nakamura A, Zhang W, et al. Ventilatory long-term facilitation in mice can be observed both during sleep and wake periods and depends on orexin. J Appl Physiol. 2008 ; 104 : 499-507.
PubMed
12) Toyama S, Sakurai T, Tatsumi K, et al. Attenuated phrenic long-term facilitation in orexin neuron-ablated mice. Respir Physiol Neurobiol. 2009 ; 168 : 295-302.
PubMed
13) Zhang W, Fukuda Y, Kuwaki T. Respiratory and cardiovascular actions of orexin-A in mice. Neurosci Lett. 2005 ; 385 : 131-6.
PubMed
14) 桑木共之. 自律神経と情動. In : 情動と呼吸. 東京 : 朝倉書店 ; 2016. p.46-68.
 
15) Kayaba Y, Nakamura A, Kasuya Y, et al. Attenuated defense response and low basal blood pressure in orexin knockout mice. Am J Physiol Regul Integr Comp Physiol. 2003 ; 285 : R581-93.
PubMed
16) Zhang W, Sakurai T, Fukuda Y, et al. Orexin neuron-mediated skeletal muscle vasodilation and shift of baroreflex during defense response in mice. Am J Physiol Regul Integr Comp Physiol. 2006 ; 290 : R1654-63.
PubMed
17) Watanabe S, Kuwaki T, Yanagisawa M, et al. Persistent pain and stress activate pain-inhibitory orexin pathways. Neuroreport. 2005 ; 16 : 5-8.
PubMed
18) Kuwaki T. Thermoregulation under pressure : a role for orexin neurons. Temperature. 2015 ; 2 : 379-91.
PubMed
19) Futatsuki T, Yamashita A, Ikbar KN, et al. Involvement of orexin neurons in fasting- and central adenosine-induced hypothermia. Sci Rep. 2018 ; 8 : 2717.
PubMed
20) Johnson PL, Truitt W, Fitz SD, et al. A key role for orexin in panic anxiety. Nat Med. 2010 ; 16 : 111-5.
PubMed
21) Carrive P, Kuwaki T. Orexin and Central Modulation of Cardiovascular and Respiratory Function. In Curr Top Behav Neurosci 33. Springer ; 2017 ; 157-96.
 
22) Matheson E, Hainer BL. Insomnia : Pharmacologic therapy. Am Fam Physician. 2017 ; 96 : 29-35.
PubMed
23) McCormick DA, Bal T. Sensory gating mechanisms of the thalamus. Curr Opin Neurobiol. 1994 ; 4 : 550-6.
PubMed
24) Iwakawa S, Kanmura Y, Kuwaki T. Aversive stimuli-induced wake from hypnotics-induced sleep in mice : Comparison between a dual orexin receptor antagonist and triazolam. J Physiol Sci. 2018 ; 68 : S129.
 
P.297 掲載の参考文献
1) 中里良彦. 特発性無汗症. Annual Review神経 2006. 東京 : 中外医学社 ; 2006. p.309-17.
 
2) Cao R, Tey HL. Prognosis of acquired idiopathic generalized anhidrosis. J Dtsch Dermatol Ges. 2017 ; 942-5.
PubMed
3) Gangadharan G, CritonS, Surendran D. Acquired idiopathic generalized anhidrosis. Indian J Dermatology. 2015 ; 60 : 422.
PubMed
4) Tay LK, Chong WS. Acquired idiopathic anhidrosis : a diagnosis often missed. J Am Acad Dermatol. 2014 ; 71 : 499-506.
PubMed
5) Wollina U. Photoletter to the editor : Acquired idiopathic generalized anhidrosis. J Dermatol Case Rep. 2014 ; 4 : 120-1.
 
6) Pargfrieder C, Struhal W, Sega W, et al. Acquired idiopathic generalized anhidrosis in a young Austrian patient. J Am Acad Dermatol. 2018 ; 4 ; 222-5.
 
7) Palm F, Loser C, Gronau W, et al. Successful treatment of acquired idiopathic generalized anhidrosis. Neurology. 2007 ; 68 : 532-3.
PubMed
8) Wolinia U. Acquired idiopathic generalized anhidrosis. J Dermatol Case Rep. 2014 ; 8 : 120-1.
 
9) Brantley E, Mutasim DF, Heaton C. Acquired idiopathic generalized anhidrosis : case report. Cutis. 2011 ; 87 : 21-3.
PubMed
10) 「特発性後天性全身性無汗症診療ガイドライン」作成委員会. 特発性後天性全身性無汗症診療ガイドライン改訂版. 自律神経. 2015 ; 52 : 352-9.
 
11) Munetsugu T, Fujimoto T, Oshima Y, et al. Revised guideline for the diagnosis and treatment of acquired idiopathic generalized anhidrosis in Japan. J Dermatol. 2017 ; 44 : 394-400.
PubMed
12) 小野彗美, 室田浩之, 進藤翔子, 他. 大阪大学皮膚科における後天性特発性全身性無汗症の臨床的検討と治療経験. 発汗学. 2016 ; 23 : 25 -5.
 
13) 中里良彦. 特発性純粋発汗不全症の臨床的特徴. 自律神経. 2018 ; 55 : 86-90.
 
14) Kong YL, Tey HL. Palmoplantar hyperhidrosis : A paradoxical presentation of acquired idiopathic generalized hypohidrosis. Indian J Dermatol Venereol Leprol. 2017 ; 83 : 480-1.
PubMed
15) 中里良彦, 二宮充喜子, 田中愛, 他. コリン性蕁麻疹およびidiopathic pure sudomotor failureの病態. -とくに汗腺AChM3受容体発現と無汗部位の分布について. 自律神経. 2014 ; 51 : 115-20.
 
16) 戸倉新樹. 減汗性コリン性蕁麻疹とAIGA. 発汗学. 2018 ; 25 : 2-5.
Medical*Online
17) Munetsugu T, Fujimoto T, Satoh T, et al. Evaluation of the correlation between severity of acquired idiopathic generalized anhidrosis and quality of life scores. J Dermatol. 2017 ; 44 : 747-52.
PubMed
18) 内山明彦, 田中修, 茂木清一郎, 他. 後天性全身性無汗症を契機に診断された中枢性尿崩症の1例. 臨皮. 2013 ; 67 : 681-4.
 
19) 朝比奈正人, 鈴木淳也, 田村典子, 他. 経過中に中枢性尿崩症を発症した特発性後天性全身性無汗症の1例. 発汗学. 2004 ; 11 : 12-4.
Medical*Online
20) 齋藤博, 山田達也. 尋常性白斑を有し, インフルエンザ感染後に発症した特発性後天性全身性無汗症例. 発汗学. 2015 ; 22 : 7-9.
Medical*Online
21) Sakaguchi M, Tsuruta D, Ishii T, et al. Development of acquired idiopathic generalized anhidrosis in a case of Vogt-Koyanagi-harada disease. Eur J Dermatol. 2013 ; 23 : 714-25.
 
22) Chin YY, Chang TC, Chang CH. Idiopathic pure sudomotor failure and cholinergic urticaria in a patient after acute infectious mononucleosis. Clin Exp Dermatol. 2013 ; 38 : 156-9.
 
23) Honma M, Nozaki H, Nagahata H, et al. Serum carcinoembryonic antigen specifically increases among various serum markers of adenocarcinoma in hypohidrosis or conditions related to hypohidrosis. J Dermatology. 2017 ; 44 : 903-8.
PubMed
24) Honma M, Iimura S, Kanno S, et al. Serum carcinoembryonic antigen (CEA) as a clinical marker in acquired idiopathic generalized anhidrosis : a close correlation between serum CEA level and disease activity. J Eur Acad Dermatol Venereol. 2016 ; 30 : 1379-83.
 
25) Nakazato Y, Tamura N, Ikeda K, et al. A case of idiopathic pure sudomotor failure associated with prolonged high levels of serum carcinoembolic antigen. Clin Auton Res. 2016 ; 26 : 451-3.
PubMed
26) 佐野健司. 特発性後天性全身性無汗症における自己抗体の探索と汗腺暗細胞形態変化. 神経内科. 2018 ; 88 : 246-52.
 
27) Yoshifuku A, Yoneda K, Sakiyama Y, et al. Case of autoimmune autonomic ganglionopathy manifesting anhidrosia. J Dermatol. 2017 ; 44 : 1160-3.
PubMed
28) Nakazato Y, Tamura N, Ohkuma A, et al. QSART in idiopathic pure sudomotor failure. Clin Auton Res. 2005 ; 15 : 414-6.
PubMed
29) Nakazato Y, Tamura N, Ohkuma A, et al. Idiopathic pure sudomotor failure : Anhidrosis due to deficits in cholinergic transmission. Neurology. 2004 ; 63 : 1476-80.
PubMed
30) Sawada Y, Nakamura M, Bito T, et al. Cholinergic urticaria : studies on the muscarinic cholinergic receptor M3 in antidrotic and hypohidrotic skin. J Invest Dermatol. 2010 ; 130 : 2683-6.
PubMed
31) Sawada Y, Nakamura M, Bito T, et al. Decreased expression of acetylcholine esterase in cholinergic urticaria with hypohidrosis or anhidrosis. J Invest Dermatol. 2014 ; 134 : 276-9.
PubMed
32) Sano K, Asahina M, Uehara T, et al. Degranulation and shrinkage of dark cekks in eccrine glands and elevated serum carcinoembryonic antigen in patients with acquired idiopathic generalized anhidrosis. J Eur Acad Dermatol Venereol. 2017 ; 31 : 2097-103.
 
33) 佐野健司, 朝比奈正人. 特発性後天性全身性無汗症 (Acquired idiopathic generalized anhidrosis : AIGA) における自己抗体の探索と汗腺暗細胞形態変化, および皮膚移植片対宿主病との類似性. 自律神経. 2018 ; 55 : 100-6.
 
34) Iwamura E, Fujimura T, Tanita K, et al. Acquired idiopathic generalized anhidrosis : An immunohistopathological investigation of peri-glands infiltrated with immunoreactive cells. Acta Derm Venereol. 2015 ; 95 : 743-4.
 
35) Fujita K, Hatta K. Acquired generalized anhidrosis : review of the literature and report of a case with lymphocytic hidradenitis and sialadenitis successfully treated with cyclosporine. Dermatology. 2013 ; 227 : 270-7.
PubMed
36) Aoshima M, Suzuki Y, Masuda Y, et al. Successful treatment of chronic intractable pain with risperidone in a patient with acquired idiopathic generalized anhidrosis. J Dermatology. 2016 ; 45 : e189-e90.
 
P.303 掲載の参考文献
1) Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies : report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010 ; 51 : 676-85.
PubMed
2) From the commission on classification and terminology of the international league against epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981 ; 22 : 489-501.
PubMed
3) Commission on classification and terminology of the international league against epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989 ; 30 : 389-99.
PubMed
4) Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies : Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 ; 58 : 512-21.
PubMed
5) 高木俊輔, 松浦雅人. てんかんと精神症状. Clinical Neuroscience. 2017 ; 35 : 808-11.
 
6) Perucca P, Mula M. Antiepileptic drug effects on mood and behavior : molecular targets. Epilepsy Behav. 2013 ; 26 : 440-9.
PubMed
7) Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study) : a prospective observational study. Lancet Neurol. 2013 ; 12 : 244-52.
PubMed
8) Christensen J, Gronborg TK, Sorensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013 ; 309 : 1696-703.
PubMed
9) Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring : a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008 ; 49 : 1239-76.
PubMed
10) Reisinger TL, Newman M, Loring DW, et al. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav. 2013 ; 29 : 13-8.
PubMed
11) 井口正寛. GRADEシステムとSystematic review. Clinical Neuroscience. 2017 ; 35 : 877-84.
 
12) Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007 ; 61 : 25-36.
PubMed
13) Michel V, Mazzola L, Lemesle M, et al. Long-term EEG in adults : sleep-deprived EEG (SDE), ambulatory EEG (Amb-EEG) and long-term video-EEG recording (LTVER). Neurophysiol Clin. 2015 ; 45 : 47-64.
PubMed
P.313 掲載の参考文献
1) Marras C, Lang A, van de Warrenburg BP, et al. Nomenclature of genetic movement disorders : recommendations of the international Parkinson and movement disorder society task force. Mov Disord. 2017 ; 32 : 724-5.
PubMed
2) Erro R, Bhatia KP, Espay AJ, et al. The epileptic and nonepileptic spectrum of paroxysmal dyskinesias : Channelopathies, synaptopathies, and transportopathies. Mov Disord. 2017 ; 32 : 310-8.
PubMed
3) Shakkottai VG, Batla A, Bhatia K, et al. Current opinions and areas of consensus on the role of the cerebellum in dystonia. Cerebellum. 2017 ; 16 : 577-94.
PubMed
4) Bruno MK, Hallett M, Gwinn-Hardy K, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia : new diagnostic criteria. Neurology. 2004 ; 63 : 2280-7.
PubMed
5) Erro R, Sheerin UM, Bhatia KP. Paroxysmal dyskinesias revisited : a review of 500 genetically proven cases and a new classification. Mov Disord. 2014 ; 29 : 1108-16.
 
6) Chen W-J, Lin Y, Xiong Z-Q, et al. Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nature Genet. 2011 ; 43 : 1252-5.
 
7) Wang J-L, Cao L, Li X-H, et al. Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias. Brain. 2011 ; 134 : 3493-501.
 
8) Coleman J, Jouannot O, Ramakrishnan SK, et al. PRRT2 regulates synaptic fusion by directly modulating SNARE complex assembly. Cell Rep. 2018 ; 22 : 820-31.
PubMed
9) Ebrahimi-Fakhari D, Saffari A, Westenberger A, et al. The evolving spectrum of PRRT2-associated paroxysmal diseases. Brain. 2015 ; 138 : 3476-95.
PubMed
10) Gardiner AR, Jaffer F, Dale RC, et al. The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain. 2015 ; 138 : 3567-80.
PubMed
11) Heron SE, Grinton BE, Kivity S, et al. PRRT2 mutations cause benign familial infantile epilepsy and infantile convulsions with choreoathetosis syndrome. Am J Hum Genet. 2012 ; 90 : 152-60.
PubMed
12) Heron SE, Dibbens LM. Role of PRRT2 in common paroxysmal neurological disorders : a gene with remarkable pleiotropy. J Med Genet. 2013 ; 50 : 133-9.
PubMed
13) Delcourt M, Riant F, Mancini J, et al. Severe phenotypic spectrum of biallelic mutations in PRRT2 gene. J Neurol Neurosurg Psychiatry. 2015 ; 86 : 782-5.
 
14) Zhao G, Liu X, Zhang Q, et al. PRRT2 mutations in a cohort of Chinese families with paroxysmal kinesigenic dyskinesia and genotype-phenotype correlation reanalysis in literatures. Int J Neurosci. 2018 ; 128 : 751-60.
 
15) Tian WT, Huang XJ, Mao X, et al. Proline-rich transmembrane protein 2-negative paroxysmal kinesigenic dyskinesia : Clinical and genetic analyses of 163 patients. Mov Disord. 2018 ; 33 : 459-67.
PubMed
16) Ono S, Yoshiura K, Kinoshita A, et al. Mutations in PRRT2 responsible for paroxysmal kinesigenic dyskinesias also cause benign familial infantile convulsions. J Hum Genet. 2012 ; 57 : 338-41.
PubMed
17) Nobile C, Striano P. PRRT2 : a major cause of infantile epilepsy and other paroxysmal disorders of childhood. Prog Brain Res. 2014 ; 213 : 141-58.
 
18) Li M, Niu F, Zhu X, et al. PRRT2 Mutant leads to dysfunction of glutamate signaling. Int J Mol Sci. 2015 ; 16 : 9134-51.
PubMed
19) Valente P, Castroflorio E, Rossi P, et al. PRRT2 Is a key component of the Ca (2+) -dependent neurotransmitter release machinery. Cell Rep. 2016 ; 15 : 117-31.
PubMed
20) Fruscione F, Valente P, Sterlini B, et al. PRRT2 controls neuronal excitability by negatively modulating Na+ channel 1.2/1.6 activity. Brain. 2018 ; 141 : 1000-16.
PubMed
21) Michetti C, Castroflorio E, Marchionni I, et al. The PRRT2 knockout mouse recapitulates the neurological diseases associated with PRRT2 mutations. Neurobiol Dis. 2017 ; 99 : 66-83.
PubMed
22) Tan GH, Liu YY, Wang L, et al. PRRT2 deficiency induces paroxysmal kinesigenic dyskinesia by regulating synaptic transmission in cerebellum. Cell Res. 2018 ; 28 : 90-110.
PubMed
23) 豊島至. 遺伝性ジストニアの概観. Clinical Neuroscience. 2010 ; 28 : 753-6.
 
24) Lee HY, Xu Y, Huang Y, et al. The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum Mol Genet. 2004 ; 13 : 3161-70.
 
25) Rainier S, Thomas D, Tokarz D, et al. Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis. Arch Neurol. 2004 ; 61 : 1025-9.
PubMed
26) Shen Y, Ge WP, Li Y, et al. Protein mutated in paroxysmal dyskinesia interacts with the active zone protein RIM and suppresses synaptic vesicle exocytosis. Proc Natl Acad Sci USA. 2015 ; 112 : 2935-41.
PubMed
27) Lance JW. Familial paroxysmal dystonic choreoathetosis and its differentiation from related syndromes. Ann Neurol. 1977 ; 2 : 285-93.
PubMed
28) Weber YG, Storc A, Wuttke TV, et al. GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Inves. 2008 ; 118 : 2157-68.
 
29) Suls A, Dedeken P, Goffin K, et al. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain. 2008 ; 131 : 1831-44.
PubMed
30) Weber YG, Kamm C, Suls A, et al. Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1 defect. Neurology. 2011 ; 77 : 959-64.
PubMed
31) Chen T, Giri M, Xia Z, et al. Genetic and epigenetic mechanisms of epilepsy : a review. Neuropsychiatr Dis Treat. 2017 ; 13 : 1841-59.
PubMed
32) Zhang ZB, Tian MQ, Gao K, et al. De novo KCNMA1 mutations in children with early-onset paroxysmal dyskinesia and developmental delay. Mov Disord. 2015 ; 30 : 1290-2.
PubMed
33) Nothnagel M, Thiele H, Altmuller J, et al. Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation. Ann Neurol. 2016 ; 79 : 428-36.
PubMed
34) Yin XM, Lin JH, Cao L, et al. Familial paroxysmal kinesigenic dyskinesia is associated with mutations in the KCNA1 gene. Hum Mol Genet. 2018 ; 27 : 625-37.
PubMed
35) Baloh RW. Episodic ataxia 1 and 2. In : Subramony SH, Durr A ed. Handbook of Clinical Neurology, vol 103, Ataxic Disorders. New York : Elsevier ; 2012. p.595-602.
 
36) Rose SJ, Kriener LH, Heinzer AK, et al. The first knock in mouse model of episodic ataxia type 2. Exp Neurol. 2014 ; 261 : 553-62.
 
37) Holm R, Toustrup-Jensen MS, Einholm AP, et al. Neurological disease mutations of α3 Na+, K+ -ATPase : Structural and functional perspectives and rescue of compromised function. Biochim Biophys Acta. 2016 ; 1857 : 1807-28.
 
38) Toyoshima C, Cornelius F. New crystal structures of PII-type ATPases : excitement continues. Curr Opin Struct Biol. 2013 ; 23 : 507-14.
 
39) Ikeda K, Satake S, Onaka T, et al. Enhanced inhibitory neurotransmission in the cerebellar cortex of Atp1a3-deficient heterozygous mice. J Physiol. 2013 ; 591 : 3433-49.
PubMed
40) Calderon DP, Fremont R, Kraenzlin F, et al. The neural substrates of rapid-onset Dystonia-Parkinsonism. Nat Neurosci. 2011 ; 14 : 357-65.
PubMed
41) 宮本亮介, 梶龍兒. ジストニアと基底核・小脳. In : 鈴木則宏. 他, 編. Annual Review神経 2017. 東京 : 中外医学社 ; 2015. p.79-86.
 
42) 高田昌彦. Wriggle mouse Sagamiを用いたジストニアの脳内病態生理の解析. In : 長谷川一子, 編著, ジストニア, 2012. 東京 : 中外医学社 ; 2012. p.203-5.
 
43) Weisheit CE, Dauer WT. A novel conditional knock-in approach defines molecular and circuit effects of the DYT1 dystonia mutation. Hum Mol Genet. 2015 ; 24 : 6459-72.
PubMed
P.321 掲載の参考文献
1) 福井聖. 最後に : 日本は慢性疼痛にどう挑戦していくのか～超高齢化社会, 変革期の時代における慢性疼痛対策の重要性～. 野口光一, 柴田政彦, 福井聖, 監修. 日本は慢性疼痛にどう挑戦していくのか, 医薬品医療機器レギュラトリーサイエンス財団. 2017. p.159-68.
 
2) Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain : Cochrane systematic review and meta-analysis BMJ. 2015 ; 350 : h444.
PubMed
3) 北原雅樹. 痛みセンターの立場から 慢性疼痛診療, 痛みセンターを取りまく内外の状況と課題. In : 野口光一, 柴田政彦, 福井聖, 監修. 日本は慢性疼痛にどう挑戦していくのか. 医薬品医療機器レギュラトリーサイエンス財団. 2017 ; p139-44.
 
4) IASP Task Force for the classification of chronic pain. A classification of chronic pain for ICD-11. Pain. 2015 ; 156 : 1003-7.
 
5) Wada K, Arakida M, Watanabe R, et al. The economic impact of loss of performance due to absenteeism and presenteeism caused by depressive symptoms and comorbid health conditions among Japanese workers. Industrial Health. 2013 ; 51 : 482-9.
PubMed
6) 矢吹省司, 牛田享宏, 竹下克志, 他. 臨整外 日本における慢性疼痛保有者の実態調査. 2010. Pain in Japan. 2012 ; 47 : 127-34.
 
7) 集学的治療 CQ47～CQ51 慢性疼痛治療ガイドライン. 東京 : 真興交易医書出版部.
 
8) Hosomi K, Saymour B, Saitoh Y. Modulating the pain network-neurostimultion for central poststroke pain. Nat Rev Neurol. 2015 ; 11 : 290-9.
 
9) Yanagisawa T, Fukuma R, Seymour B, et al. Induced sensorimotor brain plasticity controls pain in phantom limb patients. Nat Comm. 2016 ; 77 : 13209.
 
10) 齋藤洋一. 最新の脊髄刺激療法. 機能的脳神経外科最新の動向. 脳神経外科. 2018 ; 46 : 535-46.
 

書評

最近チェックした商品履歴

Loading...